MSc. Thesis – A.R. Qureshi; McMaster University – Health Research Methodology

# PREVALENCE OF CHRONIC PAIN AMONG MILITARY VETERANS AND RESEARCH PRIORITIES AMONG MILITARY VETERANS LIVING WITH CHRONIC PAIN

Abdul-Rehman Qureshi

A Thesis submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the Degree of: Master of Science (Health Research Methodology) McMaster University © Copyright by Abdul-Rehman Qureshi, 2021

# TABLE OF CONTENTS

TITLE PAGE
THESIS PANEL
ACKNOWLEDGEMENTS
LIST OF ABBREVIATIONS
CHAPTER 1 – Thesis Introduction7
1.1 THESIS INTRODUCTION
1.2. REFERENCES
CHAPTER 2 – Prevalence of Chronic Non-Cancer Pain among Military Veterans
2.1. ABSTRACT
2.2. INTRODUCTION
2.3. METHODS10
2.3.1. Search strategy
2.3.2. Study selection
2.3.2.1. Inclusion criteria
2.3.2.2. Exclusion criteria
2.3.3. Data extraction and collection
2.3.3.1. Chronic non-cancer pain
2.3.4. Risk of bias assessment (ROB)13
2.3.5. Data synthesis and analysis
2.3.5.1 Subgroup analyses, meta-regression, and sensitivity analyses14
2.3.6. Certainty of evidence
2.3.7 Small-study effects
2.4. RESULTS15
2.4.1. Study characteristics
2.4.2. Risk of bias
2.4.3. Overall analysis
2.4.4. Subgroup analyses
2.4.4.1. A priori subgroup analyses
2.4.4.2. Post hoc subgroup analyses
2.4.4.3 Small-study effects
2.4.5. Meta-regression
2.4.6. Sensitivity analysis
2.5. DISCUSSION

# MSc. Thesis – A.R. Qureshi; McMaster University – Health Research Methodology

2.5.1. Main findings	22
2.5.2. Relations to the literature and implications	23
2.5.3. Strengths and limitations	23
2.5.4. Future directions	24
2.5.5. Conclusions	25
2.6. REFERENCES	25
2.7. SUPPLEMENTARY MATERIAL	34
CHAPTER 3 - Research Priorities among Canadian Military Veterans living with Chronic Pain	74
3.2. ABSTRACT	74
3.3. INTRODUCTION	75
3.4. METHODS	76
3.4.1. Study design	76
3.4.2. Survey administration	77
3.4.3. Data analysis	77
3.4.4. Thematic analysis	79
3.5. RESULTS	79
3.5.1. Characteristics of respondents	79
3.5.2. Research priorities	86
3.5.3. Highest and lowest research priorities	88
3.5.4. Subgroup analyses	88
3.5.5. Thematic analysis	94
3.6. DISCUSSION	94
3.6.1. Main findings	94
3.6.2. Relation to other studies	95
3.6.3. Strengths and limitations	97
3.6.4. Conclusion	98
3.7. ETHICS DECLARATION	98
3.8. REFERENCES	98
3.9. SUPPLEMENTARY MATERIAL	103
CHAPTER 4 – Thesis Conclusion	127
4.1 THESIS CONCLUSION	127

# **THESIS PANEL**

MSc. Thesis Supervisor Dr. Jason Busse

MSc Thesis Committee Members Dr. Jason Busse Dr. Li Wang Dr. Behnam Sadeghirad

> External Examiner Dr. Greg Pond

# ACKNOWLEDGEMENTS

I wish to express my gratitude to Dr. Jason Busse for his guidance, support, and encouragement during the past two years as supervisor for my Master's degree. Dr. Busse displayed a genuine passion for chronic pain research and motivated me with a cheery personality to persist in hard-work and dedication throughout my time as a master's student. I would like to also thank Dr. Li Wang and Dr. Behnam Sadeghirad for taking the time to review and critique my thesis. I appreciate Dr. Greg Pond's willingness and interest to be my external committee member. I am grateful for the continued help and support that I received from Mansi, Oluwatoni and Andrew.

Finally, I'd like to thank my parents and siblings for their patience and understanding, and continually believing that I can excel. Without my family, I do not think I could have made it this far.

The following sections of this thesis have been submitted to peer-reviewed journals:

CHAPTER 2: Prevalence of Chronic Non-Cancer Pain among Military Veterans

<u>Title:</u> Prevalence of Chronic Non-Cancer Pain among Military Veterans – A Systematic Review and Meta-Analysis

Submitted to: BMJ Military Health

Status: Under consideration.

<u>**CHAPTER 3**</u>: Research Priorities among Canadian Military Veterans living with Chronic Pain <u>Title:</u> Research Priorities among Canadian Military Veterans living with Chronic Pain: A Cross-Sectional Survey

Submitted to: Military Medical Research

Status: Under consideration.

# LIST OF ABBREVIATIONS

- CNCP = Chronic non-cancer pain
- CI = Confidence interval
- GRADE = Grading of Recommendations, Assessment, Development and Evaluation
- HiREB = Hamilton Integrated Research Ethics Board
- ICEMAN = Instrument to assess the Credibility of Effect Modification Analyses
- IQR = Interquartile range
- PTSD = Post-traumatic stress disorder
- PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- Q = Question
- RCMP = Royal Canadian Mounted Police
- ROB = Risk of bias
- STROBE = Strengthening the Reporting of Observational Studies in Epidemiology
- TBI = Traumatic brain injury
- VA = Veterans Affairs

# **CHAPTER 1 – Thesis Introduction**

#### **1.1 THESIS INTRODUCTION**

Chronic non-cancer pain (CNCP) is defined as pain that persists for  $\geq$ 3 months and is not caused by cancer.<sup>1</sup> CNCP is a pervasive issue that disproportionally affects military veterans in comparison to the general public.<sup>2</sup> A previous systematic review estimated the prevalence of CNCP in military veterans to range from 25% to 72%.<sup>3</sup> However, the data from eligible studies was narratively synthesized, and this review did not attempt to generate a pooled prevalence or explain between-study heterogeneity. Furthermore, the search for this review was conducted up to 2013, and hence needs updating.<sup>3</sup> Therefore, we conducted a systematic review and metaanalysis to explore the prevalence of CNCP among veterans addressing the limitations of the former review. Determining the prevalence of CNCP will help to increase our understanding of the burden of chronic pain among military veterans.

Chronic pain is an important issue for veterans, and research is increasingly being funded to prevent and optimize management of chronic pain. While encouragement of pain research is laudable, a 2010 U.S. study estimated that \$204 billion U.S. dollars directed towards medical research is wasted, and a one reason was the lack of alignment with the needs of patients.<sup>4</sup> Consequently, there is a need for greater involvement of patients in the process of conducting and designing research. A recent qualitative study identified several research priorities of military veterans living with chronic pain;<sup>5</sup> however, the generalizability of these priorities was uncertain. Hence, we conducted a cross-sectional survey to determine the generalizability of identified research priorities among military veterans living with chronic pain. Seeking such priorities from this population will help to ensure that future research aligns with their needs.

Overall, this dissertation aims to provide insight into the following research questions:

- 1. What is the prevalence of CNCP in military veterans?
- 2. What are the research priorities of military veterans living with chronic pain?

# **1.2. REFERENCES**

- <sup>1</sup> Turk, D. C. (2010). Pain terms and taxonomies of pain. *Bonica's Management of Pain*.
- <sup>2</sup> Toblin, R. L., Quartana, P. J., Riviere, L. A., Walper, K. C., & Hoge, C. W. (2014). Chronic pain and opioid use in US soldiers after combat deployment. *JAMA Intern Med*, *174*(8), 1400-1401.
- <sup>3</sup> Van Den Kerkhof, E. G., Carley, M. E., Hopman, W. M., Ross-White, A., & Harrison, M. B. (2014). Prevalence of chronic pain and related risk factors in military veterans: A systematic review. *JBI Evidence Synthesis*, *12*(10), 152-186.
- <sup>4</sup> Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. *The Lancet*, *374*(9683), 86-89.
- <sup>5</sup> Kithulegoda N, Strachan P, Zacharias R, Buckley N, Busse JW. Exploring Canadian Veteran's Priorities Regarding Chronic Pain Research: A Qualitative Study. *Journal of Military, Veteran and Family Health*. 2021. doi.org/10.3138/jmvfh-2021-0045. Online ahead of print.

# CHAPTER 2 – Prevalence of Chronic Non-Cancer Pain among Military Veterans

# 2.1. ABSTRACT

**Introduction:** There is uncertainty in the prevalence of chronic non-cancer pain (CNCP) in military veterans. A systematic review and meta-analysis was conducted to elucidate this issue, and examine potential effect modifiers of CNCP prevalence.

**Methods:** MEDLINE, EMBASE, PsycINFO, CINAHL, Web of Science were searched from 2013 to January 21, 2021, for observational studies reporting "chronic pain" or pain  $\geq$  3 months in military veterans. The random-effects meta-analysis was used for pooling data, the Grading of Recommendations, Assessment, Development and Evaluations approach was used for rating quality of evidence, and the Instrument to Assess the Credibility of Effect Modification Analyses was used to rate credibility of the subgroup analyses.

**Results:** 41 observational studies with 5,550,375 military veterans were included. The overall pooled CNCP prevalence is 34% (95% confidence interval (CI) 25% to 45%). However, significant subgroup effect was found for type of prevalence measure (generic or specific) among military veterans (test of interaction p=0.007, moderate subgroup credibility): the pooled generic CNCP prevalence of 43%, 95% CI 29% to 57% (Low-certainty evidence) vs. the pooled specific type of CNCP prevalence of 14%, 95% CI 6.7% to 23% (Moderate-certainty evidence). A multivariable meta-regression model adjusted for proportion lost to follow-up found the type of prevalence measure to be the only significant predictor of CNCP prevalence (p < 0.0001). **Conclusion:** The overall prevalence of CNCP is 34% among military veterans. For generic CNCP, the prevalence is 43%; for a given subtype of CNCP, the prevalence is 11%. Methodologically robust studies are required to more precisely determine CNCP prevalence.

# **2.2. INTRODUCTION**

Chronic pain is defined as pain persisting for  $\geq$ 3 months.<sup>1</sup> Chronic pain is a pervasive problem among military veterans, as it has a detrimental impact on physical functioning<sup>2</sup> and physical health-related quality of life,<sup>3</sup> and is often comorbid with depression<sup>4</sup> and substance use disorders<sup>5</sup>. While it is known that chronic pain prevalence is generally higher in military veterans than in the general population,<sup>6</sup> an accurate estimate of chronic pain prevalence in military veterans has yet to be determined. A prior review found the CNCP prevalence among veterans to range from 25% to 72%; however, there was no point estimate provided, and the authors did not explore factors associated with the variability between studies using quantitative analytic methods.<sup>7</sup> Furthermore, the search of the prior review was conducted up to 2013 and is therefore in need of updating.<sup>7</sup> The objective of the present systematic review was to expand on the search of the prior review, as well as utilize meta-analyses to explore CNCP prevalence and factors that are associated with the variability in CNCP prevalence among military veterans.

#### 2.3. METHODS

We followed the reporting of Meta-analysis Of Observational Studies in Epidemiology (MOOSE) statement<sup>8</sup> and registered our protocol on the Open Science Framework (<u>https://osf.io/pe52w</u>).

#### 2.3.1. Search strategy

An academic librarian (RC) developed and adapted the search strategies from a prior review on CNCP prevalence in military veterans.<sup>7</sup> We searched MEDLINE, CINAHL, Embase, PsycINFO and Web of Science for articles dating since 2013 to March 30th, 2020. After the publication of

the protocol, the search was updated to encompass articles dating from March 31<sup>st</sup>, 2020 to January 18<sup>th</sup>, 2021. A manual search of reference lists of included studies was conducted to identify additional eligible articles.

#### 2.3.2. Study selection

Two reviewers (AQ and MP) independently screened titles and abstracts of articles retrieved from the results of the search strategy for eligibility. All potentially eligible articles were retrieved in full text and reviewed to confirm eligibility. DistillerSR (Evidence Partners, Ottawa, Canada; <u>http://systematic-review.net</u>) was used to facilitate literature screening. Reviewers resolved any disagreements on study eligibility through discussion or with assistance from an adjudicator (JWB) when required. To assess inter-rater agreement for full-text eligibility, an adjusted kappa was calculated.<sup>9</sup>

#### 2.3.2.1. Inclusion criteria

1. An observational study, including a prospective cohort study, cross-sectional study or retrospective cohort study, that explores the prevalence of CNCP among veterans.

2. Enrolled  $\geq 100$  military veterans.

3. The study is published in the English-language.

#### 2.3.2.2. Exclusion criteria

1. Solely examines a population (or subset) of military veterans that are seeking (or have sought) pain specialty care.

2. Solely examining a population (or subset) of military veterans with CNCP.

MSc. Thesis - A.R. Qureshi; McMaster University - Health Research Methodology

3. Veterans represents less than 80% of a study population unless the results for veterans are reported separately.

4. Conference abstracts, dissertations, letters to the Editor and quality improvement studies.

5. Randomized controlled trials.

6. Case-control studies.

We also excluded studies with  $n \le 100$  participants because smaller studies are more prone to bias, less representative, and these studies likely contribute very little weight to the pooled prevalence analysis.

#### 2.3.3. Data extraction and collection

A piloted electronic data extraction form was utilized. Data extraction was conducted independently by two reviewers. Reviewers resolved discrepancies by discussion, or with the help of a third reviewer if consensus was not achieved. Key variables collected pertain to study information, population characteristics, information concerning the assessment of chronic pain, and risk of bias. The complete list of data collected is available in the "Measured variables" section of the protocol of this review (<u>https://osf.io/pe52w</u>).

### 2.3.3.1. Chronic non-cancer pain

We defined chronic non-cancer pain (CNCP) as pain  $\geq$ 3 months in duration or pain simply defined by authors to be "chronic".<sup>1</sup> All outcome measures for CNCP prevalence were extracted. If the prevalence of CNCP was only reported according to subtypes (e.g., neuropathic), we considered the possibility of clustering in that some veterans may have more than one type of CNCP. Hence, authors were contacted to retrieve a single value for an independent CNCP prevalence. If contacting authors was unsuccessful, then the study was included in the qualitative analysis but not in any quantitative analysis. If a study only reported CNCP prevalence for independent subgroups, then the subgroups were combined to derive an overall CNCP prevalence. Moreover, studies were evaluated in terms of which criteria are met in the definition of primary chronic pain of the International Association for the Study of Pain; these criteria are persistence (pain in  $\geq 1$  more regions for  $\geq 3$  months), emotional distress or functional disability, and pain not being better explained by any other condition.<sup>1</sup>

#### 2.3.4. Risk of bias assessment (ROB)

Pairs of reviewers assessed each eligible study, independently and in duplicate, for the following risk of bias (ROB) items, which are based on the Users' Guide to the Medical Literature. <sup>10</sup> 1. Representativeness of study population: Is the sample representative of a general population of veterans?

2. Validity of outcome measure: Did the authors use a valid outcome measure to assess chronic non-cancer pain (CNCP) prevalence?

3. Risk of under-reporting bias: Was each participant systematically approached, asked or assessed for prevalence of CNCP?

4. Missing data: What is the percentage of missing CNCP prevalence data in this study?  $\geq 20\%$  missing data was considered as high ROB.

# 2.3.5. Data synthesis and analysis

A random-effects model was used to pool CNCP prevalence with an associated 95% confidence interval (CI),<sup>11</sup> after performing a Freeman-Tukey double arcsine transformation to stabilize the variance.<sup>12</sup> The DerSimonian and Laird method was used to compute the pooled prevalence estimates based on the transformed values and variances,<sup>13</sup> and subsequently the harmonic means of sample sizes for the back-transformation to the original units of proportions.<sup>14</sup> Subgroup analyses were only conducted if there were  $\geq 2$  studies within each subgroup.

### 2.3.5.1 Subgroup analyses, meta-regression, and sensitivity analyses

We examined heterogeneity for our pooled estimate through visual inspection of the forest plot and  $\tau^2$  (Tau<sup>2</sup>), as the I-squared and chi-squared tests of heterogeneity can be misleading when studies have large sample sizes and associated measures of precision are therefore very narrow.<sup>15,16</sup>  $\tau$  represents the standard deviation of the effects between studies and has the same units as the pooled variable (in our case, percentage).<sup>11</sup> Heterogeneity is considerable if the range of the pooled estimate  $\pm 2 \tau$  is too broad.<sup>17</sup>

We generated the following *a priori* subgroup hypotheses to explain variability between studies, assuming a higher prevalence of CNCP with: (i) smaller (n < 1000) vs larger (n > 1000) studies, (ii) female vs male veterans, (iii) patient-reported vs clinician-assessed CNCP, (iv) low threshold [e.g., any pain] vs high threshold [e.g., moderate to severe pain] for defining CNCP, and (v) high vs low risk of bias (ROB) on a criterion-by-criterion basis. Subgroup analyses were only conducted if there were  $\geq 2$  studies within each subgroup.

We also performed a *post hoc* subgroup hypothesis to explain variability between studies, assuming a higher prevalence of CNCP with studies reporting a generic CNCP prevalence *vs* a subtype of CNCP prevalence.

We performed univariable meta-regression to explore the association between proportion lost to follow-up with the prevalence of CNCP. Additionally, we expanded this meta-regression to a multivariable meta-regression by adding in any subgrouping variables that were statistically significant.

The credibility of the subgroup analyses and the meta-regression was assessed using the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) criteria.<sup>19</sup>

We performed a sensitivity analysis to examine the impact of logit transformation instead of the Freeman-Tukey double arcsine transformation on the pooled prevalence of CNCP.<sup>16</sup> All statistical analyses were conducted using R version 4.0.3 and RStudio version 1.3.1093 (R Core Team, Vienna, Austria). All comparisons were two-tailed, with a threshold p of 0.05.

#### 2.3.6. Certainty of evidence

The pooled estimates from the meta-analyses of the included studies were evaluated for their quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework (**Table 1**).<sup>20</sup>

#### 2.3.7 Small-study effects

Publication bias was assessed through the visual inspection of a funnel plot, as well as using Begg's test.<sup>21</sup>

#### 2.4. RESULTS

#### 2.4.1. Study characteristics

MSc. Thesis – A.R. Qureshi; McMaster University – Health Research Methodology

Of 4,628 potentially eligible articles, 41 studies with 5,805,656 veterans met the eligibility criteria,<sup>22-62</sup> (Figure 1; Supplementary Material 2 and 3). From the prior review, six out of the eleven studies were eligible (Supplementary Material 4). There was near-perfect agreement between the two reviewers for full-text screening ( $\kappa = 0.83$ ). The median sample size was 3,150 (IQR = 458 – 116,913), and the median of the mean age was 54.8 years (IQR = 40.2 – 63.4 years). The median proportion of military veterans lost to follow-up was 6.81% (IQR = 0% - 31.7%). Five studies (12.2%)<sup>23,41,45,53,56</sup> clearly defined CNCP prevalence as pain persisting for  $\geq$ 3 months. (Supplementary Material 5).



Figure 1. A flow chart of included and excluded studies.

# 2.4.2. Risk of bias

Most of the studies (29/41 or 70.7%) were at high risk of bias (ROB) for the representativeness of the sample to the general population,  $^{22,24-27,32,34-36,39-42,44-54,56,57,59-61}$  mainly due to selective sampling of veterans with specific conditions or diseases. In particular, there was selective recruitment of veterans who underwent surgery,  $^{24,27,35,36,41,48,49,53}$ , veterans who had  $\geq 1$ musculoskeletal disorder(s),  $^{34}$  and veterans with conditions that are associated with chronic pain,  $^{22,26,32,39,40,42,44-47,50,52,54,56,57,59-61}$  such as alcohol use disorder,  $^{63}$  depression,  $^{64}$  Gulf war illness,  $^{65}$  hepatitis C,  $^{66}$  homelessness,  $^{67}$  obstructive sleep apnea,  $^{68}$  opioid therapy,  $^{69}$  posttraumatic stress disorder,  $^{70}$  schizophrenia,  $^{71}$  sex,  $^{72}$  spinal cord disorder or injury,  $^{73}$  substance use disorder,  $^{74}$  and traumatic brain injury  $^{70}$ . Most of the studies (26/41 or 63.4%) also have a high ROB rating for the domain of outcome measurement validity.  $^{22,24-27,32,34-36,38,40-45,47-50,53,57,59-62}$ More than half of the studies (23/41 or 56.1%) are at low ROB for the risk of underreporting.  $^{22,23,25,26,28-31,37,39,43,45,46,48,51,52,55-60,62}$  Majority of the studies (23/41 or 56.1%) had  $\leq 20\%$ missing data for CNCP, and hence were at low ROB for this domain, (**Supplementary Material 6**)  $^{23,25,26,29,30,33,34,36,38,40,41,42,44,47,48,50,51,53,54,57,59-61}$ 

# 2.4.3. Overall analysis

The pooled CNCP prevalence from 41 studies<sup>22-62</sup> is 34.2% (95% CI 24.5% 44.6%: n = 5,805,656).

#### 2.4.4. Subgroup analyses

### 2.4.4.1. A priori subgroup analyses

There were no significant effects for subgroup differences with respect to sex, study size, any of the four ROB items, pain threshold, or pain reporting method (**Supplementary Materials 8-15**). The credibility of these *a priori* subgroup analyses was low (**Supplementary Material 7**).

# 2.4.4.2. Post hoc subgroup analyses

A significant subgroup effect was found for the type of CNCP prevalence measure used in the studies (p = 0.0007). The credibility of the subgroup analysis was judged to be moderate, and hence the effects of the subgroups were considered, (**Supplementary Material 7**). Low quality evidence from 30 studies<sup>22-24,28,30-33,35-39,43-46,48-58,60,62</sup> citing a generic CNCP prevalence suggested a pooled CNCP prevalence of 42.7% (95% CI 28.7% to 57.4%; n = 1,345,054). Moderate quality evidence from 11 studies<sup>25-27,29,34,40-42,47,59,61</sup> citing a specific CNCP prevalence suggested a pooled CNCP prevalence of 14.0% (95% CI 6.70% to 23.3%; n = 4,205,321), (**Figure 2**).

Study						
or Subgroup	Events	Total	Weight	IV, Random, 95% Cl		
Generic CNCP		Total	noight	10,114114011,007001		
Adams 2015	102	175	2.4%	58.3% [50.6%, 65.7%]		_
Barry 2003	263	1045	2.4%	25.2% [22.6%, 27.9%]		
Bishop 2020	5607	18940	2.4%	29.6% [29.0%, 30.3%]		
Crosby 2006	30	114	2.4%	26.3% [18.5%, 35.4%]		
Dobscha 2009	86726	251691	2.4%	34.5% [34.3%, 34.6%]		
Donaldson 2018	749	1818	2.4%	41.2% [38.9%, 43.5%]		<b>.</b>
Figoni 2015	85	178	2.4%	47.8% [40.2%, 55.4%]		
0						_ :
Gironda 2006	219	970	2.4%	22.6% [20.0%, 25.3%]		
Graham 2019	8385	280681	2.4%	3.00% [2.90%, 3.10%]	1	
Hadlandsmyth 2018	2943	6653	2.4%	44.2% [43.0%, 45.4%]		
Hall 2020	1124	2755	2.4%	40.8% [39.0%, 42.7%]	_	
Haskell 2009	3427	16611	2.4%	20.6% [20.0%, 21.3%]		•
Hendrikx 2020	159	383	2.4%	41.5% [36.5%, 46.6%]		
Kerns 2003	332	685	2.4%	48.5% [44.7%, 52.3%]		
Lagisetty 2019	398452	485513	2.4%	82.1% [82.0%, 82.2%]		
Lei 2019	237	367	2.4%	64.6% [59.4%, 69.5%]		
Mancuso 2020	558	996	2.4%	56.0% [52.9%, 59.1%]		
Mudumbai 2016	25870	49812	2.4%	51.9% [51.5%, 52.4%]		•
Mudumbai 2019	5316	5514	2.4%	96.4% [95.9%, 96.9%]		
Powell 2015	65	171	2.4%	38.0% [30.7%, 45.7%]		- <b></b> -
Reid 2002	297	516	2.4%	57.6% [53.2%, 61.9%]		
Riggs 2020	2161	5694	2.4%	38.0% [36.7%, 39.2%]		+
Rozet 2014	44	102	2.4%	43.1% [33.4%, 53.3%]		
Seal 2017	66966	116913	2.4%	57.3% [57.0%, 57.6%]		
Stroupe 2013	91	458	2.4%	19.9% [16.3%, 23.8%]	-	-
Suri 2019	110	220	2.4%	50.0% [43.2%, 56.8%]		
Tsai 2015	34582	89142	2.4%	38.8% [38.5%, 39.1%]		
VanDenKerkhof 2015	1293	3150	2.4%	41.0% [39.3%, 42.8%]		
Wallace 2019	340	630	2.4%	54.0% [50.0%, 57.9%]		
Ziobrowski 2017	596	3157	2.4%	18.9% [17.5%, 20.3%]		
Total [95% CI]	647129	1345054	73.1%	42.7% [28.7%, 57.4%]		
Heterogeneity: $Tau^2 = 1674$	04/120	1040004	/0.1/0	42.1 /0 [20.1 /0; 01.4 /0]		
fictorogeneity. Tuu = 1014						
Specific CNCP						
Burgess 2013	131778	296918	2.4%	44.4% [44.3%, 44.6%]		
Cichowski 2017	94398	516950	2.4%	18.3% [18.2%, 18.4%]		
	29080	89995	2.4%			
Copeland 2014 DeBeer 2017	1124	2755	2.4%	32.3% [32.0%, 32.6%]		·
	91			40.8% [39.0%, 42.7%]		-
Goulet 2016	1293	458	2.4%	19.9% [16.3%, 23.8%]	i i	
Ho 2018		3150	2.4%	41.0% [39.3%, 42.8%]	•	1
Huerta 2016	596	3157	2.4%	18.9% [17.5%, 20.3%]		
Kalpakci 2016	6228	345204	2.4%	1.80% [1.80%, 1.80%]		1
Mathew 2016	13936	618565	2.4%	2.30% [2.20%, 2.30%]		
Vidakovic 2016	59	101	2.4%	58.4% [48.2%, 68.1%]		
Yoon 2015	12889	309374	2.4%	4.20% [4.10%, 4.20%]	-	_
Total [95% CI]	315461	4205321	26.9%	14.0% [6.70%, 23.3%]		
Heterogeneity: Tau <sup>2</sup> = 413						
						:
Total [95% CI]	962590	5550375	100.0%	34.2% [24.5%, 44.6%]		
Test for subgroup interaction:	p = 0.0007					
					0 0	.2 0.4 0.6 0.8 1

**Figure 2.** Subgroup analysis of CNCP prevalence with respect to the type of CNCP prevalence measure. CI = confidence interval; CNCP = chronic non-cancer pain; IV = inverse variance.

# 2.4.4.3 Small-study effects

For the Generic CNCP prevalence subgroup, Begg's test is statistically significant (p =

0.008), and the funnel plot is asymmetric, (Supplementary Material 16). For the Specific

CNCP prevalence subgroup, Begg's test is *not* statistically significant (p = 0.1), and the funnel

plot is roughly symmetric (Supplementary Material 17).

Outcome	Analysis	No. of	Total No. of	Quality assessment						Summary of findings		
		studies	participant	<b>Risk of bias</b>	Risk of bias Inconsistency Indirectnes Imprecisio		Small- Overall quality		Absolute effect			
			S			S	n	study	of evidence	Prevalence (%)	95% CI	
								effects			(%)	
CNCP	Prevalence	30	1,345,054	No serious	Serious	No serious	No serious	Detected;	Low	42.8	28.7 - 57.4	
Prevalence	Type:			risk of bias <sup>1</sup>	inconsistency <sup>2</sup>	indirectness	imprecision <sup>4</sup>	asymmetric				
	Generic				; $\tau = 40.9$	3	_	funnel plot,				
								Begg's test:				
								p = 0.008.				
CNCP	Prevalence	11	4,205,321	No serious	Serious	No serious	No serious	Not	Moderate	14.0	6.71 - 23.3	
Prevalence	Type:			risk of bias <sup>1</sup>	inconsistency <sup>2</sup>	indirectness	imprecision4	detected;				
	Specific				; $\tau = 20.3$	3	_	roughly				
	_							symmetric				
								funnel plot,				
								Begg's test:				
								p = 0.1.				

Table 1. GRADE table with summary of findings.

\* GRADE = Grading of Recommendations, Assessment, Development and Evaluation; CNCP = Chronic non-cancer pain; 95% CI = 95% confidence interval; No. = Number. GRADE is herein reported for only those analyses that have shown at least moderate credibility for subgroup effects, according to the Instrument for assessing the Credibility of Effect Modification Analyses (ICEMAN) criteria. Since the subgroup effects were credible, the pooled estimate from the overall analysis is not evaluated through GRADE. <sup>1</sup> We did not rate down for risk of bias due to there being no significant subgroup differences for any of the four ROB items.

<sup>2</sup> We did rate down for inconsistency as the pooled estimate  $\pm 2\tau$  created a very broad range for both subgroups. For the "Generic" subgroup,  $42.8\% \pm 2 * 40.9\% = 0\%$  to 100%, which is very broad. For the "Specific" subgroup,  $14.0\% \pm 2 * 20.3 = 0\%$  to 54.6%, which is also very broad.

<sup>3</sup> While the majority (>50%) of the studies did use a clinician-assessed method for CNCP prevalence, we did not rate down for indirectness due to there being no significant subgroup differences for pain reporting subgroup analysis.

<sup>4</sup> We did not rate down for imprecision as no threshold is specified, and we wished to not double count with any rating decisions for inconsistency.

# 2.4.5. Meta-regression

The random-effects meta-regression model using the predictor variable of proportion lost to follow-up and the dependent variable of CNCP prevalence was statistically significant (p = 0.001, n = 35 studies<sup>23,25,26,28-34,36-42,44,46-62</sup>), (**Supplementary Material 18 and 19**). For every 1% increase in proportion lost to follow-up, CNCP prevalence increases by 35.4% (95% CI 13.7% to 57.1%). After adding in type of prevalence measure, which is the only effect modifier with a statistically significant test of interaction, the random-effects meta-regression only found type of prevalence measure to be statistically significant in predicting CNCP prevalence (p < 0.0001, n = 35 studies<sup>23,25,26,28-34,36-42,44,46-62</sup>). The model estimates that, compared to the Generic CNCP prevalence subgroup, the Specific CNCP prevalence subgroup has a lower CNCP prevalence by 30.7% (95% CI 35.0% to 26.2%), (**Supplementary Material 19**).

### 2.4.6. Sensitivity analysis

A sensitivity analysis that used logit transformation pooled all 41 studies (n = 5,550,375)<sup>22-62</sup> and found a CNCP prevalence of 39.5% (95% CI 32.8% to 46.6%),

(Supplementary Material 20 and 21).

# **2.5. DISCUSSION**

#### 2.5.1. Main findings

Moderate quality evidence suggests that prevalence of subtypes of CNCP among military veterans is 14% (95% CI 6.7% to 57%). Low quality evidence suggests that the prevalence of CNCP in general among military veterans is 43% (95% CI 29% to 57%). For either subgroup, there was high variability, as all included studies were contained within a very broad range. After

adjusting for proportion lost to follow-up, type of CNCP prevalence measure remained as a significant predictor of CNCP prevalence.

Risk of bias, sex, pain threshold, pain reporting method and study size were not found to be credible effect modifiers for CNCP prevalence.

# 2.5.2. Relations to the literature and implications

The prior systematic review posited a range of 25% to 72% for CNCP prevalence. <sup>9</sup> The present review however found a point estimate of general CNCP prevalence of 43%, and 14% for subtypes of CNCP prevalence. While the variability of the estimates in the former review spanned 47% (i.e., 72%-25% = 47%), our general CNCP prevalence estimates found a larger variation of 93% between studies of lowest and highest CNCP prevalence in the meta-analysis. Moreover, while our review adapted its search strategy from this prior review, <sup>9</sup> five studies in that review did not meet our eligibility criteria. It is likely that the range for CNCP prevalence from the prior review was distorted, as it included studies with prevalence measures for which acute and chronic pain could not be clearly differentiated, and studies that did not report a measure that was aimed at measuring CNCP prevalence.

Furthermore, the prior systematic review did not report a point estimate for CNCP prevalence,<sup>7</sup> while the meta-analysis herein found an estimate at roughly 43%. The prior review did not pool data due to variation in pain measurements.<sup>7</sup> However, we found that even features of the pain measurement such as the pain reporting method and threshold could not explain for the variation found in CNCP prevalence.

### 2.5.3. Strengths and limitations

## MSc. Thesis - A.R. Qureshi; McMaster University - Health Research Methodology

This review has several strengths. This is the first review to quantitatively examine CNCP prevalence via meta-analyses. Inherent variability in prevalence estimates was considered, and hence the Freeman-Tukey double arcsine transformation was used to stabilize the variance. Furthermore, this is the first review to quantitatively examine promising effect modifiers for explaining the variability in CNCP prevalence among military veterans. Moreover, a carefully selected eligibility criteria helped to isolate prevalence estimates that pertain to CNCP. In addition, given the distortion of the I<sup>2</sup> from having large sample sizes per study,<sup>15-17</sup> visual inspection and  $\tau$  was used as the metric for examining heterogeneity. From this, we were able to comprehend the variability of the point estimates more accurately between studies. Finally, the eligibility criteria were broad enough such that it enhances the generalizability of the results to various samples of military veterans.

There are some limitations with this systematic review. Our meta-regression did not incorporate other variables that may be associated with CNCP prevalence, such as mental illness and age. Further, although there are other potential subgroup hypotheses we could have explored, we restricted our exploration of factors associated with between study variability to reduce the risk of spurious associations.<sup>19</sup>

# 2.5.4. Future directions

To retrieve a more precise pooled prevalence estimate of CNCP among military veterans, future studies pursuing this endeavor need to enhance their research methodology. CNCP should be measured in a representative sample using the definition from the International Association for the Study of Pain,<sup>1</sup> be patient-reported, and be systematically assessed in every participant recruited in the study. Furthermore, considering that nearly 30% of the studies in our review had

proportion of lost to follow up of  $\geq 20\%$ , surveying procedures need to ensure participant retention.

#### 2.5.5. Conclusions

Moderate quality evidence suggests that among military veterans, the prevalence of a given subtype of CNCP among military veterans is 14%. Low quality evidence suggests that the CNCP prevalence in general among military veterans is 43%. Methodologically robust studies are required to more precisely determine CNCP prevalence.

### **2.6. REFERENCES**

- Treede RD, Rief W, Barke A, *et al.* Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). *Pain* 2019;160(1):19–27.
- Helmer DA, Chandler HK, Quigley KS, Blatt M, Teichman R, Lange G. Chronic widespread pain, mental health, and physical role function in OEF/OIF veterans. *Pain Med* 2009;10(7):1174–82.
- 3. Thompson J, Hopman W, Sweet J, *et al.* Health-related quality of life of Canadian Forces veterans after transition to civilian life. *Can J Public Health* 2013;104(1):e15–21.
- Runnals JJ, Van Voorhees E, Robbins AT, *et al.* Self-reported pain complaints among Afghanistan/Iraq era men and women veterans with comorbid posttraumatic stress disorder and major depressive disorder. *Pain Med* 2013;14(10):1529–33.

- Caldeiro RM, Malte CA, Calsyn DA, *et al.* The association of persistent pain with outpatient addiction treatment outcomes and service utilization. *Addiction* 2008;103(12):1996–2005.
- Nahin RL. Severe pain in veterans: The effect of age and sex, and comparisons with the general population. *J Pain* 2017;18(3):247–54.
- Van Den Kerkhof EG, Carley ME, Hopman WM, Ross-White A, Harrison MB.
  Prevalence of chronic pain and related risk factors in military veterans: A systematic review. *JBI Evid Synth* 2014;12(10):152–86.
- Stroup DF, Berlin JA, Morton SC, *et al.* Meta-analysis of observational studies in epidemiology: a proposal for reporting. *JAMA* 2000;283(15):2008–12.
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;159–74.
- Guyatt G, Rennie D, Meade M, Cook D, editors. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press; 2002 Feb 1.
- Higgins JP, Thomas J, Chandler J, *et al.* Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019 Sep 23.
- 12. Freeman MF, Tukey JW. Transformations related to the angular and the square root. *Ann Math Stat* 1950;607–11.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177–88.
- Miller JJ. The inverse of the Freeman–Tukey double arcsine transformation. *Am Stat* 1978;32(4):138.

- 15. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I 2 in assessing heterogeneity may mislead. *BMC Med Res Methodol* 2008;8(1):1–9.
- 16. Iorio A, Spencer FA, Falavigna M, *et al.* Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ* 2015;350.
- 17. Serghiou S, Goodman SN. Random-effects meta-analysis: summarizing evidence with caveats. *JAMA* 2019;321(3):301–2.
- Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health 2013;67(11):974–8.
- Schandelmaier S, Briel M, Varadhan R, *et al.* Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. *CMAJ* 2020;192(32):E901–6.
- 20. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J. GRADE guidelines: introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64(4):383–94.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;1088–101.
- 22. Adams MH, Lovejoy TI, Turk DC, Dobscha SK, Hauser P, Morasco BJ. Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C. *Gen Hosp Psychiatry* 2015;37(6):533–7.
- 23. Barry LC, Guo Z, Kerns RD, Duong BD, Reid MC. Functional self-efficacy and painrelated disability among older veterans with chronic pain in a primary care setting. *Pain* 2003;104(1-2):131–7.

- Bishop MO, Bayman EO, Hadlandsmyth K, Lund BC, Kang S. Opioid use trajectories after thoracic surgery among veterans in the United States. *Eur J Pain* 2020;24(8):156– 84.
- 25. Burgess DJ, Gravely AA, Nelson DB, *et al.* A national study of racial differences in pain screening rates in the VA health care system. *Clin J Pain* 2013;29(2):118–23.
- 26. Cichowski SB, Rogers RG, Clark EA, Murata E, Murata A, Murata G. Military sexual trauma in female veterans is associated with chronic pain conditions. *Mil Med* 2017;182(9-10):e1895–9.
- 27. Copeland LA, McIntyre RT, Stock EM, Zeber JE, MacCarthy DJ, Pugh MJ. Prevalence of suicidality among Hispanic and African American veterans following surgery. *Am J Public Health* 2014;104(S4):S603–8.
- Crosby FE, Colestro J, Ventura MR, Graham K. Survey of pain among veterans in Western New York. *Pain Mang Nurs* 2006;7(1):12–22.
- 29. DeBeer BB, Davidson D, Meyer EC, Kimbrel NA, Gulliver SB, Morissette SB. The association between toxic exposures and chronic multisymptom illness in Veterans of the Wars of Iraq and Afghanistan. *J Occup Environ Med* 2017;59(1):54.
- 30. Dobscha SK, Soleck GD, Dickinson KC, *et al.* Associations between race and ethnicity and treatment for chronic pain in the VA. *J Pain* 2009;10(10):1078–87.
- 31. Donaldson MT, Polusny MA, MacLehose RF, et al. Patterns of conventional and complementary non-pharmacological health practice use by US military veterans: a cross-sectional latent class analysis. BMC Complement Altern Med 2018;18(1):246.
- 32. Fassio V, Aspinall SL, Zhao X, *et al.* Trends in opioid and nonsteroidal antiinflammatory use and adverse events. *Am J Manag Care* 2018;24(3):e61–72.

- Figoni SF, Chen LK. Cardiovascular Characteristics of SCI/D Outpatients Referred to a Kinesiotherapy Wellness Exercise Program. *Clin Kinesiol* 2015;3(69):11–20.
- 34. Gironda RJ, Clark ME, Massengale JP, Walker RL. Pain among veterans of operations enduring freedom and Iraqi freedom. *Pain Med* 2006 Jul 1;7(4):339–43.
- 35. Goulet JL, Kerns RD, Bair M, Becker W, Brennan P, Burgess DJ, Carroll C, Dobscha S, Driscoll M, Fenton BT, Fraenkel L. The musculoskeletal diagnosis cohort: examining pain and pain care among veterans. *Pain* 2016;157(8):1696–703.
- 36. Graham LA, Wagner TH, Richman JS, Morris MS, Copeland LA, Harris AH, Itani KM, Hawn MT. Exploring Trajectories of Health Care Utilization Before and After Surgery. J Am Coll Surg 2019;228(1):116–28.
- 37. Hadlandsmyth K, Vander Weg MW, McCoy KD, Mosher HJ, Vaughan-Sarrazin MS, Lund BC. Risk for prolonged opioid use following total knee arthroplasty in veterans. J Arthoplasty 2018;33(1):119–23.
- 38. Hall AL, Sweet J, Tweel M, MacLean MB. Comparing negative health indicators in male and female veterans with the Canadian general population. *BMJ Mil Health* 2020;0:1–6.
- 39. Hendrikx LJ, Murphy D. Understanding the link between traumatic brain injury accompanied by loss of consciousness and well-being: a sample of UK military veterans. *J Head Trauma Rehabil* 2021;36(1):34–43.
- 40. Ho P, Rosenheck R. Substance use disorder among current cancer patients: Rates and correlates nationally in the Department of Veterans Affairs. *Psychosomatics* 2018;59(3):267–76.

- 41. Huerta S, Patel PM, Mokdad AA, Chang J. Predictors of inguinodynia, recurrence, and metachronous hernias after inguinal herniorrhaphy in veteran patients. *Am J Surg* 2016;212(3):391–8.
- 42. Kalpakci A, Sofuoglu M, Petrakis I, Rosenheck RA. Gender differences among Veterans with alcohol use disorder nationally in the Veterans Health Administration. *J Addict Dis* 2018;37(3-4):185–94.
- 43. Kerns RD, Otis J, Rosenberg R, Reid MC. Veterans' reports of pain and associations with ratings of health, health-risk behaviors, affective distress, and use of the healthcare system. *J Rehabil Res Dev* 2003;40(5):371–80.
- 44. Lagisetty PA, Lin LA, Ganoczy D, Haffajee RL, Iwashyna TJ, Bohnert AS. Opioid Prescribing After Opioid-related Inpatient Hospitalizations by Diagnosis. *Med Care* 2019;57(10):815–21.
- 45. Lei K, Metzger-Smith V, Golshan S, Javors J, Leung A. The prevalence of headaches, pain, and other associated symptoms in different Persian Gulf deployment periods and deployment durations. *Sage Open Med* 2019;7:2050312119871418.
- 46. Mancuso AC, Summers KM, Mengeling MA, Torner JC, Ryan GL, Sadler AG. Infertility and Health-Related Quality of Life in United States Women Veterans. *J Womens Health* 2020;29(3):412–9.
- 47. Mathew N, Rosenheck RA. Prescription opioid use among seriously mentally ill veterans nationally in the veterans health administration. *Community Ment Health J* 2016;52(2):165–73.

- 48. Mudumbai SC, Oliva EM, Lewis ET, *et al.* Time-to-cessation of postoperative opioids: a population-level analysis of the veterans affairs health care system. *Pain Med* 2016;17(9):1732–43.
- 49. Mudumbai SC, Chung P, Nguyen N, *et al.* Perioperative opioid prescribing patterns and readmissions after total knee arthroplasty in a national cohort of Veterans Health Administration patients. *Pain Med* 2020;21(3):595–603.
- 50. Powell MA, Corbo V, Fonda JR, Otis JD, Milberg WP, McGlinchey RE. Sleep quality and reexperiencing symptoms of PTSD are associated with current pain in US OEF/OIF/OND veterans with and without mTBIs. *J Trauma Stress* 2015;28(4):322–9.
- Reid MC, Crone KT, Otis J, Kerns RD. Differences in pain-related characteristics among younger and older veterans receiving primary care. *Pain Med* 2002;3(2):102–7.
- 52. Riggs KR, Hoge AE, DeRussy AJ, *et al.* Prevalence of and risk factors associated with nonfatal overdose among veterans who have experienced homelessness. *JAMA Netw Open* 2020;3(3):e201190.
- 53. Rozet I, Nishio I, Robbertze R, Rotter D, Chansky H, Hernandez AV. Prolonged opioid use after knee arthroscopy in military veterans. *Anesth Analg* 2014;119(2):454–9.
- 54. Seal KH, Bertenthal D, Barnes DE, Byers AL, Strigo I, Yaffe K, Chronic Effects of Neurotrauma Consortium Study Group. Association of traumatic brain injury with chronic pain in Iraq and Afghanistan veterans: effect of comorbid mental health conditions. *Arch Phys Med Rehabil* 2017;98(8):1636–45.
- 55. Stroupe KT, Smith BM, Hogan TP, *et al.* Medication acquisition across systems of care and patient–provider communication among older veterans. *Am J Health Syst Pharm* 2013;70(9):804–13.

- 56. Suri P, Boyko EJ, Smith NL, *et al.* Post-traumatic stress disorder symptoms are associated with incident chronic back pain: a longitudinal twin study of older male veterans. *Spine* 2019;44(17):1220–7.
- 57. Tsai J, Rosenheck RA, Kasprow WJ, Kane V. Characteristics and use of services among literally homeless and unstably housed US veterans with custody of minor children. *Psychiatr Serv* 2015;66(10):1083–90.
- 58. VanDenKerkhof EG, VanTil L, Thompson JM, *et al.* Pain in Canadian veterans: analysis of data from the survey on transition to civilian life. *Pain Res Manag* 2015;20(2):89–95.
- 59. Vidaković B, Uljanić I, Perić B, Grgurević J, Sonicki Z. Myofascial pain of the head and neck among Croatian war veterans treated for depression and posttraumatic stress disorder. *Psychiatr Danub* 2016;28(1):0–76.
- 60. Wallace DM, Wohlgemuth WK. Predictors of Insomnia Severity Index profiles in United States veterans with obstructive sleep apnea. *J Clin Sleep Med* 2019;15(12):1827–37.
- 61. Yoon G, Petrakis IL, Rosenheck RA. Correlates of major depressive disorder with and without comorbid alcohol use disorder nationally in the veterans health administration. *Am J Addict* 2015;24(5):419–26.
- 62. Ziobrowski H, Sartor CE, Tsai J, Pietrzak RH. Gender differences in mental and physical health conditions in US veterans: Results from the National Health and Resilience in Veterans Study. J Psychosom Res 2017;101:110–3.
- 63. Saba SK, Davis JP, Prindle JJ, Castro CA, Pedersen ER. Associations between symptoms of posttraumatic stress disorder, pain, and alcohol use disorder among OEF/OIF/OND veterans. *Addict Behav* 2021;122:107031.

- 64. Angst F, Benz T, Lehmann S, *et al.* Extended overview of the longitudinal paindepression association: a comparison of six cohorts treated for specific chronic pain conditions. *J Affect Disord* 2020;273:508–16.
- 65. Kang HK, Li B, Mahan CM, Eisen SA, Engel CC. Health of US veterans in 1991 gulf war: a follow-up survey in 10 years. *J Occup Environ Med* 2009;51(4):401–10.
- 66. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. *Am J Gastroenterol Suppl* 1999;94(5):1355–60.
- 67. Bicket MC, Park JN, Torrie A, Allen ST, Weir BW, Sherman SG. Factors associated with chronic pain and non-medical opioid use among people who inject drugs. *Addict Behav* 2020;102:106172.
- 68. Aytekin E, Demir SE, Komut EA, *et al.* Chronic widespread musculoskeletal pain in patients with obstructive sleep apnea syndrome and the relationship between sleep disorder and pain level, quality of life, and disability. *J Phys Ther Sci* 2015;27(9):2951–4.
- 69. Rosenberg JM, Bilka BM, Wilson SM, Spevak C. Opioid therapy for chronic pain: overview of the 2017 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline. *Pain Med* 2018;19(5):928–41.
- 70. Lew HL, Otis JD, Tun C, Kerns RD, Clark ME, Cifu DX. Prevalence of chronic pain, posttraumatic stress disorder, and persistent postconcussive symptoms in OIF/OEF veterans: polytrauma clinical triad. *J Rehabil Res Dev* 2009;46(6).
- 71. Birgenheir DG, Ilgen MA, Bohnert AS, Abraham KM, Bowersox NW, Austin K, Kilbourne AM. Pain conditions among veterans with schizophrenia or bipolar disorder. *Gen Hosp Psychiatry* 2013;35(5):480–4.

- 72. Gaffey AE, Burg MM, Rosman L, *et al.* Baseline characteristics from the Women Veterans Cohort Study: Gender differences and similarities in health and healthcare utilization. *J Womens Health* 2021;30(7):944–955.
- 73. Turner JA, Cardenas DD, Warms CA, McClellan CB. Chronic pain associated with spinal cord injuries: a community survey. *Arch Phys Med Rehabil* 2001;82(4):501–8.
- 74. Morasco BJ, Dobscha SK. Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. *Gen Hosp Psychiatry* 2008;30(2):93–9.

#### 2.7. SUPPLEMENTARY MATERIAL

Supplementary Material 1. Eligible articles (n=41)

- Adams MH, Lovejoy TI, Turk DC, Dobscha SK, Hauser P, Morasco BJ. Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C. *Gen Hosp Psychiatry* 2015;37(6):533–7.
- Barry LC, Guo Z, Kerns RD, Duong BD, Reid MC. Functional self-efficacy and painrelated disability among older veterans with chronic pain in a primary care setting. *Pain* 2003;104(1-2):131–7.
- Bishop MO, Bayman EO, Hadlandsmyth K, Lund BC, Kang S. Opioid use trajectories after thoracic surgery among veterans in the United States. *Eur J Pain* 2020;24(8):156– 84.
- Burgess DJ, Gravely AA, Nelson DB, *et al.* A national study of racial differences in pain screening rates in the VA health care system. *Clin J Pain* 2013;29(2):118–23.
- Cichowski SB, Rogers RG, Clark EA, Murata E, Murata A, Murata G. Military sexual trauma in female veterans is associated with chronic pain conditions. *Mil Med* 2017;182(9-10):e1895–9.

- Copeland LA, McIntyre RT, Stock EM, Zeber JE, MacCarthy DJ, Pugh MJ. Prevalence of suicidality among Hispanic and African American veterans following surgery. *Am J Public Health* 2014;104(S4):S603–8.
- Crosby FE, Colestro J, Ventura MR, Graham K. Survey of pain among veterans in Western New York. *Pain Mang Nurs* 2006;7(1):12–22.
- DeBeer BB, Davidson D, Meyer EC, Kimbrel NA, Gulliver SB, Morissette SB. The association between toxic exposures and chronic multisymptom illness in Veterans of the Wars of Iraq and Afghanistan. *J Occup Environ Med* 2017;59(1):54.
- Dobscha SK, Soleck GD, Dickinson KC, *et al.* Associations between race and ethnicity and treatment for chronic pain in the VA. *J Pain* 2009;10(10):1078–87.
- Donaldson MT, Polusny MA, MacLehose RF, *et al.* Patterns of conventional and complementary non-pharmacological health practice use by US military veterans: a cross-sectional latent class analysis. *BMC Complement Altern Med* 2018;18(1):246.
- 11. Fassio V, Aspinall SL, Zhao X, *et al.* Trends in opioid and nonsteroidal antiinflammatory use and adverse events. *Am J Manag Care* 2018;24(3):e61–72.
- Figoni SF, Chen LK. Cardiovascular Characteristics of SCI/D Outpatients Referred to a Kinesiotherapy Wellness Exercise Program. *Clin Kinesiol* 2015;3(69):11–20.
- Gironda RJ, Clark ME, Massengale JP, Walker RL. Pain among veterans of operations enduring freedom and Iraqi freedom. *Pain Med* 2006 Jul 1;7(4):339–43.
- 14. Goulet JL, Kerns RD, Bair M, Becker W, Brennan P, Burgess DJ, Carroll C, Dobscha S, Driscoll M, Fenton BT, Fraenkel L. The musculoskeletal diagnosis cohort: examining pain and pain care among veterans. *Pain* 2016;157(8):1696–703.

- 15. Graham LA, Wagner TH, Richman JS, Morris MS, Copeland LA, Harris AH, Itani KM, Hawn MT. Exploring Trajectories of Health Care Utilization Before and After Surgery. J Am Coll Surg 2019;228(1):116–28.
- 16. Hadlandsmyth K, Vander Weg MW, McCoy KD, Mosher HJ, Vaughan-Sarrazin MS, Lund BC. Risk for prolonged opioid use following total knee arthroplasty in veterans. J Arthoplasty 2018;33(1):119–23.
- 17. Hall AL, Sweet J, Tweel M, MacLean MB. Comparing negative health indicators in male and female veterans with the Canadian general population. *BMJ Mil Health* 2020;0:1–6.
- Hendrikx LJ, Murphy D. Understanding the link between traumatic brain injury accompanied by loss of consciousness and well-being: a sample of UK military veterans. *J Head Trauma Rehabil* 2021;36(1):34–43.
- Ho P, Rosenheck R. Substance use disorder among current cancer patients: Rates and correlates nationally in the Department of Veterans Affairs. *Psychosomatics* 2018;59(3):267–76.
- Huerta S, Patel PM, Mokdad AA, Chang J. Predictors of inguinodynia, recurrence, and metachronous hernias after inguinal herniorrhaphy in veteran patients. *Am J Surg* 2016;212(3):391–8.
- 21. Kalpakci A, Sofuoglu M, Petrakis I, Rosenheck RA. Gender differences among Veterans with alcohol use disorder nationally in the Veterans Health Administration. *J Addict Dis* 2018;37(3-4):185–94.
- 22. Kerns RD, Otis J, Rosenberg R, Reid MC. Veterans' reports of pain and associations with ratings of health, health-risk behaviors, affective distress, and use of the healthcare system. *J Rehabil Res Dev* 2003;40(5):371–80.
- 23. Lagisetty PA, Lin LA, Ganoczy D, Haffajee RL, Iwashyna TJ, Bohnert AS. Opioid Prescribing After Opioid-related Inpatient Hospitalizations by Diagnosis. *Med Care* 2019;57(10):815–21.
- 24. Lei K, Metzger-Smith V, Golshan S, Javors J, Leung A. The prevalence of headaches, pain, and other associated symptoms in different Persian Gulf deployment periods and deployment durations. *Sage Open Med* 2019;7:2050312119871418.
- 25. Mancuso AC, Summers KM, Mengeling MA, Torner JC, Ryan GL, Sadler AG. Infertility and Health-Related Quality of Life in United States Women Veterans. *J Womens Health* 2020;29(3):412–9.
- 26. Mathew N, Rosenheck RA. Prescription opioid use among seriously mentally ill veterans nationally in the veterans health administration. *Community Ment Health J* 2016;52(2):165–73.
- Mudumbai SC, Oliva EM, Lewis ET, *et al.* Time-to-cessation of postoperative opioids: a population-level analysis of the veterans affairs health care system. *Pain Med* 2016;17(9):1732–43.
- 28. Mudumbai SC, Chung P, Nguyen N, *et al.* Perioperative opioid prescribing patterns and readmissions after total knee arthroplasty in a national cohort of Veterans Health Administration patients. *Pain Med* 2020;21(3):595–603.
- 29. Powell MA, Corbo V, Fonda JR, Otis JD, Milberg WP, McGlinchey RE. Sleep quality and reexperiencing symptoms of PTSD are associated with current pain in US OEF/OIF/OND veterans with and without mTBIs. *J Trauma Stress* 2015;28(4):322–9.
- 30. Reid MC, Crone KT, Otis J, Kerns RD. Differences in pain-related characteristics among younger and older veterans receiving primary care. *Pain Med* 2002;3(2):102–7.

- 31. Riggs KR, Hoge AE, DeRussy AJ, *et al.* Prevalence of and risk factors associated with nonfatal overdose among veterans who have experienced homelessness. *JAMA Netw Open* 2020;3(3):e201190.
- 32. Rozet I, Nishio I, Robbertze R, Rotter D, Chansky H, Hernandez AV. Prolonged opioid use after knee arthroscopy in military veterans. *Anesth Analg* 2014;119(2):454–9.
- 33. Seal KH, Bertenthal D, Barnes DE, Byers AL, Strigo I, Yaffe K, Chronic Effects of Neurotrauma Consortium Study Group. Association of traumatic brain injury with chronic pain in Iraq and Afghanistan veterans: effect of comorbid mental health conditions. *Arch Phys Med Rehabil* 2017;98(8):1636–45.
- 34. Stroupe KT, Smith BM, Hogan TP, *et al.* Medication acquisition across systems of care and patient–provider communication among older veterans. *Am J Health Syst Pharm* 2013;70(9):804–13.
- 35. Suri P, Boyko EJ, Smith NL, *et al.* Post-traumatic stress disorder symptoms are associated with incident chronic back pain: a longitudinal twin study of older male veterans. *Spine* 2019;44(17):1220–7.
- 36. Tsai J, Rosenheck RA, Kasprow WJ, Kane V. Characteristics and use of services among literally homeless and unstably housed US veterans with custody of minor children. *Psychiatr Serv* 2015;66(10):1083–90.
- 37. VanDenKerkhof EG, VanTil L, Thompson JM, *et al.* Pain in Canadian veterans: analysis of data from the survey on transition to civilian life. *Pain Res Manag* 2015;20(2):89–95.
- 38. Vidaković B, Uljanić I, Perić B, Grgurević J, Sonicki Z. Myofascial pain of the head and neck among Croatian war veterans treated for depression and posttraumatic stress disorder. *Psychiatr Danub* 2016;28(1):0–76.

- Wallace DM, Wohlgemuth WK. Predictors of Insomnia Severity Index profiles in United States veterans with obstructive sleep apnea. *J Clin Sleep Med* 2019;15(12):1827–37.
- 40. Yoon G, Petrakis IL, Rosenheck RA. Correlates of major depressive disorder with and without comorbid alcohol use disorder nationally in the veterans health administration. *Am J Addict* 2015;24(5):419–26.
- 41. Ziobrowski H, Sartor CE, Tsai J, Pietrzak RH. Gender differences in mental and physical health conditions in US veterans: Results from the National Health and Resilience in Veterans Study. J Psychosom Res 2017;101:110–3.

**Supplementary Material 2.** Studies excluded for Population Overlap (n=19)

- Agudelo C, Ramos AR, Williams NJ, Wallace DM. Do symptoms of sleepiness and insomnia in US veterans with obstructive sleep apnea vary by age?. *Sleep Breath* 2019;1– 8.
- Birgenheir DG, Ilgen MA, Bohnert AS, *et al.* Pain conditions among veterans with schizophrenia or bipolar disorder. *Gen Hosp Psychiatry* 2013;35(5):480–4.
- Chui PW, Bastian LA, DeRycke E, Brandt CA, Becker WC, Goulet JL. Dual Use of Department of Veterans Affairs and Medicare Benefits on High-Risk Opioid Prescriptions in Veterans Aged 65 Years and Older: Insights from the VA Musculoskeletal Disorders Cohort. *Health Serv Res* 2018;53:5402–18.
- Cichowski SB, Rogers RG, Komesu Y, *et al.* A 10-yr analysis of chronic pelvic pain and chronic opioid therapy in the women veteran population. *Mil Med* 2018;183(11-12):e635–40.

- Driscoll MA, Higgins D, Shamaskin-Garroway A, *et al.* Examining gender as a correlate of self-reported pain treatment use among recent service veterans with deploymentrelated musculoskeletal disorders. *Pain Med* 2017;18(9):1767–77.
- El-Gabalawy R, Blaney C, Tsai J, Sumner JA, Pietrzak RH. Physical health conditions associated with full and subthreshold PTSD in US military veterans: Results from the National Health and Resilience in Veterans Study. *J Affect Disord* 2018;227:849–53.
- Fenton BT, Goulet JL, Bair MJ, Cowley T, Kerns RD. Relationships between temporomandibular disorders, MSD conditions, and mental health comorbidities: findings from the veterans musculoskeletal disorders cohort. *Pain Med* 2018;19(suppl\_1):S618.
- Gibson CJ, Li Y, Bertenthal D, Huang AJ, Seal KH. Menopause symptoms and chronic pain in a national sample of midlife women veterans. *Menopause* 2019;26(7):708–13.
- Gibson CJ, Maguen S, Xia F, Barnes DE, Peltz CB, Yaffe K. Military sexual trauma in older women veterans: prevalence and comorbidities. *J Gen Intern Med* 2020;35(1):207– 13.
- Gressler LE, Martin BC, Hudson TJ, Painter JT. Relationship between concomitant benzodiazepine-opioid use and adverse outcomes among US veterans. *Pain* 2018;159(3):451–9.
- Ilgen MA, Kleinberg F, Ignacio RV, *et al.* Noncancer pain conditions and risk of suicide. JAMA Psychiat 2013;70(7):692–7.
- Lee CJ, Felix ER, Levitt RC, *et al.* Traumatic brain injury, dry eye and comorbid pain diagnoses in US veterans. *Br J Ophthalmol* 2018;102(5):667–73.

- Mosher HJ, Hofmeyer BA, Hadlandsmyth K, Richardson KK, Lund BC. Predictors of long-term opioid use after opioid initiation at discharge from medical and surgical hospitalizations. *J Hosp Med* 2018;13(4):243.
- 14. Outcalt SD, Hoen HM, Yu Z, Franks TM, Krebs EE. Does comorbid chronic pain affect posttraumatic stress disorder diagnosis and treatment? Outcomes of posttraumatic stress disorder screening in Department of Veterans Affairs primary care. *J Rehabil Res Dev* 2016;53(1):37–44.
- 15. Petrakis IL, Sofuoglu M, Rosenheck R. VA patients with high numbers of opioid prescriptions: A national study of sociodemographic and diagnostic characteristics, health service, and psychotropic medication use. *Addict Disord Treat* 2015;14(4):167–75.
- 16. Ryan GL, Mengeling MA, Summers KM, *et al.* Hysterectomy risk in premenopausalaged military veterans: associations with sexual assault and gynecologic symptoms. *Am J Obstet Gynecol* 2016;214(3): 352.e1–352.e13.
- 17. Stefanovics EA, Potenza MN, Pietrzak RH. PTSD and obesity in US military veterans: Prevalence, health burden, and suicidality. *Psychiatry Res* 2020;291:113242.
- Stefanovics EA, Potenza MN, Pietrzak RH. Smoking, obesity, and their co-occurrence in the US military veterans: results from the national health and resilience in veterans study. *J Affect Disord* 2020;274:354–62.
- 19. Thomas MM, Harpaz-Rotem I, Tsai J, Southwick SM, Pietrzak RH. Mental and physical health conditions in US combat veterans: Results from the National Health and Resilience in Veterans Study. *Prim Care Companion CNS Disord* 2017;19(3).

Author	Year	Study Design	Country	Enrollment period	CNCP Prev.	Total eligible	Age mean ± SD /	Gender (%) Male	Population description			Race/Ethnie	city†		
						patients	median (range)			White n (%)	Black n (%)	Hispanic n (%)	Asian n (%)	Other n (%)	Unk. (n%)
Adams	2015	PC	USA	NR	58.3%	175	56.2 (5.80)	93.0	VHA patients with Hepatitis C virus.	123 (70.0%)	25 (14.3%)	NR	NR	NR	NR
Barry	2003	CS	USA	2001	25.2%	1,045	75.4 (5.09)	84.1	VHA patients ≥65 years of age and are receiving primary care at the West Haven campus of the VA Connecticut Healthcare System.	236 (96.3%) §	NR	NR	NR	NR	NR
Bishop	2020	RC	USA	2006 - 2015	29.6%	16,612	NR	96.4	Veterans who underwent thoracic surgery, either thoracotomy or video assisted thoracoscopic surgery (VATS), at a VHA facility from January 1, 2006 through September 30, 2015.	12,766 (76.8%)	2,525 (15.2%)	NR	NR	NR	1,093 (6.58 %)
Burgess	2013	CS	USA	2007	44.4%	542,422	NR	93.8	A sample of VA patients from the 2007 Survey of Health Care Experiences of Patients – ambulatory care module.	220,122 (40.6%)	25,382 (4.68%)	NR	NR	NR	51,414 (9.48 %)
Cichowski	2017	RC	USA	1997 – 2017	40.9%	516,950	65.4 (18.3)	0.00	Veterans in the VHA with an alcohol use disorder diagnosis.	NR	NR	28,581 (5.53%)	NR	NR	51,813 (10.0 %)
Copeland	2014	RC	USA	2005 - 2006	31.3%	179,990	63.4 (5.96)	95.4	VHA patients who experienced inpatient surgical treatment from fiscal year 2006 (FY2006; October 1, 2005, to September 30, 2006) to FY2009.	NR	NR	5,251 (5.83%)	NR	NR	NR
Crosby	2006	CS	USA	NR	26.3%	114	67.1 (3.06)	90.4	Veterans registered at two primary clinics in the Veterans Administration Western New York Healthcare System.	NR	NR	NR	NR	NR	NR
DeBeer	2017	PC	USA	NR	0.482 %	224	36.6 (9.09)	66.1	Veterans who served in support of the wars in Iraq of Afghanistan after September 11, 2001.	132 (58.9%)	75 (33.5%)	NR	NR	NR	NR

Supplementary Material 3. Baseline characteristics of the eligible studies (n = 41).\*

Dobscha	2009	RC	USA	2004 - 2005	34.5%	251,691	67.4 (0.424)	96.4	VHA patients who participated in the national VA survey of the Health Experiences of Patients (SHEP) for fiscal year 2005 (FY2005; October 1, 2004 to September 30, 2005).	215,979 (84.5%)	15,110 (5.91%)	11,033 (4.32%)	NR	8,187 (3.20 %)	NR
Donaldson	2018	CS	USA	2015 - 2016	41.2%	1,850	38.7 (9.20)	90.2	Minnesota military veterans from the Readiness and Resilience in National Guard Soldiers study.	1,656 (89.5%)	NR	NR	NR	NR	NR
Figoni	2015	RC	USA	2013 & 2014	47.8%	178	64.0 (12.0)	94.0	Adult veteran outpatients with spinal cord injury (or disorder) referred for a kinesiotherapy wellness exercise program.	96 (53.9%)	52 (29.2%)	25 (14.0%)	NR	NR	NR
Gironda	2006	RC	USA	2001 - 2004	22.6%	970	31.4 (8.47)	93.0 ¶	Veterans of the Operations Enduring Freedom and Iraqi Freedom and are seeking treatment in a Southeastern VA medical center.	49 (60.0%)	15 (18.0%)	18 (22.0%)	NR	NR	NR
Goulet	2016	RC	USA	2001 - 2011	2.70%	5,237,85 3	NR	93.8	All veterans that have ≥1 musculoskeletal disorder diagnosis.	3,854,51 3 (72.9%)	804,834 (15.2%)	245,420 (4.64%)	NR	NR	NR
Graham	2019	RC	USA	2007 - 2014	2.99%	280,681	63.4 (11.6)	93.5	VHA patients undergoing non-cardiac inpatient surgery.	214,830 (76.5%)	49,257 (17.5%)	NR	NR	NR	11,484 (4.09 %)
Hadlandsmyth	2018	RC	USA	2013 - 2015	44.2%	13,306	NR	93.0	Veterans who underwent total knee arthroplasty.	5,196 (78.1%)	929 (14.0%)	NR	NR	NR	384 (5.77 %)
Hall	2020	CS	Canada	2016	40.8%	2,755	NR	87.6	Veterans that were released from the Canadian Regular Forces between 1998 and 2015.	NR	NR	NR	NR	NR	NR
Haskell	2009	RC	USA	2001 - 2008	20.6%	16,611	32.3 (0.0700)	87.9	Veterans who were discharged from the military from October 1, 2001 to November 30, 2007 and enrolled in VA services OR received VA care prior to January 1, 2008, made ≥1 VA visit	102,606 (67.0%)	24,732 (16.1%)	17,894 (11.7%)	NR	4,113 (2.68 %)	3,867 (2.52 %)

									in the year after their discharge.						
Hendrikx	2020	CS	UK	2015 - 2016	41.5%	383	NR	95.8	Veterans recruited from Combat Stress, the largest UK charity offering treatment to veterans seeking mental health support.	NR	NR	NR	NR	NR	NR
Но	2018	CS	USA	2011 - 2012	1.61%	917,377	62.7 (6.28)	96.6	Veterans currently in treatment for cancer	NR	NR	NR	NR	NR	NR
Huerta	2016	RC	USA	2005 - 2015	18.9%	874	60.4 (12.4)	99.0	Veteran patients that underwent inguinal herniorrhaphy	638 (73.0%)	192 (22.0%)	44 (5.03%)	NR	NR	NR
Kalpakci	2018	RC	USA	2011 - 2012	1.80%	345,204	53.0	50.0	Veterans in VHA with a diagnosis of alcohol use disorder.	NR	77,703 (22.5%)	NR	NR	NR	NR
Kerns	2003	CS	USA	1996 – 1997	48.5%	685	65.6 (12.3)	96.5	Veterans from a primary care practice in the West Haven campus of the VA Connecticut Healthcare System.	NR	NR	NR	NR	NR	NR
Lagisetty	2019	RC	USA	2011 - 2014	82.1%	485,513	NR	91.9	VHA patients hospitalized between fiscal years 2011 and 2014 and had ≥1 prescription opioid medication filled through the VA pharmacy within 6 months before hospitalization.	355,894 (73.3%)	92,759 (19.1%)	25,205 (5.19%)	NR	NR	NR
Lei	2019	RC	USA	2013 - 2015	64.6%	367	62.7 (6.28)	90.1	Veterans who had a documented Gulf War Registry computerized medical record note between Jul 2013 and Jun 2015.	178 (48.5%)	67 (18.3%)	79 (21.5%)	47 (12.8 %)	NR	NR
Mancuso	2020	CS	USA	2005 - 2008	56.0%	996	38.9 (5.95)	0.00	Female veterans enrolled in the VHA.	NR	NR	NR	NR	NR	NR
Mathew	2016	RC	USA	2011 - 2012	2.25%	618,565	54.5 (9.49)	90.6	All veterans who attended at least one outpatient visit during fiscal year 2012	NR	NR	NR	NR	NR	NR
Mudumbai	2016	RC	USA	2011	51.9%	49,812	NR	93.9	All VHA patients who underwent surgery in 2011	NR	NR	NR	NR	NR	NR
Mudumbai	2019	RC	USA	2010 - 2011	96.4%	5,514	NR	94.3	All VHA patients who underwent total knee	4,450 (80.7%)	929 (16.8%)	NR	44	65	NR

									arthroplasty over one fiscal year across VHA hospitals nationwide.				(0.798 %)	(1.18 %)	
Powell	2015	CS	USA	NR	38.0%	171	33.3 (8.56)	86.5	Veterans enrolled in the Veterans Affairs Center of Excellence	117 (68.4%)	18 (10.5%)	29 (17.0%)	NR	NR	NR
Reid	2002	PC	USA	1997 – 1998	57.6%	1,290	NR	NR	Veterans enrolled in the primary care practice at VA Connecticut Healthcare System, West Haven, Connecticut.	NR	NR	NR	NR	NR	NR
Riggs	2020	PC	USA	2018	38.0%	5,694	55.1 (18.8)	89.6	Veterans who had received primary care at 1 of these Veterans Affairs medical centers and had a history of experiencing homelessness according to administrative data.	79 (1.39%)	2,225 (39.1%)	NR	NR	NR	NR
Rozet	2014	RC	USA	2007 - 2010	43.1%	102	38.9 (1.51)	87.6	Veterans who underwent ambulatory knee ambulatory surgery at VA Puget Sound Health Care System, which is a tertiary medical center.	105 (72.4%)	20 (13.8%)	NR	NR	11 (7.59 %)	9 (6.21 %)
Seal	2017	RC	USA	2007 – 2015	57.3%	183,879	32.0 (8.30)	93.5	Veterans who completed a Comprehensive Traumatic Brain Injury Evaluation and received a criterion standard diagnosis of TBI (none, mild, or moderate to severe).	70,235 (60.1%)	NR	NR	NR	NR	NR
Stroupe	2013	CS	USA	2008	19.9%	916	78.8 (3.41)	NR	Veterans from a midwestern VA medical center.	431 (94.1%)	NR	15 (3.28%)	NR	NR	NR
Suri	2019	PC	USA	2010 - 2012	50.0%	409	61.6 (1.67)	NR	Veterans from the Vietnam Era Twin Registry.	213 (93.8%)	NR	NR	NR	NR	NR
Tsai	2015	RC	USA	2007 - 2015	38.8%	81,046	47.1 (7.47)	100	Literally homeless and unstably housed male veterans with custody of minor children.	43,587 (53.8%)	33,854 (41.8%)	NR	NR	NR	NR
VanDenKerkh of	2015	CS	Canada	1998 – 2007	41.0%	3,154	44.0 (10.0)	88.0	Canadian Armed Forces Regular Force veterans released from service between 1998 and 2007.	NR	NR	NR	NR	NR	NR

Vidakovic	2016	CS	Croatia	2010	58.4%	101	47.2 (33.0)	100	Male war veterans with PTSD and depression.	101 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00 %)	0 (0.00 %)	0 (0.00 %)
Wallace	2019	RC	USA	2013	54.0%	630	52.0 (13.0)	14.8	Veterans with a diagnosis of obstructive sleep apnea at the Miami VAHS sleep center	NR	42 (6.7%)	32 (5.1%)	NR	NŔ	NŔ
Yoon	2015	CS	USA	2011 - 2012	7.38%	309,374	53.9 (9.39)	88.3	Veterans with major depressive disorder.	235,473 (76.1%)	60,184 (19.5%)	52,122 (16.8%)	NR	NR	NR
Ziobrowski	2017	CS	USA	2011	18.9%	3,157	NR	50.0	Veterans from the National Health and Resilience Study	2,638 (83.6%)	189 (5.99%)	152 (4.81%)	NR	NR	NR

\* TBI = Traumatic Brain Injury; VHA = Veterans Health Affairs; OEF/OIF/OND = Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn; VA = Veterans Affairs; VAMC = Veterans Affairs Medical Center; PTSD = Post-traumatic stress disorder; RC = Retrospective cohort study; CS = Cross-sectional study; PC = Prospective cohort study; USA = United States of American

<sup>†</sup> - Total, after combining independent subgroups that are *not* comprising fully/majorly of veterans that already have chronic pain.

‡ - Race/ethnicity data is often missing from a considerable number of veterans, and hence counts may underestimate the total eligible patients included in the study. The top six most predominant race/ethnicity categories are listed here.

§ The % is based on the number of patients with CNCP prevalence, and not the number of total patients.

¶ The N for race/ethnicity is 82.

Study	Reason
Magruder 2012	The measured prevalence for pain cannot be
-	clearly differentiated between acute vs chronic.
Seal 2012	The measured prevalence for pain cannot be
	clearly differentiated between acute vs chronic.
Haskell 2012	The measured prevalence for pain cannot be
	clearly differentiated between acute vs chronic.
Benedetto 1998	Did not report a measure that is aimed at
	measuring CNCP.
Leskinen 2010	Did not report a measure that is aimed at
	measuring CNCP.

<b>Supplementary</b> N	terial 4. Reasons for the exclusion of studies from the prior systematic review (n=5)	)
C ( )	D.	

Supplementary Material 5. Characteristics concerning the CNCP prevalence among eligible stud	lies.*
--	--------

Study First Author and Year	Method of establishing presence of CNCP	Reporting Method	Threshold †	Chronic	pain definition/criteria	a from the IASP <sup>1</sup> ‡
				Persistence	Associated with emotional function and/or disability	Not mainly due to another condition
Adams 2015	The military veteran reports whether they have ever been diagnosed with a chronic pain condition and are currently experiencing pain using a self-report health measurement tool (exact tool not specified). Their answer to this question is confirmed using the electronic health record.	Clinician- Assessed	Low	No	No	No
Barry 2003	The military veteran reports whether in the previous 12 months, they have had chronic pain of a non-cancer cause for $\geq 3$ months.	Patient- Reported	Low	Yes	No	No
Bishop 2020	<ul> <li>A military veteran would be classed as having chronic pain if they met one of the following criteria by Tian et al.:</li> <li>(i) Positive for ≥1 ICD-9 code listed as "highly likely" to represent chronic pain.</li> <li>(ii) Positive for ≥2 ICD-9 codes listed as "likely" to represent chronic pain.</li> <li>(iii) Positive for 1 ICD-9 code listed as "likely" to represent chronic pain and reported ≥2 more scores that are &gt;4 on a numeric pain rating scale.</li> </ul>	Clinician- Assessed	Low	No	No	No

Burgess 2013	ICD-9 codes corresponding to chronic pain that the military	Clinician-	Low	No	No	No
a 1 10014	veteran was positive for 2 years prior to their index visit.	Assessed	-			
Copeland 2014	ICD-9 codes corresponding to a chronic pain condition.	Clinician- Assessed	Low	No	No	No
Cichowski 2017	ICD-9 codes corresponding to a chronic pain condition.	Clinician- Assessed	Low	No	No	No
Crosby 2006	Military veterans reported via a survey questionnaire as to whether they "always" had chronic pain at $\geq 1$ site.	Patient- Reported	Low	No	No	No
DeBeer 2017	Military veterans reported via a chronic pain at <u></u> r site. Military veterans reported via a chronic pain screening questionnaire as to whether they had chronic pain. The chronic pain assessed was musculoskeletal pain.	Patient- Reported	Low	No	No	No
Dobscha 2009	Military veterans reported whether they received chronic pain treatment in the past 12 months.	Patient- Reported	Low	No	No	No
Donaldson 2018	Utilized the National Pain Strategy population health pain persistence item, which has 5 possible responses. Defined "Chronic pain" as the presence of pain on at least half the days in the previous 6 months.	Patient- Reported	Low	Yes	No	No
Figoni 2015	"Chronic pain" is listed in the electronic medical record for the military veteran.	Clinician- Assessed	Low	No	No	No
Gironda 2006	Military veterans reported during a medical visit as to whether they had moderate or severe chronic pain intensity.	Patient- Reported	High	No	No	No
Goulet 2016	ICD-9 codes corresponding to a musculoskeletal disorder (e.g., fibromyalgia).	Clinician- Assessed	Low	No	No	No
Graham 2019	ICD-9 codes corresponding to a history of chronic pain.	Clinician- Assessed	Low	No	No	No
Hadlandsmyth 2018	To determine chronic pain, the military veteran had to meet         one of the following criteria by Tian et al. was applied in the         year prior to total knee arthroscopy:         (i)       Positive for ≥1 ICD-9 code listed as "highly         likely" to represent chronic pain.         (ii)       Positive for ≥2 ICD-9 codes listed as "likely"         to represent chronic pain, and these positive         results are separated by ≥30 days.         (iii)       Positive for 1 ICD-9 code listed as "likely" to         represent chronic pain and reported ≥2 more         scores that are >4 on a numeric pain rating         scale.         (iv)       Received opioid medication for ≥90 days.         (v)       Positive for 1 ICD-9 code listed as "likely" to         represent chronic pain and reported ≥2 more         scores that are >4 on a numeric pain rating         scores that are >4 on a numeric pain rating         scores that are >4 on a numeric pain rating         scores that are >4 on a numeric pain rating         scores that are >4 on a numeric pain rating         scores that are >4 on a numeric pain rating         scores that are >4 on a numeric pain rating         scores that are >4 on a numeric pain rating	Clinician- Assessed	Low	No	No	No
Hall 2020	Chronic pain is determined by the military veteran by indicating that the pain prevents few (level 3), some (level 4)	Patient- Reported	Low	No	Yes	No

	or most (level 5) activities. The pertinent question on the Life After Service Survey is "How many activities does your pain or discomfort prevent?". This question uses a 5-level scale. If					
	a patient indicates "few", "some" or "most" activities for this question, then they are determined to have chronic pain.					
Haskell 2009	Military veterans reported whether they have persistent pain, which is defined as scoring $\geq 4$ in $\geq 3$ pain scores on a numeric pain rating scale, in three different months. This is only assessed in military veterans that scored $\geq 1$ on the numeric pain rating scale and have their data is available for $\geq 3$ pain scores.	Patient- Reported	Low	No	No	No
Hendrikx 2020	The military veteran indicates the presence of 14 physical health complaints using the National Health Institute screening tool, with one of the physical health complaints being "Chronic pain".	Patient- Reported	Low	No	No	No
Но 2018	ICD-9 codes corresponding to a chronic pain condition.	Clinician- Assessed	Low	No	No	No
Huerta 2016	Inguinodynia was defined as having pain lasting for $\geq 3$ months after heniorrhaphy.	Clinician- Assessed	Low	Yes	No	No
Kalpakci 2018	ICD-9 codes corresponding to a pain diagnosis (e.g., fibromyalgia).	Clinician- Assessed	Low	No	No	No
Kerns 2003	Military veterans were asked two questions using the self- report Health-Risk Behavior Screening Questionnaire. A "yes" response must be given to both questions: (i) "Do you experience pain on a regular basis?" (ii) "Is this a concern to you?"	Patient- Reported	Low	No	No	No
Lagisetty 2019	ICD-9 codes corresponding to a chronic pain condition.	Clinician- Assessed	Low	No	No	No
Lei 2019	The military veteran's medical record explicitly lists them having pain lasting for $\geq 3$ months.	Clinician- Assessed	Low	Yes	No	No
Mancuso 2020	Patients were asked via an interview as to whether they had ever been diagnosed for fibromyalgia or other chronic pain.	Patient- Reported	Low	No	No	No
Mathew 2016	ICD-9 codes corresponding to a chronic pain condition.	Clinician- Assessed	Low	No	No	No
Mudumbai 2016	$\geq$ 2 pain diagnoses that are in the year before admission for surgery and are at least 90 days apart and are recorded in the in-patient or out-patient file.	Clinician- Assessed	Low	No	No	No
Mudumbai 2019	$\geq$ 2 pain diagnoses that are in the year before admission for total knee arthroscopy and are at least 90 days apart and are recorded in the in-patient or out-patient file, and of which one of the diagnoses comes from an in-patient visit within that time period.	Clinician- Assessed	High: diagnosis also has a condition of it being from an in- patient visit	No	No	No

			within the			
			time period.			
Powell 2015	<ul> <li>Chronic pain is defined as pain lasting for ≥3 months. The diagnosis of chronic pain was determined by one of three assessments:</li> <li>(1) The military veteran had to have chronic pain listed as an active problem in their Centralized Patient Record System on a date prior to the day that they are being assessed at the Translational Research Center for TBI and Stress Related Disorders.</li> <li>(2) A psychological consensus results in the military veteran being referred to a chronic pain specialist.</li> <li>(3) During a psychological interview, the military veteran discusses pain that has lasted for more than 3 months.</li> </ul>	Clinician- Assessed	Low	Yes	No	No
Reid 2002	The military veteran answered the following question on a brief, self-administered questionnaire, and had to give an answer of "constant": - "Would you best describe your pain as (circle one) intermittent or constant?"	Patient- Reported	Low	No	No	No
Riggs 2020	"Severe chronic pain" is defined as indicating "yes" for chronic pain and rating current pain at a score of ≥7 on a 10- point numeric rating scale. A duration requirement for "Severe chronic pain" is not specified.	Patient- Reported	High: requires chronic pain to be "severe".	No	No	No
Rozet 2014	Chronic post-operative pain was identified using the surrogate outcome of prolonged post-operative opioid prescription (PPOP). PPOP was defined as opioids being prescribed for $\geq$ 3 months after knee arthroscopy.	Clinician- Assessed	Low	No	No	No
Seal 2017	≥2 of the same pain diagnoses ≥90 days apart, before or 1 year after the CTBIE. The specific pain diagnosis is identified using ICD-9-CM codes.	Clinician- Assessed	Low	No	No	No
Stroupe 2013	A question on the mailed survey asks the military veteran to indicate the status of eight health conditions, of which one of them is "Chronic pain".	Patient- Reported	Low	No	No	No
Suri 2019	Military veterans reported via a survey as to whether they ever had "chronic back pain" in the past for $\geq 3$ months.	Patient- Reported	Low	Yes	No	No
Tsai 2015	Military veteran is asked whether a doctor or nurse has ever told them that they had a list of medical conditions, with "Chronic pain" being one of the medical conditions.	Clinician- Assessed	Low	No	No	No
VanDenKerkhof 2015	Constant or reoccurring pain or discomfort that is confirmed to be present by responding "yes" to both of the following questions from the 2010 Survey on Transition to Civilian Life:	Patient- Reported	Low	No	No	No

	<ul> <li>(1) Do you have any pain or discomfort that is always present? (yes/no)</li> <li>(2) Do you have any pain or discomfort that reoccurs from time to time? (yes/no)</li> </ul>					
Vidakovic 2016	To determine whether the military veteran has a diagnosis of myofascial pain syndrome, the clinician studied amnestic history (which included variables such as the pain's duration, intensity, location, and type), and conducted a detailed clinical examination.	Clinician- Assessed	High: Must go through multiple strands of evidence (e.g., amnestic history, clinical exams) to determine the diagnosis of chronic pain.	No	No	No
Wallace 2019	<ul> <li>Chronic pain is diagnosed by the sleep physician through one of two ways:</li> <li>(1) The military veteran is prescribed medication for pain complaints for ≥6 months preceding diagnostic polysomnography</li> <li>(2) The military veteran is attending the Miami Veterans Affairs Health Services Pain clinic in the 12 months prior to undergoing their diagnostic polysomnography.</li> </ul>	Clinician- Assessed	High: $\geq 6$ months as opposed to $\geq 3$ months for the duration.	No	No	No
Yoon 2015	ICD-9 codes corresponding to a chronic pain condition.	Clinician- Assessed	Low	No	No	No
Ziobrowski 2017	Military veteran is asked "Has a doctor or health care professional ever told you that you have any of the following medical conditions?", with "Chronic pain" being one of the medical conditions.	Clinician- Assessed	Low	No	No	No

\* CNCP = Chronic non-cancer pain; CTBIE = Comprehensive Traumatic Brain Injury Evaluation; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; TBI = Traumatic Brain Injury.

<sup>†</sup> High threshold corresponds to a study that adds criteria for defining CNCP prevalence that make it more difficult to establish its presence; such criteria goes beyond  $\geq$ 3 months of persistent pain, simply asking patients if they have chronic pain, or retrieving this information from medical records or ICD-9 codes.

‡ Retrieved from the IASP's definition of chronic primary pain.

Study	RB1	RB1	RB2	RB2	RB3	RB3	RB4	<b>RB4; Amount of</b>
	Rating	Explanation	Rating	Explanation	Rating	Explanation	Rating	missing data †
		To be eligible, all patients		Instead of asking patients		All military veterans were		
		must have Hepatitis C,		directly, they used an		systematically asked through		
		which is associated with		electronic medical record to		a survey whether they have		
		chronic pain. <sup>65</sup>		confirm the diagnosis of		chronic pain.		
Adams 2015	High	-	High	CNCP prevalence.	Low	-	High	NR
		Majority of the military		Patients reported whether or		Patients were systematically		
		veterans do not have any		not they had CNCP.		screened for the presence of		
		condition(s) that is/are				CNCP.		
		associated with chronic						
Barry 2003	Low	pain.	Low		Low		Low	8.65%
		Selectively recruited		2/3 of the methods for		Data on chronic pain was		
		military veterans who		diagnosing chronic pain		retrieved from electronic		
		underwent thoracic		were determined using ICD-		medical records for all 3		
		surgery.		9 codes. The remaining 1		methods of data collection,		
				method was through patient		and it is not certain that		
				reporting $\geq 2$ scores		every military veteran was		
				indicating greater than mild		systematically asked about		
				pain $\geq$ 4 on a numeric rating		CNCP prevalence.		
Bishop 2020	High		High	scale.	High	-	High	NR
		Majority of the military		Diagnoses of CNCP were		Data retrospectively		
		veterans do not have any		determined using ICD-9		retrieved from survey that		
		condition(s) that is/are		codes.		directly asked military		
		associated with chronic				veterans about CNCP		
Burgess 2013	High	pain.	High		Low	prevalence.	Low	0.668%
		Selectively recruited		Diagnoses of chronic pain		Data on chronic pain was		
		female military veterans;		were determined using ICD-		retrieved from electronic		
		sex differences have		9 codes.		medical records and it is not		
		previously been shown for				certain that every military		
		chronic pain. <sup>71</sup>				veteran was systematically		
		*				asked about CNCP		
Cichowski 2017	High		High		High	prevalence.	Low	8.90%
		Selectively recruited		Diagnoses of chronic pain		Data on chronic pain was		
		military veterans who		were determined using ICD-		retrieved from electronic		
		received inpatient surgical		9 codes.		medical records and it is not		
		treatment.				certain that every military		
						veteran was systematically		
						asked about CNCP		
Copeland 2014	High		High		High	prevalence.	High	NR
		Majority of the military		Patients reported whether or		All military veterans were		
		veterans do not have any		not they had constant pain.		systematically asked through		
Crosby 2006	Low	condition(s) that is/are	Low	_	Low		High	24.0%

**Supplementary Material 6.** Reasoning for ROB item ratings for each included study in the quantitative synthesis (n=41).\*

		associated with chronic				a survey as about constant		
		pain.				pain.		
		Majority of the military		Patients reported whether or		All military veterans were		
		veterans do not have any		not they have chronic pain.		systematically asked through		
		condition(s) that is/are				a survey whether they have		
		associated with chronic				chronic pain through a		
		pain.				chronic pain screening		
DeBeer 2017	Low	•	Low		Low	questionnaire.	Low	10.4%
		Data retrospectively		Patients reported whether or		Data retrospectively		
		retrieved from survey that		not they received treatment		retrieved from survey that		
		directly asked military		for chronic pain in the VA in		directly asked military		
		veterans about CNCP		the previous 12 months.		veterans whether they were		
		prevalence.				receiving treatment for		
Dobscha 2009	Low	*	Low		Low	chronic pain.	Low	1.50%
		Majority of the military		Patients reported whether or		All military veterans were		
		veterans do not have any		not they had chronic pain.		systematically asked through		
		condition(s) that is/are				a survey whether they have		
		associated with chronic				chronic pain.		
Donaldson 2018	Low	pain.	Low		Low	_	High	53.2%
		To be eligible, all patients		Instead of asking patients		Data on chronic pain was		
		must have spinal cord		directly, they used an		retrieved from electronic		
		injury or spinal cord		electronic medical record to		medical records and it is not		
		disorder, which is known to		confirm the diagnosis of		certain that every military		
		be associated with chronic		chronic pain.		veteran was systematically		
		pain. <sup>72</sup>		_		asked about CNCP		
Figoni 2015	High	-	High		High	prevalence.	High	0
		Majority of the military		Patients reported whether or		Data on chronic pain was		
		veterans do not have any		not they had chronic pain.		retrieved from electronic		
		condition(s) that is/are				medical records and it is not		
		associated with chronic				certain that every military		
		pain.				veteran was systematically		
						asked about CNCP		
Gironda 2006	Low		Low		High	prevalence.	Low	2.16%
		Selectively recruited		Diagnoses of chronic pain		Data on chronic pain was		
		military veterans with a		were determined using ICD-		retrieved from electronic		
		musculoskeletal disorder		9 codes.		medical records and it is not		
		diagnosis.				certain that every military		
						veteran was systematically		
						asked about CNCP		
Goulet 2016	High		High		High	prevalence.	Low	0
		Selectively recruited		Diagnoses of chronic pain		Data on chronic pain was		
		military veterans that are		were determined using ICD-		retrieved from administrative		
		undergoing non-cardiac		9 codes.		databases and so it is not		
Graham 2019	High	inpatient surgery.	High		High	certain that every military	High	NR

		Selectively recruited military veterans that		Diagnoses of chronic pain were determined using ICD-		Data on chronic pain was retrieved from administrative		
		underwent total knee		9 codes.		databases and so it is not		
		arthroplasty.				certain that every military		
Hadlandsmyth						veteran was systematically asked about CNCP		
2018	High		High		High	prevalence.	Low	6.81
		Majority of the military		Patients reported whether or		All military veterans were		
		veterans do not have any		not they had chronic pain.		systematically asked through		
		condition(s) that is/are associated with chronic				a survey whether they have chronic pain.		
Hall 2020	Low	pain.	Low		Low	emonie pani.	High	33.1
		Majority of the military		"Persistent pain" is		Data on chronic pain was	8	
		veterans do not have any		subjective and so we are less		retrieved from electronic		
		condition(s) that is/are associated with chronic		confident that they are directly referring to chronic		medical records and it is not certain that every military		
		pain.		pain.		veteran was systematically		
		puni.		puni.		asked about CNCP		
Haskell 2009	Low		High		High	prevalence.	Low	18.2
		Majority (86%) of the		Patients reported whether or		All military veterans were		
		patients have PTSD, which is associated with chronic		not they had chronic pain.		systematically asked through a survey whether they have		
Hendrikx 2020	High	pain. <sup>60</sup>	Low		Low	chronic pain.	High	42.2
		Selectively recruited for		Diagnoses of chronic pain		Data on chronic pain was		
		military veterans with		were determined using ICD-		retrieved from administrative		
		substance use disorder, which is associated with		9 codes.		databases and so it is not certain that every military		
		chronic pain. <sup>73</sup>				veteran was systematically		
		1				asked about CNCP		
Ho 2018	High		High		High	prevalence.	Low	0
		Selectively recruited military veterans that		A clinician reported whether		Data on chronic pain was retrieved from electronic		
		underwent inguinal		or not the patient had a diagnosis of chronic post-		medical records and it is not		
		herniorrhaphy (i.e., a		operative pain (inguinodynia		certain that every military		
		specific type of surgery).		in this case).		veteran was systematically		
H ( 001/	TT' 1		TT' 1		TT' 1	asked about CNCP	T	0
Huerta 2016	High	Selectively recruited	High	Diagnoses of chronic pain	High	prevalence. Data on chronic pain was	Low	0
		military veterans with an		were determined using ICD-		retrieved from administrative		
		alcohol use disorder		9 codes.		databases and so it is not		
Kalpakci 2018	High	diagnosis, which is	High	1	High	certain that every military	Low	0

		associated with chronic pain. <sup>62</sup>				veteran was systematically asked about CNCP prevalence.		
Kerns 2003	Low	Majority of the military veterans do not have any condition(s) that is/are associated with chronic pain.	High	"Regular pain" is subjective and so we are less confident that they are directly referring to chronic pain.	Low	All military veterans were systematically asked through a survey whether they experience regular pain and if it's a concern to them on a regular basis.	High	NR
Reffis 2005	LOW	The study selectively	Ingn	Diagnoses of chronic pain	LOW	Data on chronic pain was	Ingn	
		recruited for military veterans with ≥1 prescription opioid medication from a VA pharmacy 6 months prior to		was determined using ICD-9 codes.		retrieved from electronic medical records and it is not certain that every military veteran was systematically asked about CNCP		
Lagisetty 2019	High	their hospitalization.	High		High	prevalence.	Low	1.07%
		Majority of the military veterans in the sample have Gulf War illness (GWI; $\geq$ 3/6 GWI symptoms), which is associated with chronic pain. <sup>64</sup>		A clinician reviews the Gulf War registry computerized note and reports whether there is a diagnosis of chronic pain.		Data on chronic pain was retrieved from electronic medical records and it is not certain that every military veteran was systematically asked about CNCP		
Lei 2019	High	-	High		High	prevalence.	High	NR
		Selectively recruited female military veterans; sex differences have previously been shown for chronic pain. <sup>71</sup>		Patients reported if they were ever diagnosed for chronic pain; hence, it was not themselves that reported if they had chronic pain.		Data retrospectively retrieved from study interviews that systematically asked military veterans to report whether they had ever been		
Mancuso 2020	High		High		Low	diagnosed with chronic pain.	High	58.7%
		Selectively recruited for military veterans with an ICD-9 diagnosis of schizophrenia, which includes schizoaffective disorder, bipolar disorder, or major depressive disorder, and is associated		Diagnosis of chronic pain (i.e, fibromyalgia) was determined using ICD-9 codes.		Data on chronic pain was retrieved from administrative databases and so it is not certain that every military veteran was systematically asked about CNCP prevalence.		
Mathew 2016	High	with chronic pain.70	High		High		Low	0
		Study selectively recruited military veterans that underwent surgery in 2011.		Instead of asking patients directly, they used outpatient or inpatient files to confirm the diagnosis of chronic		Data on chronic pain was retrieved from outpatient and inpatient files and it is not certain that every military		
Mudumbai 2016	High		High	pain.	Low	veteran was systematically	Low	6.34%

						asked about CNCP		
						prevalence.		
		Selectively recruited for		Diagnoses of chronic pain		Data on chronic pain was		
		military veterans that		was determined using ICD-9		retrieved from electronic		
		underwent total knee		codes.		medical records and so it is		
		arthroplasty.				not certain that every		
						military veteran was		
						systematically asked about		
Mudumbai 2019	High		High		High	CNCP prevalence.	High	47.8%
		Majority (68%) of the		Most of the diagnoses for		Most of the data on chronic		
		patients have ≥1 TBI,		chronic pain (95% or 62/65)		pain was retrieved from the		
		which is associated with		occurred through the		centralized patient record		
		chronic pain. <sup>69</sup>		assessment of clinicians.		system, and it is not certain		
						that every military veteran		
						was systematically asked	-	
Powell 2015	High		High		High	about CNCP prevalence.	Low	3.39%
		Majority of the military		Patients reported whether		All military veterans were		
		veterans do not have any		they have "constant pain".		systematically asked through		
		condition(s) that is/are				a survey whether they have		
		associated with chronic	-		-	"constant pain".	-	4.0.000
Reid 2002	High	pain.	Low		Low		Low	19.5%
		Majority (56%) of the		Patients reported whether		All military veterans were		
		patients have Depression,		they have "severe chronic		systematically asked through		
D: 2020	TT: 1	which is associated with	т	pain".	т	a survey whether they have	TT: 1	50.50/
Riggs 2020	High	chronic pain. <sup>63</sup>	Low		Low	"severe chronic pain".	High	59.5%
		Selectively recruited		The surrogate of prolonged		Data on chronic pain was		
		military veterans that		post-operative opioid		retrieved from electronic		
		underwent elective knee		prescription was used to		medical records and so it is		
		arthroscopy.		indicate a diagnosis of		not certain that every		
				chronic post-operative pain.		military veteran was systematically asked about		
Rozet 2014	High		High		Iliah	CNCP prevalence.	Low	0
Kozet 2014	nign	Majority (66%) of the	пign	Diagnoses of chronic pain	High	Data on chronic pain	Low	0
		patients have PTSD and at		was determined using ICD-9		diagnoses was retrieved from		
		least mild TBI, which are		codes.		electronic medical records		
		both known to be				and it is not certain that		
		associated with chronic				every military veteran was		
		pain. <sup>69</sup>				systematically asked about		
Seal 2017	High	pani.	Low		High	CNCP prevalence.	Low	12.8%
2011 2017		Majority of the military	2011	Patients reported whether or		All military veterans were	2011	12.070
		veterans do not have any		not they had chronic pain.		systematically asked through		
		condition(s) that are known		net may had ememo pulli.		a survey as to whether they		
		to be associated with				had chronic pain.		
	1	chronic pain.	1		1	Panne Panne	High	42.0%

		Study selectively recruited		Patients reported whether		All military veterans were		
		male military veterans.		they had "any chronic low		systematically asked through		
				back pain".		a survey as to whether they		
				Such punt s		had "any chronic low back		
Suri 2019	High		Low		Low	pain".	High	35.7%
	8	Majority of the patients in		Patients reported if a		Data retrospectively		
		the study are homeless,		physician ever told them that		retrieved originated from a		
		which is a factor that is		they have chronic pain, and		structured form that asked		
		associated with chronic		hence chronic pain		military veterans about		
		pain. <sup>66</sup>		prevalence is not reported by		chronic pain.		
Tsai 2015	High	*	High	patients directly.	Low		Low	0
		Majority of the military		Patients reported whether		All military veterans were		
		veterans do not have any		they had "constant pain".		systematically asked through		
		condition(s) that is/are				a survey as to whether they		
VanDenKerkhof		associated with chronic				had "constant pain".		
2015	Low	pain.	Low		Low		High	33.2%
		Selectively recruited		The examining clinician		All military veterans		
		military veterans that have		reported whether or not		underwent a detailed clinical		
		PTSD and depression, both		military veterans had		examination to determine		
		of which are associated		chronic myofascial		whether they had chronic		
		with chronic pain.63,69		syndrome.		pain (chronic myofascial		
Vidakovic 2016	High		High		Low	syndrome in this case).	Low	0
		To be eligible, all patients		Chronic pain diagnosis was		Data on chronic pain was		
		must have obstructive sleep		determined indirectly		retrieved from electronic		
		apnea, which is associated		through medication		medical records and it is not		
		with chronic pain. <sup>67</sup>		prescription or attendance to		certain that every military		
				a pain clinic.		veteran was systematically		
	*** 1		*** 1		-	asked about CNCP		0
Wallace 2019	High	~	High		Low	prevalence.	Low	0
		Selectively recruited		Diagnoses of chronic pain		Data on chronic pain was		
		military veterans that had		was determined using ICD-9		retrieved from administrative		
		an ICD-9 diagnosis of		codes.		databases and so it is not		
		major depressive disorder,				certain that every military		
		which is associated with				veteran was systematically asked about CNCP		
Yoon 2015	High	chronic pain. <sup>63</sup>	High		High	prevalence.	Low	0
100112013	mgn	Majority of the military	riigii	Patients reported if a	ingn	Data retrospectively	LOW	0
		veterans do not have any		physician or healthcare		retrieved originated from a		
		condition(s) that are known		professional ever told them		survey that asked military		
		to be associated with		that they have chronic pain,		veterans about chronic pain.		
		chronic pain.		and hence chronic pain		veterans about enrome pain.		
		emonie pani.		prevalence is not reported by				

\* RB1 = Representativeness to the study sample to the study population; RB2 = Outcome measurement validity; RB3 = Risk of underreporting; CNCP = Chronic non-cancer pain.

† If a study excluded data but failed to report how many individuals were excluded, then a high ROB rating was given, and "NR" is written instead of a percentage. For all studies that lost  $\geq$ 20% of missing data, a high ROB rating was given, and low ROB rating if otherwise.

Subgroup		-			Criteria					
analysis	1 Is the analysis of effect modification based on comparison within rather than between studies?	2 For within- trial comparisons, is the effect modification similar from study to study?	3 For between- study comparisons, is the number of trials large? †	4 Was the direction of effect modification correctly hypothesized <i>a priori</i> ?	<b>5</b> Does a test of interaction suggest that chance is an unlikely explanation of the apparent effect modification?	6 Did the authors test only a small number of effect modifiers or consider the number in their statistical analysis?	7 Did the authors use a random effects model?	8 If the effect modifier is a continuous variable, were arbitrary cut- points avoided?	9 Are there any additional consideratio ns that may increase or decrease credibility?	Overall credibility rating
Study size	Completely between	Not applicable	Large (17 studies)	Definitely yes‡	Chance a very likely explanation (p = 0.2)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Not applicable	Low
Pain reporting	Completely between	Not applicable	Large (16 studies)	Definitely yes ‡	Chance a very likely explanation (p = 0.4)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Not applicable	Low
Threshold	Completely between	Not applicable	Rather large (5 studies)	Definitely yes ‡	Chance a very likely explanation (p = 0.2)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Not applicable	Low
Representa tiveness of study population (ROB Item 1)	Completely between	Not applicable	Large (12 studies)	Definitely yes ‡	Chance a very likely explanation (p = 0.6)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Effect modification supported by external evidence <sup>62-73</sup>	Low
Validity of outcome measure (ROB Item 2)	Completely between	Not applicable	Large (15 studies)	Definitely yes ‡	Chance a very likely explanation (p = 0.3)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Not applicable	Low
Risk of under- reporting (ROB Item 3)	Completely between	Not applicable	Large (18 studies)	Definitely yes ‡	Chance a likely explanation (p = 0.05)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Not applicable	Low

Supplementary Material 7. ICEMAN assessment of the credibility of subgroup analyses.\*

Missing data (ROB Item 4)	Completely between	Not applicable	Large (18 studies)	Definitely yes ‡	Chance a very likely explanation (p = 0.2)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Not applicable	Low
Sex	Completely within	Probably not similar or unclear	Not applicable	Definitely yes ‡	Chance a very likely explanation (p = 0.8)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Not applicable	Low
Loss to follow-up (meta- regression)	Completely between	Not applicable	Rather large (35 studies)	Definitely yes ‡	Chance an unlikely explanation (p = 0.001)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Not applicable	Moderate
Prevalence Measure Type	Completely between	Not applicable	Large (11 studies)	Definitely yes §	Chance an unlikely explanation (p = 0.0007)	Probably no (10 effect modifiers)	Definitely yes	Not applicable	Effect modification supported by external evidence #	Moderate

\* ICEMAN – Instrument for assessing the Credibility of Effect Modification Analyses; ROB = Risk of bias. Two items that definitely decrease the credibility are given a "Low" rating. If all of the items definitely decrease credibility, a "Very low" rating is given. Additional considerations (Item 9) may either increase or decrease the credibility of the effect modifier.

<sup>†</sup> The number of studies in the parentheses corresponds to the number of studies in the *smallest* subgroup for a given effect modifier.

‡ These effect modifiers were all hypothesized is *a priori* via the study protocol, which is published in the Open Science Framework (https://osf.io/pgukx)

§ This effect modifier overlaps with the representativeness of the sample to the general population. Studies in which a specific form of pain is being studied are less likely to be representative of the general population of military veterans.

# When exploring the proportion (prevalence) of a subset of chronic pain, it should be less than the whole range of chronic pain t

Study or Subgroup	Events	Total	Weight	IV, Random, 95% Cl						
<b>Male</b> Dobscha 2009	83776	246401	7.00/	24 00/ [22 00/ 24 20/]						
Hall 2020	956	246401	7.2% 7.1%	34.0% [33.8%, 34.2%] 39.6% [37.6%, 41.6%]						
Haskell 2009	3427	16611	7.1%	18.0% [17.8%, 18.2%]						
	6228	345204	7.2%				-			
Kalpakci 2018 Seal 2017	66966	345204 116913					-			
Tsai 2015	34582	89142	7.2%	56.8% [56.6%, 57.1%]						
Ziobrowski 2017	3458Z 596		7.2%	38.8% [38.4%, 39.1%]						
		3157	7.1%			*				
Total [95% CI]	208666	908609	50.1%	27.3% [10.0%, 49.1%]						
Heterogeneity: Tau <sup>2</sup> = 940							-			
Female										
Dobscha 2009	4013	9121	7.2%	44.0% [43.0%, 45.0%]						
Hall 2020	168	341	7.1%	49.3% [43.8%, 54.7%]				-		
Haskell 2009	3918	18481	7.2%	21.2% [20.6%, 21.8%]						
Kalpakci 2018	907	13797	7.2%	6.60% [6.20%, 7.00%]			-			
Seal 2017	4566	7139	7.2%	64.0% [62.8%, 65.1%]			-			
Tsai 2015	3160	8096	7.2%	39.0% [38.0%, 40.1%]			+			
Ziobrowski 2017	57	321	7.1%	17.8% [13.7%, 22.4%]		-				
Total [95% Cl]	16789	57296	49.9%	32.9% [17.2%, 50.9%]				-		
Heterogeneity: Tau <sup>2</sup> = 607	10/03	57250	40.076	02.070 [17.270, 00.070]						
Total [95% CI]	225455	965905	100.0%	30.1% [16.9%, 45.2%]						
Test for subgroup interaction			/•							
					0	0.2	0.4	0.6	0.8	

**Supplementary Material 8.** Subgroup analysis of chronic noncancer pain prevalence with respect to sex. CI = confidence interval; IV = inverse variance.

Study					
or Subgroup	Events	Total	Weight	IV, Random, 95% CI	
Clinician-Assessed	2101110	Total			
Adams 2015	102	175	2.4%	58.3% [50.6%, 65.7%]	
Bishop 2020	5607	18940	2.4%	29.6% [29.0%, 30.3%]	•
Burgess 2013	131778	296918	2.4%	44.4% [44.3%, 44.6%]	•
Cichowski 2017	94398	516950	2.4%	18.3% [18.2%, 18.4%]	· · · · · · · · · · · · · · · · · · ·
Copeland 2014	29080	89995	2.4%	32.3% [32.0%, 32.6%]	
Figoni 2015	85	178	2.4%	47.8% [40.2%, 55.4%]	
Goulet 2016	91	458	2.4%	19.9% [16.3%, 23.8%]	
Graham 2019	8385	280681	2.4%	3.00% [2.90%, 3.10%]	
Hadlandsmyth 2018	2943	6653	2.4%	44.2% [43.0%, 45.4%]	-
Ho 2018	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Huerta 2016	596	3157	2.4%	18.9% [17.5%, 20.3%]	•
Kalpakci 2018	6228	345204	2.4%	1.80% [1.80%, 1.80%]	
Lagisetty 2019	398452	485513	2.4%	82.1% [82.0%, 82.2%]	
Lei 2019	237	367	2.4%	64.6% [59.4%, 69.5%]	-
Mathew 2016	13936	618565	2.4%	2.30% [2.20%, 2.30%]	•
Mudumbai 2016	25870	49812	2.4%	51.9% [51.5%, 52.4%]	•
Mudumbai 2019	5316	5514	2.4%	96.4% [95.9%, 96.9%]	+
Powell 2015	65	171	2.4%	38.0% [30.7%, 45.7%]	
Rozet 2014	44	102	2.4%	43.1% [33.4%, 53.3%]	÷
Seal 2017	66966	116913	2.4%	57.3% [57.0%, 57.6%]	
Tsai 2015	34582	89142	2.4%	38.8% [38.5%, 39.1%]	<b>1</b>
Vidakovic 2016	59	101	2.4%	58.4% [48.2%, 68.1%]	——————————————————————————————————————
Wallace 2019	340	630	2.4%	54.0% [50.0%, 57.9%]	
Yoon 2015	12889	309374	2.4%	4.20% [4.10%, 4.20%]	•
Ziobrowski 2017	596	3157	2.4%	18.9% [17.5%, 20.3%]	
Total [95% CI]	864943	5263045	61.0%	31.9% [19.8%, 45.4%]	-
Heterogeneity: Tau <sup>2</sup> = 1245					
Detient Demosted					
Patient-Reported	000	1045	0 40/	25 29/ 122 69/ 27 09/1	_
Barry 2003	263	1045	2.4%	25.2% [22.6%, 27.9%]	
Crosby 2006	30	114	2.4%	26.3% [18.5%, 35.4%]	- <mark></mark>
DeBeer 2017	1124 86726	2755 251691	2.4%	40.8% [39.0%, 42.7%]	
Dobscha 2009			2.4%	34.5% [34.3%, 34.6%]	
Donaldson 2018	749	1818	2.4%	41.2% [38.9%, 43.5%]	<b>+</b>
Gironda 2006	219	970 2755	2.4%	22.6% [20.0%, 25.3%]	<del></del>
Hall 2020	1124		2.4%	40.8% [39.0%, 42.7%]	+
Haskell 2009	3427	16611	2.4% 2.4%	20.6% [20.0%, 21.3%]	•
Hendrikx 2020	159	383		41.5% [36.5%, 46.6%]	
Kerns 2003 Manaulan 2020	332	685	2.4%	48.5% [44.7%, 52.3%]	
Mancuso 2020	558	996	2.4%	56.0% [52.9%, 59.1%]	
Reid 2002	297	516	2.4%	57.6% [53.2%, 61.9%]	-
Riggs 2020	2161	5694	2.4%	38.0% [36.7%, 39.2%]	-
Stroupe 2013	91	458	2.4%	19.9% [16.3%, 23.8%]	<b>-</b>
Suri 2019 VanDanKarkhaf 2015	110	220	2.4%	50.0% [43.2%, 56.8%]	
VanDenKerkhof 2015	1293	3150	2.4%	41.0% [39.3%, 42.8%]	=
Total [95% CI]	97647	287330	39.0%	37.8% [33.3%, 42.4%]	•
Heterogeneity: Tau <sup>2</sup> = 88					
Total [95% CI]	962950	5550375	100.0%	34.2% [24.5%, 44.6%]	
Test for subgroup interaction:					
•	•				
					0 0.2 0.4 0.6 0.8 1

**Supplementary Material 9.** Subgroup analysis of chronic non-cancer pain prevalence with respect to pain reporting method. CI = confidence interval; IV = inverse variance.

Study					
or Subgroup	Events	Total	Weight	IV, Random, 95% CI	
Low Threshold	Lvents	Total	weight		
Adams 2015	102	175	2.4%	58.3% [50.6%, 65.7%]	
Barry 2003	263	1045	2.4%	25.2% [22.6%, 27.9%]	
Bishop 2020	5607	18940	2.4%	29.6% [29.0%, 30.3%]	
Burgess 2013	131778	296918	2.4%	44.4% [44.3%, 44.6%]	
Cichowski 2017	94398	516950	2.4%	18.3% [18.2%, 18.4%]	_
Copeland 2014	29080	89995	2.4%	32.3% [32.0%, 32.6%]	
Crosby 2006	23080	114	2.4%	26.3% [18.5%, 35.4%]	
DeBeer 2017	1124	2755	2.4%	40.8% [39.0%, 42.7%]	_
Dobscha 2009	86726	251691	2.4%	34.5% [34.3%, 34.6%]	
			2.4%		
Donaldson 2018	749	1818		41.2% [38.9%, 43.5%]	
Figoni 2015	85 91	178 458	2.4%	47.8% [40.2%, 55.4%]	_
Goulet 2016			2.4%	19.9% [16.3%, 23.8%]	1.0
Graham 2019	8385	280681	2.4%	3.00% [2.90%, 3.10%]	1
Hadlandsmyth 2018	2943	6653	2.4%	44.2% [43.0%, 45.4%]	
Hall 2020	1124	2755	2.4%	40.8% [39.0%, 42.7%]	
Haskell 2009	3427	16611	2.4%	20.6% [20.0%, 21.3%]	•
Hendrikx 2020	159	383	2.4%	41.5% [36.5%, 46.6%]	
Ho 2018	1293	3150	2.4%	41.0% [39.3%, 42.8%]	1
Huerta 2016	596	3157	2.4%	18.9% [17.5%, 20.3%]	+
Kalpakci 2018	6228	345204	2.4%	1.80% [1.80%, 1.80%]	
Kerns 2003	332	685	2.4%	48.5% [44.7%, 52.3%]	_
Lagisetty 2019	398452	485513	2.4%	82.1% [82.0%, 82.2%]	
Lei 2019	237	367	2.4%	64.6% [59.4%, 69.5%]	
Mancuso 2020	558	996	2.4%	56.0% [52.9%, 59.1%]	
Mathew 2016	13936	618565	2.4%	2.30% [2.20%, 2.30%]	
Mudumbai 2016	25870	49812	2.4%	51.9% [51.5%, 52.4%]	_
Powell 2015	65	171	2.4%	38.0% [30.7%, 45.7%]	
Reid 2002	297	516	2.4%	57.6% [53.2%, 61.9%]	
Rozet 2014	44	102	2.4%	43.1% [33.4%, 53.3%]	
Seal 2017	66966	116913	2.4%	57.3% [57.0%, 57.6%]	
Stroupe 2013	91	458	2.4%	19.9% [16.3%, 23.8%]	-
Suri 2019	110	220	2.4%	50.0% [43.2%, 56.8%]	
Tsai 2015	34582	89142	2.4%	38.8% [38.5%, 39.1%]	
VanDenKerkhof 2015	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Yoon 2015	12889	309374	2.4%	4.20% [4.10%, 4.20%]	
Ziobrowski 2017	596	3157	2.4%	18.9% [17.5%, 20.3%]	- <b>-</b>
Total [95% CI]	954495	5537466	87.8%	31.3% [21.3%, 42.3%]	
Heterogeneity: Tau <sup>2</sup> = 1204					
High Threshold					
Gironda 2006	219	970	2.4%	22.6% [20.0%, 25.3%]	
Mudumbai 2019	5316	5514	2.4%	96.4% [95.9%, 96.9%]	
Riggs 2020	2161	5694	2.4%	38.0% [36.7%, 39.2%]	
Vidakovic 2016	59	101	2.4%	58.4% [48.2%, 68.1%]	
Wallace 2019	340	630	2.4%	54.0% [50.0%, 57.9%]	
Total [95% CI]	8095	12909	12.2%	56.1% [18.2%, 90.3%]	_
Heterogeneity: Tau <sup>2</sup> = 2131			/0		-
Total [95% CI]	962950	5550375	100.0%	34.2% [24.5%, 44.6%]	
Test for subgroup interaction:	p = 0.2				
	-				0 0.2
					0 0.1

**Supplementary Material 10.** Subgroup analysis of chronic non-cancer pain prevalence with respect to threshold. CI = confidence interval; IV = inverse variance.

Study					
or Subgroup	Events	Total	Weight	IV, Random, 95% CI	
High ROB (Item #1)	Lvento	Total	mengine		
Adams 2015	102	175	2.4%	58.3% [50.6%, 65.7%]	÷ – <mark>+</mark> -
Bishop 2020	5607	18940	2.4%	29.6% [29.0%, 30.3%]	•
Burgess 2013	131778	296918	2.4%	44.4% [44.3%, 44.6%]	
Cichowski 2017	94398	516950	2.4%	18.3% [18.2%, 18.4%]	
Copeland 2014	29080	89995	2.4%	32.3% [32.0%, 32.6%]	•
Figoni 2015	85	178	2.4%	47.8% [40.2%, 55.4%]	÷
Goulet 2016	91	458	2.4%	19.9% [16.3%, 23.8%]	•
Graham 2019	8385	280681	2.4%	3.00% [2.90%, 3.10%]	•
Hadlandsmyth 2018	2943	6653	2.4%	44.2% [43.0%, 45.4%]	+
Hendrikx 2020	159	383	2.4%	41.5% [36.5%, 46.6%]	-
Ho 2018	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Huerta 2016	596	3157	2.4%	18.9% [17.5%, 20.3%]	+
Kalpakci 2016	6228	345204	2.4%	1.80% [1.80%, 1.80%]	
Lagisetty 2019	398452	485513	2.4%	82.1% [82.0%, 82.2%]	
Lei 2019	237	367	2.4%	64.6% [59.4%, 69.5%]	
Mancuso 2020	558	996	2.4%	56.0% [52.9%, 59.1%]	
Mathew 2016	13936	618565	2.4%	2.30% [2.20%, 2.30%]	
Mudumbai 2016	25870	49812	2.4%	51.9% [51.5%, 52.4%]	
Mudumbai 2019	5316	5514	2.4%	96.4% [95.9%, 96.9%]	
Powell 2015	65	171	2.4%	38.0% [30.7%, 45.7%]	
Reid 2002	297	516	2.4%	57.6% [53.2%, 61.9%]	
Riggs 2020	2161	5694	2.4%	38.0% [36.7%, 39.2%]	
Rozet 2014	44	102	2.4%	43.1% [33.4%, 53.3%]	
Seal 2017	66966	116913	2.4%	57.3% [57.0%, 57.6%]	
Suri 2019	110	220	2.4%	50.0% [43.2%, 56.8%]	
Tsai 2015	34582	89142	2.4%	38.8% [38.5%, 39.1%]	
Vidakovic 2016	59	101	2.4%	58.4% [48.2%, 68.1%]	<b>—</b>
Wallace 2019	340	630	2.4%	54.0% [50.0%, 57.9%]	
Yoon 2015	12889	309374	2.4%	4.20% [4.10%, 4.20%]	<b>•</b>
Total [95% CI]	867632	5267697	70.7%	35.2% [23.5%, 47.9%]	
Heterogeneity: $Tau^2 = 1246$					
0					
Low ROB (Item #1)					_
Barry 2003	263	1045	2.4%	25.2% [22.6%, 27.9%]	
Crosby 2006	30	114	2.4%	26.3% [18.5%, 35.4%]	- <b></b>
DeBeer 2017	1124	2755	2.4%	40.8% [39.0%, 42.7%]	<u>_</u>
Dobscha 2009	86726	251691	2.4%	34.5% [34.3%, 34.6%]	<u> </u>
Donaldson 2018	749	1818	2.4%	41.2% [38.9%, 43.5%]	=
Gironda 2006	219	970	2.4%	22.6% [20.0%, 25.3%]	• • • • • • • • • • • • • • • • • • •
Hall 2020	1124	2755	2.4%	40.8% [39.0%, 42.7%]	
Haskell 2009	3427	16611	2.4%	20.6% [20.0%, 21.3%]	•
Kerns 2003	332	685	2.4%	48.5% [44.7%, 52.3%]	_ =
Stroupe 2013	91	458	2.4%	19.9% [16.3%, 23.8%]	<u>⊷</u> :
VanDenKerkhof 2015	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Ziobrowski 2017	596	3157	2.4%	18.9% [17.5%, 20.3%]	+
Total [95% Cl]	94958	282678	29.3%	31.8% [26.6%, 37.3%]	<b>*</b>
Heterogeneity: Tau <sup>2</sup> = 413					
Total [95% CI]	962590	5550375	100.0%	34.2% [24.5%, 44.6%]	
Test for subgroup interaction:					
	F 0.0				0 0.2 0.4 0.6 0.8 1
					0 0.2 0.4 0.6 0.8 1

**Supplementary Material 11.** Subgroup analysis of chronic non-cancer pain prevalence with respect to ROB item #1. CI = confidence interval; IV = inverse variance.

or Subgroup High ROB (Item #2) Adams 2015         Events 102         Total         Weight Weight         IV, Random, 95% CI High ROB (Item #2)           Bishop 2020         5607         18940         2.4%         28.6% [20.%, 30.3%]           Burgess 2013         131778         226918         2.4%         44.4%         44.4%         44.4%         44.4%         44.4%         44.4%         64.4%         55.6%           Cichowski 2017         94398         516950         2.4%         42.4%         19.4%         12.4%         44.4%         12.4%         56.4%         10.6%         10.6%         10.6%         10.6%         12.4%         24.4%         19.4%         12.4%         24.4%         19.4%         12.4%         24.4%         19.4%         12.4%         24.4%         19.4%         10.6%	Study								
High ROB (item #2)         Adams 2015       102       175       2.4%       58.3% [50.6%, 65.7%]         Bishop 2020       5607       18940       2.4%       44.4% [44.3%, 44.6%]         Cichowski 2017       94.398       516950       2.4%       44.4% [44.3%, 44.6%]         Cichowski 2017       94.398       516950       2.4%       18.3% [18.2%, 18.4%]         Copeland 2014       29080       89995       2.4%       32.3% [32.0%, 32.6%]       9         Goulet 2016       91       458       2.4%       44.4% [44.3%, 44.6%]       16.3%, 23.8%]       9         Graham 2019       8385       280681       2.4%       41.0% [39.3%, 42.8%]       9         Haskell 2009       3427       16611       2.4%       2.6% [20.0%, 13.0%]       9         Haskell 2016       6228       345204       44.10% [39.3%, 42.8%]       9       18         Huetta 2016       6396       3157       2.4%       46.6% [59.4%, 60.5%]       18         Lagisetty 2019       39842       44551       44.7%, 52.3%]       9       14         Lagisetty 2019       3946       6485       54.4%       2.30% [2.0%, 2.30%]       14         Mudumbal 2016       13936       618565       2.	-	Events	Total	Weiaht	IV, Random, 95% CI				
Adams 2015       102       175       2.4%       56.3%       50.6%%, 65.7%       30.3%         Burgess 2013       131778       296918       2.4%       44.4%       [44.3%, 44.6%]         Clchowski 2017       94398       516950       2.4%       13.3%       [18.2%, 18.4%]         Copeland 2014       29080       89995       2.4%       43.3%       [18.2%, 18.4%]       [18.2%, 18.4%]         Goulet 2016       91       458       2.4%       47.8%       [40.2%, 55.4%]       [18.3%]         Graham 2019       8385       280681       2.4%       3.00%       [2.90%, 3.10%]       [18.4%, 45.4%]         Hadlandsmyth 2018       2043       6653       2.4%       44.0%       [3.9.3%, 42.8%]       [18.4%, 62.3%]         Hearta 2016       596       3157       2.4%       45.5%       [47.%, 52.3%]       [18.4%, 64.6%]         Kalpakci 2016       6228       345204       2.4%       45.5%       [47.4%, 52.3%]       [18.20%, 42.7%]       [18.4%, 64.6%]         Lei 2019       396452       485513       2.4%       45.4%       [5.9%, 61.5%]       [18.4%, 53.3%]       [18.4%, 64.6%]       [18.5%, 53.4%]       [18.4000000000000000000000000000000000000									
Burge'ss 2013 131778 296918 24% 44.4% [44.3%, 44.6%] Cichowski 2017 94398 516950 2.4% 18.3% [18.2%, 18.4%] Copeland 2014 29000 89995 2.4% 32.3% [32.0%, 32.6%] Figoni 2015 85 178 2.4% 47.8% [40.2%, 55.4%] Graham 2019 8385 280681 2.4% 3.00% [2.90%, 3.10%] Hadlandsmyth 2018 2943 6653 2.4% 44.2% [43.0%, 45.4%] Haskell 2009 3427 16611 2.4% 20.6% [20.0%, 21.3%] Hakakel 2016 596 3157 2.4% 18.9% [17.5%, 20.3%] Kalpakci 2016 6228 345204 2.4% 1.80% [18.0%, 18.0%] Kalpakci 2016 6228 345204 2.4% 1.80% [18.0%, 62.2%] Laigisetty 2019 398452 485513 2.4% 66.5% [44.7%, 52.3%] Laigisetty 2019 398452 485513 2.4% 66.5% [44.7%, 52.3%] Laigisetty 2019 398452 485513 2.4% 66.1% [59.4%, 69.5%] Mudumbai 2016 13936 618565 2.4% 2.30% [2.0%, 62.2%] Laigisetty 2019 398452 485513 2.4% 66.4% [59.4%, 69.5%] Mudumbai 2016 13936 618565 2.4% 2.30% [2.0%, 62.2%] Laigisetty 2019 5316 5514 2.4% 96.4% [59.4%, 69.5%] Mudumbai 2015 65 171 2.4% 83.6% [30.7%, 45.7%] Rozet 2014 44 102 2.4% 43.1% [33.4%, 53.3%] Mudumbai 2015 65 171 2.4% 83.6% [30.7%, 45.7%] Rozet 2014 444 102 2.4% 43.0% [30.7%, 45.7%] Rozet 2014 344 102 2.4% 43.8% [38.5%, 39.1%] Vidakcovic 2015 59 101 2.4% 58.4% [48.2%, 68.1%] Vidakcovic 2015 59 101 2.4% 58.4% [48.2%, 68.1%] Vidakcovic 2015 51 2889 309374 2.4% 4.20% [4.10%, 4.20%] Ziobrowski 2017 596 3157 2.4% 40.8% [39.0%, 42.7%] Heterogeneity: Tau <sup>2</sup> = 1204 Low ROB (Item #2) Barry 2003 263 1045 2.4% 25.2% [22.6%, 27.9%] Crosby 2006 30 114 2.4% 25.2% [28.6%, 34.6%] Donaldson 2018 749 1818 2.4% 41.2% [38.9%, 43.5%] Gironda 2006 219 970 2.4% 25.6% [39.0%, 42.7%] Hendrikx 2020 159 333 2.4% 41.5% [36.5%, 46.6%] Powell 2017 66966 116913 2.4% 57.6% [53.2%, 61.9%] Reid 2002 297 516 2.4% 57.6% [53.2%, 61.9%] Reid 2002 297 516 2.4% 57.6% [53.2%, 61.9%] Reid 2002 297 516 2.4% 57.6% [53.2%, 61.9%] Rodus 2020 558 996 5550375 100.0% 34.2% [24.5%, 44.6%] Fettorgeneity: Tau <sup>2</sup> = 235 Total [95% CI] 962590 5550375 100.0% 34.2% [24.5%, 44.6%]		102	175	2.4%	58.3% [50.6%, 65.7%]				
Burgess 2013 131778 296918 24% 44.4% [44.3%, 44.6%] Cichowski 2017 94398 516950 2.4% 18.3% [18.2%, 18.4%] Copeland 2014 29080 89995 2.4% 32.3% [32.0%, 52.6%] Figoni 2015 85 178 2.4% 47.8% [40.2%, 55.4%] Goulet 2016 91 458 2.4% 30.0% [2.90%, 3.10%] Graham 2019 8385 280681 2.4% 30.0% [2.90%, 3.10%] Hadlandsmyth 2018 2943 6653 2.4% 44.2% [43.0%, 45.4%] Haskell 2009 3427 16611 2.4% 20.6% [20.0%, 21.3%] Ho 2018 1293 3150 2.4% 41.0% [39.3%, 42.8%] Huerta 2016 596 3157 2.4% 18.9% [17.5%, 20.3%] Kalpakci 2016 6228 345204 2.4% 1.80% [18.0%, 1.80%, 1.80%] Kalpakci 2016 6228 345204 2.4% 1.80% [18.0%, 1.80%, 1.80%] Kalpakci 2016 6228 345204 2.4% 51.6% [44.7%, 65.3%] Lagisetty 2019 398452 485513 2.4% 82.1% [82.0%, 82.2%] Lei 2019 237 367 2.4% 64.6% [59.4%, 69.5%] Mudumbai 2016 13936 618565 2.4% 2.30% [2.0%, 62.2%] Lei 2019 5316 5141 2.4% 38.0% [30.7%, 45.7%] Rozet 2014 44 102 2.4% 51.3% [3.3.4%, 53.3%] Powell 2015 65 171 2.4% 88.0% [30.7%, 45.7%] Rozet 2014 444 102 2.4% 38.0% [30.7%, 45.7%] Rozet 2014 44 102 2.4% 43.1% [33.4%, 53.3%] Vidakovic 2015 59 101 2.4% 58.4% [48.2%, 68.1%] Vidakovic 2015 51 2889 309374 2.4% 4.20% [4.10%, 4.20%] Ziobrowski 2017 596 3157 2.4% 18.9% [17.5%, 20.3%] Mudumbai 2019 340 630 2.4% 54.0% [50.0%, 57.9%] Yoon 2015 12889 309374 2.4% 4.20% [4.10%, 4.20%] Ziobrowski 2017 596 3157 2.4% 40.8% [39.0%, 42.7%] Heterogeneity: Tau <sup>2</sup> = 1204 Low ROB (Item #2) Barry 2003 263 1045 2.4% 25.2% [22.6%, 27.9%] Gronda 2006 219 970 2.4% 25.6% [3.5%, 36.4%] Doscha 2009 86726 251691 2.4% 33.0% [30.6%, 34.6%] Donaldson 2018 749 1818 2.4% 41.2% [38.9%, 43.5%] Gironda 2006 219 970 2.4% 25.6% [3.9%, 42.7%] Hendrikx 2020 159 333 2.4% 41.5% [36.5%, 46.6%] Reid 2002 297 516 2.4% 57.6% [3.2%, 61.9%] Reid 2002 297 516 2.4% 41.0% [39.3%, 42.8%] Total [95% CI] 962590 5550375 100.0% 34.2% [24.5%, 44.6%] Fest for subgr	Bishop 2020	5607	18940	2.4%	29.6% [29.0%, 30.3%]			•	
Copeland 2014       29080       89995       2.4%       32.3%       [32.0%, 32.6%]       1         Figoni 2015       85       178       2.4%       47.8%       [40.2%, 55.4%]       1         Goulet 2016       91       458       2.4%       47.8%       [40.2%, 55.4%]       1         Graham 2019       8385       280681       2.4%       47.8%       [40.2%, 42.5%]       1         Hadlandsmyth 2018       1293       3150       2.4%       41.0%       [39.3%, 42.8%]       1         Huerta 2016       596       3157       2.4%       48.5%       [44.7%, 52.3%]       1         Lagisetty 2019       398452       485513       2.4%       48.5%       [44.7%, 52.3%]       1         Lei 2019       237       367       2.4%       64.6%       [59.4%, 69.5%]       1         Mudumbai 2016       13936       618656       2.4%       48.5%       [44.7%, 52.3%]       1         Nudumbai 2015       34522       2.4%       38.6%       [30.7%, 45.7%]       1       1         Rozet 2014       44       102       2.4%       38.6%       [30.5%, 39.1%]       1       1         Vidakovic 2016       59       101       2.4%		131778	296918	2.4%					•
Copeland 2014       29080       89995       2.4%       32.3%       [32.0%, 32.6%]       Image: Second Seco	0						1		
Figoni 2015851782.4%47.8% $[40.2\%, 55.4\%]$ Goulet 2016914582.4%19.9% $[16.3\%, 23.8\%]$ Graham 201983852806812.4%3.00% $[2.90\%, 3.10\%]$ Haskell 20093427166112.4%2.0.8% $[2.00\%, 2.1.3\%]$ Ho 2018129331502.4%41.0% $[39.3\%, 42.8\%]$ Huerta 201659631572.4%48.5% $[44.7\%, 52.3\%]$ Lagisetty 20193984524855132.4%81.0% $[1.80\%, 1.80\%]$ Lagisetty 20193984524855132.4%82.1% $[82.0\%]$ Mudumbai 201625870498122.4%51.9% $[5.5\%, 52.4\%]$ Mudumbai 201655142.4%96.4% $[95.9\%, 96.9\%]$ Powell 2015651712.4%88.0% $[30.7\%, 45.7\%]$ Rozet 2014441022.4%53.4% $[83.4\%, 53.3\%]$ Vidakovic 2016591012.4%54.0% $[83.4\%, 68.1\%]$ Vidakovic 2016591012.4%54.0% $[83.9\%, 45.7\%]$ Volacvic 2016591012.4%54.4% $[83.9\%, 45.7\%]$ Vidakovic 2016591012.4%54.4% $[40.9\%, 42.7\%]$ Vidakovic 2016591012.4%54.4% $[43.9\%, 34.5\%]$ Vidakovic 2016591012.4%54.3% $[43.3\%, 34.4\%]$ Vidakovic 2016501142.4%4.20% $[4.10\%, 4.20\%]$ Vidakovic	Copeland 2014	29080		2.4%				•	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$									ł
Graham 201983852806812.4%3.00% $[2.90\%, 3.10\%]$ Hadlandsmyth 2018294366532.4%44.2% $[43.0\%, 45.4\%]$ Haskell 20093427166112.4%20.6% $[20.0\%, 21.3\%]$ Ho 2018129331502.4%41.0% $[39.3\%, 42.8\%]$ Kalpakci 201662283452042.4%1.80% $[1.80\%, 1.80\%]$ Kalpakci 201662283452042.4%48.5% $[44.7\%, 52.3\%]$ Lagisetty 20193984524855132.4%82.1% $[82.0\%, 82.2\%]$ Lei 20192373672.4%64.6% $[59.4\%, 60.5\%]$ Mathew 2016139366185652.4%2.30% $[2.20\%, 2.30\%]$ Mudumbai 201565112.4%96.4%[95.9%, 96.9%]Powell 2015665112.4%38.0%(30.7\%, 45.7\%)Rozet 2014441022.4%43.1%[33.4\%, 53.3\%]Tsai 2015128893093742.4%4.20%(4.10\%, 4.20%]Vidakovic 2016591012.4%2.4%38.0%[30.7\%, 45.7\%]Vidakovic 2016591012.4%2.4%38.9%(38.5%, 31.%)Vidakovic 2015128893093742.4%4.20%(4.10%, 4.20%]Zobrowski 201759631572.4%18.9%(17.5%, 20.3%)Zobrowski 201759631572.4%18.9%(38.9%, 63.4%)Doscha 2009867262516912.4%4.20% <td< td=""><td>5</td><td></td><td></td><td>2.4%</td><td></td><td></td><td></td><td></td><td></td></td<>	5			2.4%					
Hadlandsmyth 2018294366532.4%44.2%[43.0%, 45.4%]Haskell 20093427166112.4%20.0%, 21.3%]1Ho 2018129331502.4%14.0%[39.3%, 42.8%]1Huerta 201659631572.4%18.0%[1.80%, 1.80%]1Kalpakci 201662283452042.4%18.0%[1.80%, 1.80%]1Lagisetty 20193984524855132.4%48.5%[4.47%, 52.3%]1Lagisetty 20193984524855132.4%64.6%[5.9%, 52.4%]1Mudumbai 201625870498122.4%51.5%, 52.3%]1Mudumbai 2015651712.4%38.0%[30.7%, 45.7%]1Rozet 2014441022.4%54.0%[50.0%, 57.9%]1Vidakovic 2016591012.4%54.0%[50.0%, 57.9%]1Vidakovic 2016591012.4%54.0%[50.0%, 57.9%]1Vallace 2019340632.4%4.20%(4.10%, 4.20%]1Vallace 2019340632.4%4.20%[4.10%, 4.20%]1Vallace 2019340632.4%31.1%[19.6%, 44.1%]Heterogeneity: Tau² = 1204124%25.2%[2.6%, 27.9%]1Low ROB (Item #2)867262516912.4%31.4%39.0%, 42.7%]Barry 200326310452.4%25.2%[2.6%, 27.9%]Gronda 2006 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
Haskell 2009 $3427$ 16611 $2.4\%$ $20.6\%$ $[20.0\%, 21.3\%]$ Ho 201812933150 $2.4\%$ $11.0\%$ $[39.3\%, 42.8\%]$ Huerta 2016596 $3157$ $2.4\%$ $11.0\%$ $[39.3\%, 42.8\%]$ Kalpakci 20166228 $345204$ $2.4\%$ $18.0\%$ $[1.80\%]$ Lagisetty 2019398452 $485513$ $2.4\%$ $82.1\%$ $[82.0\%, 82.2\%]$ Lei 2019237367 $2.4\%$ $64.6\%$ $[59.4\%, 69.5\%]$ Mathew 201613936 $618565$ $2.4\%$ $64.6\%$ $[59.4\%, 69.5\%]$ Mudumbai 201953165514 $2.4\%$ $64.\%$ $[95.9\%, 96.9\%]$ Powell 201565171 $2.4\%$ $38.0\%$ $[30.7\%, 45.7\%]$ Rozet 201444102 $2.4\%$ $43.1\%$ $[33.4\%, 53.3\%]$ Yolakovic 201659101 $2.4\%$ $88.4\%$ $88.5\%$ $[84.2\%, 68.1\%]$ Vidakovic 201659101 $2.4\%$ $42.0\%$ $42.0\%$ Yolakovic 2017596 $31752$ $2.4\%$ $42.0\%$ $42.0\%$ Yolakovic 2017596 $31752$ $2.4\%$ $40.8\%$ $39.0\%$ $42.7\%$ Postel 201711242755 $2.4\%$ $40.8\%$ $39.0\%$ $42.7\%$ Dobscha 200986726251691 $2.4\%$ $40.8\%$ $39.0\%$ $42.7\%$ Hall 202011242755 $2.4\%$ $40.8\%$ $39.0\%$ $42.7\%$ Hand 2020159 $383$ $2.4\%$ $40.8\%$ $36.5\%$ $46.8\%$ <td>Hadlandsmyth 2018</td> <td>2943</td> <td>6653</td> <td>2.4%</td> <td></td> <td>_</td> <td></td> <td></td> <td>+</td>	Hadlandsmyth 2018	2943	6653	2.4%		_			+
Ho 2018       1293       3150       2.4%       41.0%       [39.3%, 42.8%]       Image: Construct the second seco		3427		2.4%				1	
Huerta 201659631572.4%18.9% $[17.5\%, 20.3\%]$ Kalpakci 201662283452042.4%1.80% $[1.80\%, 1.80\%]$ Lagisetty 20193984524855132.4%82.1% $[82.0\%, 82.2\%]$ Lei 20192373672.4%82.1% $[82.0\%, 82.2\%]$ Mathew 2016139366158652.4%2.30% $[2.20\%, 2.30\%]$ Mudumbai 201625870498122.4%51.9% $[51.5\%, 52.4\%]$ Mudumbai 201655142.4%96.4% $[95.9\%, 96.9\%]$ Powell 2015651712.4%83.0% $[30.7\%, 45.7\%]$ Rozet 2014441022.4%83.8% $[38.5\%, 39.1\%]$ Vidakovic 2016591012.4%54.0% $[50.0\%, 57.9\%]$ Yoon 2015128893093742.4%4.20% $[4.10\%, 4.20\%]$ Ziobrowski 201759631572.4%83.4% $[31.1\%, [19.6\%, 44.1\%]$ Heterogeneity: Tau <sup>2</sup> = 1204Low ROB (Item #2)Barry 200326310452.4%26.5% $[20.0\%, 25.3\%]$ Dobscha 2009867262516912.4%38.6% $[33.0\%, 42.7\%]$ Donaldson 201874918182.4%41.2% $[38.9\%, 43.5\%]$ Jonaldson 201874918182.4%41.2% $[38.9\%, 43.5\%]$ Jonaldson 201874918182.4%41.5% $[36.5\%, 46.6\%]$ Mancuso 20201593832.4%41.5% $[36.5\%, 46.6\%]$ <							_	-	
Kerns 20033326852.4%48.5%44.7%, 52.3%Lagisetty 20193984524855132.4%82.1%[82.0%, 68.2%]Lei 20192373672.4%64.6% (59.4%, 69.5%)Mathew 2016139366185652.4%2.30% [52.0%, 2.30%]Mudumbai 201625870498122.4%51.9% [51.5%, 52.4%]Powell 2015651712.4%38.0% [30.7%, 45.7%]Rozet 2014441022.4%43.1% [33.4%, 53.3%]Tsai 201534582891422.4%48.2% (68.1%]Vidakovic 2016591012.4%54.0% [50.0%, 57.9%]Yoon 2015128893093742.4%42.0% [41.0%, 4.20%]Ziobrowski 201759631572.4%18.9% [17.5%, 20.3%]Total [95% CI]801736516342863.4%31.1% [19.6%, 44.1%]Heterogeneity: Tau <sup>2</sup> = 1204112427552.4%40.8% [39.0%, 42.7%]Low ROB (Item #2)Barry 200326310452.4%25.2% [22.6%, 27.9%]Gronda 20062199702.4%22.6% [30.0%, 42.7%]Dobscha 2009867262516912.4%38.9% (33.5%, 36.4%]Donaldson 201874918182.4%41.2% [38.9%, 43.5%]Gironda 20062199702.4%50.0% [53.2%, 61.9%]Mancuso 20205589962.4%57.0% [53.2%, 61.9%]Reid 2002216156942.4%57.3% [57.0%, 57.6%]Stroupe 201391<						+		-	
Kerns 20033326852.4%48.5%44.7%, 52.3%Lagisetty 20193984524855132.4%82.1%[82.0%, 82.2%]Lei 20192373672.4%64.6%, 59.4%, 69.5%]Mathew 2016139366185652.4%2.30% [52.0%, 2.30%]Mudumbai 201625870498122.4%51.9% [51.5%, 52.4%]Powell 2015651712.4%38.0% [30.7%, 45.7%]Rozet 2014441022.4%43.1% [33.4%, 53.3%]Yoakovic 2016591012.4%58.4% [48.2%, 68.1%]Vidakovic 2016591012.4%54.0% [50.0%, 57.9%]Yoon 2015128893093742.4%42.0% [41.0%, 4.20%]Ziobrowski 201759631572.4%18.9% [17.5%, 20.3%]Joodscha 2009867262516912.4%38.9% [39.0%, 42.7%]Peterogeneity: Tau <sup>2</sup> = 1204Low ROB (Item #2)Barry 200326310452.4%40.8% [39.0%, 42.7%]Dobscha 2009867262516912.4%50.0% [53.9%, 59.1%]Obscha 2009867262516912.4%50.0% [53.9%, 59.1%]Hendrikx 20201593832.4%41.5% [36.5%, 46.6%]Mancuso 20205589962.4%50.0% [53.2%, 61.9%]Reid 2002216156942.4%50.0% [53.2%, 61.9%]Stroupe 2013914582.4%50.0% [53.2%, 67.6%]Seal 2017669661169132.4%50.0% [53.2%, 67.6%] <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
Lagisetty 2019 398452 485513 2.4% 82.1% [82.0%, 82.2%] Lei 2019 237 367 2.4% 64.6% [59.4%, 69.5%] Mathew 2016 13936 618665 2.4% 2.30% [2.20%, 2.30%] Mudumbai 2016 25870 49812 2.4% 51.9% [51.5%, 52.4%] Mudumbai 2019 5316 5514 2.4% 96.4% [95.9%, 96.9%] Powell 2015 65 171 2.4% 38.0% [30.7%, 45.7%] Rozet 2014 44 102 2.4% 38.0% [30.7%, 45.7%] Rozet 2014 44 102 2.4% 38.8% [38.5%, 39.1%] Vidakovic 2016 59 101 2.4% 58.4% [38.2%, 68.1%] Wallace 2019 340 630 2.4% 54.0% [50.0%, 57.9%] Yoon 2015 12889 309374 2.4% 4.20% [4.10%, 4.20%] Ziobrowski 2017 596 3157 2.4% 18.9% [17.5%, 20.3%] Total [95% CI] 801736 5163428 63.4% 31.1% [19.6%, 44.1%] Heterogeneity: Tau <sup>2</sup> = 1204 Low ROB (Item #2) Barry 2003 263 1045 2.4% 25.2% [22.6%, 27.9%] Crosby 2006 30 114 2.4% 26.3% [18.5%, 35.4%] Dobscha 2009 86726 251691 2.4% 34.5% [34.3%, 34.6%] Donaldson 2018 749 1818 2.4% 41.2% [38.9%, 43.5%] Diobscha 2009 86726 251691 2.4% 34.5% [39.0%, 42.7%] Hendrikx 2020 159 383 2.4% 41.5% [36.5%, 46.6%] Hall 2020 1124 2755 2.4% 40.8% [39.0%, 42.7%] Hendrikx 2020 159 383 2.4% 41.5% [36.5%, 46.6%] Mancuso 2020 558 996 2.4% 57.6% [53.2%, 61.9%] Riggs 2020 2.161 5694 2.4% 57.6% [53.2%, 61.9%] Riggs 2020 2.161 5694 2.4% 57.6% [53.2%, 61.9%] Strupe 2013 91 458 2.4% 57.3% [57.0%, 57.6%] Strupe 2013 91 458 2.4% 57.3% [57.0%, 57.6%] Strupe 2013 91 458 2.4% 57.3% [57.0%, 57.6%] Strupe 2013 91 458 2.4% 57.3% [57.0%, 57.6%] Suri 2019 110 220 2.4% 50.0% [43.2%, 56.8%] VanDenkerkhof 2015 1293 3150 2.4% 41.0% [39.3%, 42.8%] Total [95% CI] 962590 5550375 100.0% 34.2% [24.5%, 44.6%] Test for subgroup interaction: $p = 0.3$						_		1	
Lei 2019 237 367 2.4% 64.6% [59.4%, 69.5%] Mathew 2016 13936 618565 2.4% 2.30% [2.20%, 2.30%] Mudumbai 2019 5316 5514 2.4% 51.9% [51.5%, 52.4%] Mudumbai 2019 5316 5514 2.4% 98.0% [30.7%, 45.7%] Rozet 2014 44 102 2.4% 43.1% [33.4%, 53.3%] Tsai 2015 34582 89142 2.4% 38.8% [38.5%, 39.1%] Vidakovic 2016 59 101 2.4% 58.4% [48.2%, 68.1%] Wallace 2019 340 630 2.4% 54.0% [50.0%, 57.9%] Yoon 2015 12889 309374 2.4% 4.20% [4.10%, 4.20%] Ziobrowski 2017 596 3157 2.4% 18.9% [17.5%, 20.3%] Total [95% CI] 801736 5163428 63.4% 31.1% [19.6%, 44.1%] Heterogeneity: Tau <sup>2</sup> = 1204 Low ROB (Item #2) Barry 2003 263 1045 2.4% 25.2% [22.6%, 27.9%] Crosby 2006 30 114 2.4% 26.3% [18.5%, 35.4%] DeBeer 2017 1124 2755 2.4% 40.8% [39.0%, 42.7%] Dobscha 2009 86726 251691 2.4% 34.5% [36.5%, 46.6%] Mancuso 2020 1124 2755 2.4% 40.8% [39.0%, 42.7%] Hendrikx 2020 1124 2755 2.4% 40.8% [39.0%, 42.7%] Hendrikx 2020 159 333 2.4% 41.5% [36.5%, 46.6%] Mancuso 2020 558 996 2.4% 56.0% [52.9%, 59.1%] Riggs 2020 2.161 5594 2.4% 38.0% [36.5%, 46.6%] Mancuso 2020 2.97 516 2.4% 57.6% [53.2%, 61.9%] Riggs 2020 2.161 5694 2.4% 19.9% [16.3%, 23.8%] Suri 2017 66966 116913 2.4% 57.6% [53.2%, 61.9%] Stroupe 2013 91 458 2.4% 19.9% [16.3%, 23.8%] Suri 2019 110 220 2.4% 50.0% [43.2%, 56.8%] VanDenkerkhof 2015 123 3150 2.4% 41.0% [39.3%, 42.8%] Total [95% CI] 60854 386947 36.6% 39.7% [32.2%, 47.5%] Heterogeneity: Tau <sup>2</sup> = 235 Total [95% CI] 962590 5550375 100.0% 34.2% [24.5%, 44.6%]									
Mathew 2016139366185652.4%2.30%2.20%2.30%1Mudumbai 201625870498122.4%51.9%56.9%6.9%Powell 2015651712.4%38.0%(30.7%, 45.7%)Rozet 2014441022.4%38.8%(38.5%, 39.1%)Vidakovic 2016591012.4%38.4%(58.5%, 96.9%)Yoon 201534582891422.4%38.8%(38.5%, 39.1%)Vidakovic 2016591012.4%58.4%[48.2%, 68.1%]Valace 20193406302.4%54.0%[50.0%, 57.9%]Yoon 2015128893093742.4%4.20%[4.10%, 4.20%]Ziobrowski 201759631572.4%48.9%[17.5%, 22.3%]Total [95% CI]801736516342863.4%31.1%[19.6%, 44.1%]Heterogeneity: Tau <sup>2</sup> = 1204263[14.2%, 26.3%[18.5%, 35.4%]Dobscha 2009867262516912.4%34.5%35.4%]Dobscha 2009867262516912.4%34.5%[39.0%, 42.7%]Dobscha 20062199702.4%41.2%[38.9%, 43.5%]Gironda 20062199702.4%40.8%[39.0%, 42.7%]Hendrikx 20201593332.4%41.5%[36.5%, 46.6%]Mancuso 20205589962.4%57.6%[53.2%, 61.9%]Stroupe 2013914582.4%19.9%[16.3%, 23.8%]Suri 2017 </td <td>• •</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td>	• •							-	
Mudumbai 201625870498122.4%51.9%[51.5%, 52.4%]Mudumbai 2019531655142.4%96.4%[95.9%, 96.9%]Powell 2015651712.4%38.0%[30.7%, 45.7%]Rozet 2014441022.4%38.8%[38.5%, 39.1%]Vidakovic 2016591012.4%58.4%[48.2%, 68.1%]Vidakovic 2016591012.4%58.4%[48.2%, 68.1%]Vallace 20193406302.4%54.0%[50.0%, 57.9%]Yoon 2015128893093742.4%4.20%[4.10%, 4.20%]Ziobrowski 201759631572.4%18.9%[17.5%, 20.3%]Total [95% CI]801736516342863.4%31.1%[19.6%, 44.1%]Heterogeneity: Tau <sup>2</sup> = 1204Low ROB (Item #2)Barry 200326310452.4%25.2%[22.6%, 27.9%]Crosby 2006301142.4%26.3%[18.5%, 35.4%]Debscha 2009867262516912.4%34.5%[39.0%, 42.7%]Donaldson 201874918182.4%41.2%[38.9%, 43.5%]Gironda 20062199702.4%22.6%[20.0%, 25.3%]Hendrikx 20201593832.4%41.5%[36.5%, 46.6%]Mancuso 20205589962.4%56.0%[52.9%, 59.1%]Reig 2020216156942.4%57.3%[57.0%, 57.6%]Stroupe 2013914582.4% </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td>								-	
Mudumbai 2019531655142.4%96.4%[95.9%, 96.9%]Powell 2015651712.4%38.0%[30.7%, 45.7%]Rozet 2014441022.4%43.1%[33.4%, 53.3%]Tsai 201534582891422.4%38.8%[38.5%, 39.1%]Vidakovic 2016591012.4%58.4%[48.2%, 68.1%]Wallace 20193406302.4%54.0%[50.0%, 57.9%]Yoon 2015128893093742.4%4.20%[4.10%, 4.20%]Ziobrowski 201759631572.4%18.9%[17.5%, 20.3%]Total [95% CI]801736516342863.4%31.1%[19.6%, 44.1%]Heterogeneity: Tau <sup>2</sup> = 120425222.6%27.9%]27.5%Dobscha 2009867262516912.4%34.5%[38.9%, 43.5%]Dobscha 2009867262516912.4%34.5%[38.9%, 43.5%]Dobscha 2009867262516912.4%38.0%[39.0%, 42.7%]Dobscha 2009112427552.4%40.8%[39.0%, 42.7%]Hendrikx 20201593832.4%41.5%[36.5%, 46.6%]Mancuso 20205589962.4%56.0%[52.9%, 59.1%]Reid 2002216156942.4%38.0%[36.7%, 39.2%]Seal 2017669661169132.4%57.3%[57.0%, 57.6%]Stroupe 2013914582.4%19.9%[16.3%, 23.8%]Suri 2019110<						_			
Powell 2015651712.4%38.0% $[30.7\%, 45.7\%]$ Rozet 2014441022.4%43.1% $[33.4\%]$ $[33.3\%]$ Tsai 201534582891422.4%38.8% $[38.5\%, 39.1\%]$ Vidakovic 2016591012.4%58.4% $[48.2\%, 68.1\%]$ Wallace 20193406302.4%54.0% $[50.0\%, 57.9\%]$ Yoon 2015128893093742.4%4.20% $[4.10\%, 4.20\%]$ Ziobrowski 201759631572.4%18.9% $[17.5\%, 20.3\%]$ Total [95% CI]801736516342863.4%31.1% $[19.6\%, 44.1\%]$ Heterogeneity: Tau <sup>2</sup> = 1204Low ROB (Item #2)Barry 200326310452.4%25.2% $[22.6\%, 27.9\%]$ Crosby 2006301142.4%26.3% $[18.5\%, 35.4\%]$ Deber 2017112427552.4%40.8% $[39.0\%, 42.7\%]$ Donaldson 201874918182.4%41.2% $[38.9\%, 43.5\%]$ Gironda 20062199702.4%26.6% $[20.0\%, 25.3\%]$ Hendrikx 20201593832.4%41.5% $[36.7\%, 39.2\%]$ Reid 20022975162.4%56.0% $[52.9\%, 59.1\%]$ Reid 2002216156942.4%58.0% $[43.2\%, 56.8\%]$ Storupe 2013914582.4%19.9% $[63.2\%, 65.8\%]$ Storupe 2013914582.4%19.9% $[63.2\%, 65.8\%]$ Storupe 2013	Mudumbai 2019	5316	5514	2.4%					
Rozet 2014441022.4%43.1%[33.4%, 53.3%]Tsai 201534582891422.4%38.8%[38.5%, 39.1%]Vidakovic 2016591012.4%58.4%[48.2%, 68.1%]Wallace 20193406302.4%54.0%[50.0%, 57.9%]Yoon 2015128893093742.4%4.20%[4.10%, 4.20%]Ziobrowski 201759631572.4%18.9%[17.5%, 20.3%]Total [95% CI]801736516342863.4%31.1%[19.6%, 44.1%]Heterogeneity: Tau <sup>2</sup> = 120425.2%[22.6%, 27.9%]Low ROB (Item #2)63.4%31.1%[19.6%, 44.1%]Barry 200326310452.4%26.3%[18.5%, 35.4%]DeBeer 2017112427552.4%40.8%[39.0%, 42.7%]Dobscha 2009867262516912.4%34.5%[34.3%, 34.6%]Donaldson 201874918182.4%41.2%[38.9%, 43.5%]Hall 2020112427552.4%40.8%[39.0%, 42.7%]Hendrikx 20201593832.4%41.5%[36.5%, 46.6%]Mancuso 20205589962.4%56.0%[52.9%, 59.1%]Reid 2002216156942.4%51.3%[6.3%, 32.2%, 47.5%]Stroupe 2013914582.4%19.9%[16.3%, 22.6%, 27.5%]Stroupe 2013914582.4%19.0%[32.2%, 47.5%]VanDenKerkhof								-	
Tsai 201534582891422.4%38.8% $[38.5\%, 39.1\%]$ Vidakovic 2016591012.4%58.4% $[48.2\%, 68.1\%]$ Wallace 20193406302.4%54.0% $[50.0\%, 57.9\%]$ Yoon 2015128893093742.4%4.20% [4.10%, 4.20%]Ziobrowski 201759631572.4%18.9% [17.5%, 20.3%]Total [95% CI]801736516342863.4%31.1% [19.6%, 44.1%]Heterogeneity: Tau <sup>2</sup> = 12041142.4%26.3% [18.5%, 35.4%]DeBeer 2017112427552.4%40.8% [39.0%, 42.7%]Dobscha 2009867262516912.4%34.5% [34.3%, 34.6%]Donaldson 201874918182.4%41.2% [38.9%, 43.5%]Gironda 20062199702.4%22.6% [20.0%, 25.3%]Hall 2020112427552.4%40.8% [39.0%, 42.7%]Hendrikx 20201593832.4%41.5% [36.5%, 46.6%]Mancuso 20205589962.4%50.0% [52.9%, 59.1%]Reid 2002216156942.4%38.0% [36.7%, 39.2%]Stroupe 2013914582.4%19.9% [16.3%, 23.8%]Suri 20191102202.4%50.0% [43.2%, 56.8%]VanDenKerkhof 2015129331502.4%41.0% [39.3%, 42.8%]Total [95% CI]16085438694736.6%39.7% [32.2%, 47.5%]Heterogeneity: Tau <sup>2</sup> = 2355550375100.0%34.2% [24.5%, 44.6%]									
Vidakovic 2016591012.4%58.4%[48.2%, 68.1%]Wallace 20193406302.4%54.0%[50.0%, 57.9%]Yoon 2015128893093742.4%4.20%[4.10%, 4.20%]Ziobrowski 201759631572.4%4.8.9%[17.5%, 20.3%]Total [95% CI]801736516342863.4%31.1%[19.6%, 44.1%]Heterogeneity: Tau <sup>2</sup> = 120463.4%31.1%[19.6%, 44.1%]Low ROB (Item #2)Barry 200326310452.4%25.2%[22.6%, 27.9%]Crosby 2006301142.4%26.3%[18.5%, 35.4%]DeBeer 2017112427552.4%40.8% [39.0%, 42.7%]Donaldson 201874918182.4%41.2% [38.9%, 43.5%]Gironda 20062199702.4%22.6% [20.0%, 25.3%]Hall 2020112427552.4%40.8% [39.0%, 42.7%]Hendrikx 20201593832.4%41.5% [36.5%, 46.6%]Mancuso 20205589962.4%56.0% [53.2%, 61.9%]Reid 2002216156942.4%38.0% [36.7%, 39.2%]Seal 2017669661169132.4%19.9% [16.3%, 23.8%]Suri 20191102202.4%50.0% [43.2%, 56.8%]VanDenKerkhof 2015129331502.4%41.0% [39.3%, 42.8%]Total [95% CI]9625905550375100.0%34.2% [24.5%, 44.6%]Heterogeneity: Tau <sup>2</sup> = 235550375100.0%34		34582							Ē
Wallace 20193406302.4%54.0% $[50.0\%, 57.9\%]$ Yoon 2015128893093742.4%4.20% $[4.10\%, 4.20\%]$ Ziobrowski 201759631572.4%18.9% $[17.5\%, 20.3\%]$ Total [95% CI]801736516342863.4%31.1% $[19.6\%, 44.1\%]$ Heterogeneity: Tau <sup>2</sup> = 1204E63.4%31.1% $[19.6\%, 44.1\%]$ Low ROB (Item #2)Barry 200326310452.4%25.2% $[22.6\%, 27.9\%]$ DeBeer 2017112427552.4%40.8% $[39.0\%, 42.7\%]$ Dobscha 2009867262516912.4%34.5% $[34.3\%, 34.6\%]$ Donaldson 201874918182.4%41.2% $[38.9\%, 43.5\%]$ Gironda 20062199702.4%22.6% $[20.0\%, 25.3\%]$ Hendrikx 20201593832.4%41.5% $[35.2\%, 61.9\%]$ Mancuso 20205589962.4%56.0% $[52.9\%, 59.1\%]$ Riggs 2020216156942.4%38.0% $[67.\%, 39.2\%]$ Stroupe 2013914582.4%19.9% $[13.3\%, 42.8\%]$ Suri 20191102202.4%50.0% $[43.2\%, 56.8\%]$ VanDenKerkhof 2015129331502.4%41.0% $[39.3\%, 42.8\%]$ VanDenKerkhof 2015129331502.4%41.0% $[39.3\%, 42.8\%]$ Heterogeneity: Tau <sup>2</sup> = 2355550375100.0%34.2% $[24.5\%, 44.6\%]$	Vidakovic 2016	59	101	2.4%					
Yoon 201512889 $309374$ 2.4%4.20% $[4.10\%, 4.20\%]$ Ziobrowski 2017596 $3157$ 2.4% $18.9\%$ $[17.5\%, 20.3\%]$ Total [95% CI]801736516342863.4% $31.1\%$ $[19.6\%, 44.1\%]$ Heterogeneity: Tau <sup>2</sup> = 1204Earry 200326310452.4%25.2%[22.6%, 27.9\%]Crosby 2006301142.4%26.3%[18.5%, 35.4%]DeBeer 2017112427552.4%40.8%[39.0%, 42.7%]Dobscha 2009867262516912.4%34.5%[34.3%, 34.6%]Donaldson 201874918182.4%41.2%[38.9%, 43.5%]Gironda 20062199702.4%22.6%[20.0%, 25.3%]Hendrikx 20201593832.4%41.5%[36.5%, 46.6%]Mancuso 20205589962.4%56.0%[52.9%, 59.1%]Reid 20022975162.4%57.0%, 57.0%, 57.0%]Stroupe 2013914582.4%19.9%Suri 20191102202.4%50.0%VanDenKerkhof 2015129331502.4%41.0%VanDenKerkhof 2015129331502.4%39.7%Heterogeneity: Tau <sup>2</sup> = 2355550375100.0%34.2%Total [95% CI]9625905550375100.0%34.2%Fest for subgroup interaction: p = 0.3550375100.0%34.2%	Wallace 2019			2.4%				-	
Ziobrowski 201759631572.4%18.9% $[17.5\%, 20.3\%]$ Total [95% CI]801736516342863.4%31.1% $[19.6\%, 44.1\%]$ Heterogeneity: Tau <sup>2</sup> = 1204Low ROB (item #2)Barry 200326310452.4%25.2% $[22.6\%, 27.9\%]$ DeBeer 2017112427552.4%40.8% $[39.0\%, 42.7\%]$ Dobscha 2009867262516912.4%34.5% $[34.3\%, 34.6\%]$ Donaldson 201874918182.4%41.2% $[38.9\%, 43.5\%]$ Gironda 20062199702.4%22.6% $[20.0\%, 25.3\%]$ Hall 2020112427552.4%40.8% $[39.0\%, 42.7\%]$ Handrikx 20201593832.4%41.5% $[36.5\%, 46.6\%]$ Mancuso 20205589962.4%56.0% $[52.9\%, 59.1\%]$ Reid 20022975162.4%57.3% $[57.0\%, 57.6\%]$ Stroupe 2013914582.4%19.9% $[16.3\%, 23.8\%]$ Suri 20191102202.4%50.0% $[32.2\%, 47.5\%]$ VanDenKerkhof 2015129331502.4%41.0% $[39.3\%, 42.8\%]$ Total [95% CI]9625905550375100.0%34.2% $[24.5\%, 44.6\%]$	Yoon 2015								
Total [95% CI]       801736       5163428       63.4%       31.1% [19.6%, 44.1%]         Heterogeneity: Tau <sup>2</sup> = 1204       Earry 2003       263       1045       2.4%       25.2% [22.6%, 27.9%]         Barry 2003       263       1045       2.4%       25.2% [22.6%, 27.9%]         Crosby 2006       30       114       2.4%       26.3% [18.5%, 35.4%]         DeBeer 2017       1124       2755       2.4%       40.8% [39.0%, 42.7%]         Dobscha 2009       86726       251691       2.4%       34.5% [34.3%, 34.6%]         Donaldson 2018       749       1818       2.4%       41.2% [38.9%, 43.5%]         Gironda 2006       219       970       2.4%       22.6% [20.0%, 25.3%]         Hall 2020       1124       2755       2.4%       40.8% [39.0%, 42.7%]         Hendrikx 2020       159       383       2.4%       41.5% [36.5%, 46.6%]         Mancuso 2020       159       383       2.4%       41.9% [39.0%, 42.7%]         Reig 2002       2161       5694       2.4%       56.0% [52.9%, 59.1%]         Riggs 2020       2161       5694       2.4%       57.3% [57.0%, 57.6%]         Stroupe 2013       91       458       2.4%       50.0% [43.2%, 56.8%]							+		
Heterogeneity: Tau <sup>2</sup> = 1204Low ROB (Item #2)Barry 200326310452.4%25.2% [22.6%, 27.9%]Crosby 2006301142.4%26.3% [18.5%, 35.4%]DeBeer 2017112427552.4%40.8% [39.0%, 42.7%]Dobscha 2009867262516912.4%34.5% [34.3%, 34.6%]Donaldson 201874918182.4%41.2% [38.9%, 43.5%]Gironda 20062199702.4%22.6% [20.0%, 25.3%]Hall 2020112427552.4%40.8% [39.0%, 42.7%]Hendrikx 20201593832.4%41.5% [36.5%, 46.6%]Mancuso 20205589962.4%56.0% [52.9%, 59.1%]Reid 20022975162.4%57.6% [53.2%, 61.9%]Riggs 2020216156942.4%38.0% [36.7%, 39.2%]Seal 2017669661169132.4%57.3% [57.0%, 57.6%]Stroupe 2013914582.4%19.9% [16.3%, 23.8%]Suri 20191102202.4%50.0% [43.2%, 56.8%]VanDenKerkhof 2015129331502.4%41.0% [39.3%, 42.8%]Total [95% CI]16085438694736.6%39.7% [32.2%, 47.5%]Heterogeneity: Tau <sup>2</sup> = 2359625905550375100.0%34.2% [24.5%, 44.6%]		801736	5163428				-	-	-
Barry 200326310452.4%25.2%[22.6%, 27.9%]Crosby 2006301142.4%26.3%[18.5%, 35.4%]DeBeer 2017112427552.4%40.8%[39.0%, 42.7%]Dobscha 2009867262516912.4%34.5%[34.3%, 34.6%]Donaldson 201874918182.4%41.2%[38.9%, 43.5%]Gironda 20062199702.4%22.6%[20.0%, 25.3%]Hall 2020112427552.4%40.8%[39.0%, 42.7%]Hendrikx 20201593832.4%41.5%[53.2%, 61.9%]Reid 20022975162.4%56.0%[52.9%, 59.1%]Reid 20022975162.4%57.6%[53.2%, 61.9%]Stroupe 2013914582.4%41.0%[39.3%, 42.8%]Suri 20191102202.4%50.0%[43.2%, 56.8%]VanDenKerkhof 2015129331502.4%41.0%[39.3%, 42.8%]Total [95% CI]9625905550375100.0%34.2%[24.5%, 44.6%]Test for subgroup interaction: $p = 0.3$									
Barry 200326310452.4%25.2%[22.6%, 27.9%]Crosby 2006301142.4%26.3%[18.5%, 35.4%]DeBeer 2017112427552.4%40.8%[39.0%, 42.7%]Dobscha 2009867262516912.4%34.5%[34.3%, 34.6%]Donaldson 201874918182.4%41.2%[38.9%, 43.5%]Gironda 20062199702.4%22.6%[20.0%, 25.3%]Hall 2020112427552.4%40.8%[39.0%, 42.7%]Hendrikx 20201593832.4%41.5%[36.5%, 46.6%]Mancuso 20205589962.4%56.0%[52.9%, 59.1%]Reid 20022975162.4%57.6%[53.2%, 61.9%]Riggs 2020216156942.4%38.0%[36.7%, 39.2%]Seal 2017669661169132.4%57.0%, 57.6%]Stroupe 2013914582.4%41.0%[39.3%, 42.8%]Suri 20191102202.4%50.0%[43.2%, 56.8%]VanDenKerkhof 2015129331502.4%41.0%[39.3%, 42.8%]Total [95% CI]9625905550375100.0%34.2%[24.5%, 44.6%]Test for subgroup interaction: $p = 0.3$ 100.0%34.2%[24.5%, 44.6%]									
Crosby 2006301142.4%26.3%[18.5%, 35.4%]DeBeer 2017112427552.4%40.8%[39.0%, 42.7%]Dobscha 2009867262516912.4%34.5%[34.3%, 34.6%]Donaldson 201874918182.4%41.2%[38.9%, 43.5%]Gironda 20062199702.4%22.6%[20.0%, 25.3%]Hall 2020112427552.4%40.8%[39.0%, 42.7%]Hendrikx 20201593832.4%41.5%[36.5%, 46.6%]Mancuso 20205589962.4%56.0%[52.9%, 59.1%]Reid 20022975162.4%57.6%[53.2%, 61.9%]Riggs 2020216156942.4%38.0%[36.7%, 39.2%]Seal 2017669661169132.4%57.3%[57.0%, 57.6%]Stroupe 2013914582.4%19.9%[16.3%, 23.8%]Suri 20191102202.4%50.0%[43.2%, 56.8%]VanDenKerkhof 2015129331502.4%41.0%[39.3%, 42.8%]Total [95% CI]16085438694736.6%39.7%[32.2%, 47.5%]Heterogeneity: Tau <sup>2</sup> = 2359625905550375100.0%34.2%[24.5%, 44.6%]					05 00/ F00 00/ 07 00/-		_		
DeBeer 2017112427552.4%40.8% [39.0%, 42.7%]Dobscha 2009867262516912.4%34.5% [34.3%, 34.6%]Donaldson 201874918182.4%34.5% [34.3%, 34.6%]Gironda 20062199702.4%22.6% [20.0%, 25.3%]Hall 2020112427552.4%40.8% [39.0%, 42.7%]Hendrikx 20201593832.4%41.5% [36.5%, 46.6%]Mancuso 20205589962.4%56.0% [52.9%, 59.1%]Reid 20022975162.4%57.6% [53.2%, 61.9%]Riggs 2020216156942.4%38.0% [36.7%, 39.2%]Seal 2017669661169132.4%57.3% [57.0%, 57.6%]Stroupe 2013914582.4%19.9% [16.3%, 23.8%]Suri 20191102202.4%50.0% [43.2%, 56.8%]VanDenKerkhof 2015129331502.4%41.0% [39.3%, 42.8%]Total [95% CI]16085438694736.6%39.7% [32.2%, 47.5%]Heterogeneity: Tau <sup>2</sup> = 2355550375100.0%34.2% [24.5%, 44.6%]							-+-		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								÷	-
Gironda 20062199702.4%22.6% $[20.0\%, 25.3\%]$ Hall 2020112427552.4%40.8% $[39.0\%, 42.7\%]$ Hendrikx 20201593832.4%41.5% $[36.5\%, 46.6\%]$ Mancuso 20205589962.4%56.0% $[52.9\%, 59.1\%]$ Reid 20022975162.4%57.6% $[53.2\%, 61.9\%]$ Riggs 2020216156942.4%38.0% $[36.7\%, 39.2\%]$ Seal 2017669661169132.4%57.3% $[57.0\%, 57.6\%]$ Stroupe 2013914582.4%19.9% $[16.3\%, 23.8\%]$ Suri 20191102202.4%50.0% $[43.2\%, 56.8\%]$ VanDenKerkhof 2015129331502.4%41.0% $[39.3\%, 42.8\%]$ Total [95% CI]9625905550375100.0%34.2%[24.5\%, 44.6\%]Test for subgroup interaction: $p = 0.3$ 5550375100.0%34.2%[24.5\%, 44.6\%]								1	
Hall 2020112427552.4%40.8% $[39.0\%, 42.7\%]$ Hendrikx 20201593832.4%41.5% $[36.5\%, 46.6\%]$ Mancuso 20205589962.4%56.0% $[52.9\%, 59.1\%]$ Reid 20022975162.4%57.6% $[53.2\%, 61.9\%]$ Riggs 2020216156942.4%38.0% $[36.7\%, 39.2\%]$ Seal 2017669661169132.4%57.3% $[57.0\%, 57.6\%]$ Stroupe 2013914582.4%19.9% $[16.3\%, 23.8\%]$ Suri 20191102202.4%50.0% $[43.2\%, 56.8\%]$ VanDenKerkhof 2015129331502.4%41.0% $[39.3\%, 42.8\%]$ Total [95% CI]9625905550375100.0%34.2% [24.5%, 44.6%]Test for subgroup interaction: $p = 0.3$ 5550375100.0%34.2% $[24.5\%, 44.6\%]$							_		+
Hendrikx 20201593832.4%41.5%[36.5%, 46.6%]Mancuso 20205589962.4%56.0%[52.9%, 59.1%]Reid 20022975162.4%57.6%[53.2%, 61.9%]Riggs 2020216156942.4%38.0%[36.7%, 39.2%]Seal 2017669661169132.4%57.3%[57.0%, 57.6%]Stroupe 2013914582.4%19.9%[16.3%, 23.8%]Suri 20191102202.4%50.0%[43.2%, 56.8%]VanDenKerkhof 2015129331502.4%41.0%[39.3%, 42.8%]Total [95% CI]16085438694736.6%39.7%[32.2%, 47.5%]Heterogeneity: Tau <sup>2</sup> = 2359625905550375100.0%34.2%[24.5%, 44.6%]							-+-		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $									+-
Reid 20022975162.4%57.6% $[53.2\%, 61.9\%]$ Riggs 2020216156942.4%38.0% $[36.7\%, 39.2\%]$ Seal 2017669661169132.4%57.3% $[57.0\%, 57.6\%]$ Stroupe 2013914582.4%59.9% $[16.3\%, 23.8\%]$ Suri 20191102202.4%50.0% $[43.2\%, 56.8\%]$ VanDenKerkhof 2015129331502.4%41.0% $[39.3\%, 42.8\%]$ Total [95% CI]16085438694736.6%39.7% $[32.2\%, 47.5\%]$ Heterogeneity: Tau <sup>2</sup> = 2359625905550375100.0%34.2%[24.5%, 44.6%]									÷
Riggs 2020216156942.4% $38.0\%$ $[36.7\%, 39.2\%]$ Seal 2017669661169132.4%57.3% $[57.0\%, 57.6\%]$ Stroupe 2013914582.4%19.9% $[16.3\%, 23.8\%]$ Suri 20191102202.4%50.0% $[43.2\%, 56.8\%]$ VanDenKerkhof 2015129331502.4%41.0% $[39.3\%, 42.8\%]$ Total [95% CI]16085438694736.6%39.7% $[32.2\%, 47.5\%]$ Heterogeneity: Tau <sup>2</sup> = 2359625905550375100.0%34.2%[24.5%, 44.6%]									
Seal 2017       66966       116913       2.4%       57.3%       [57.0%, 57.6%]         Stroupe 2013       91       458       2.4%       19.9%       [16.3%, 23.8%]         Suri 2019       110       220       2.4%       50.0%       [43.2%, 56.8%]         VanDenKerkhof 2015       1293       3150       2.4%       41.0%       [39.3%, 42.8%]         Total [95% CI]       160854       386947       36.6%       39.7%       [32.2%, 47.5%]         Heterogeneity: Tau <sup>2</sup> = 235       962590       5550375       100.0%       34.2%       [24.5%, 44.6%]									
Stroupe 2013       91       458       2.4%       19.9% [16.3%, 23.8%]         Suri 2019       110       220       2.4%       50.0% [43.2%, 56.8%]         VanDenKerkhof 2015       1293       3150       2.4%       41.0% [39.3%, 42.8%]         Total [95% CI]       160854       386947       36.6%       39.7% [32.2%, 47.5%]         Heterogeneity: Tau <sup>2</sup> = 235       962590       5550375       100.0%       34.2% [24.5%, 44.6%]         Test for subgroup interaction: p = 0.3       0.3       0.3       0.2%       0.3									
Suri 2019         110         220         2.4%         50.0% [43.2%, 56.8%]           VanDenKerkhof 2015         1293         3150         2.4%         41.0% [39.3%, 42.8%]           Total [95% CI]         160854         386947         36.6%         39.7% [32.2%, 47.5%]           Heterogeneity: Tau <sup>2</sup> = 235         962590         5550375         100.0%         34.2% [24.5%, 44.6%]           Test for subgroup interaction: p = 0.3         9.3         34.2% [24.5%, 44.6%]         34.2%									
VanDenKerkhof 2015         1293         3150         2.4%         41.0%         [39.3%, 42.8%]           Total [95% CI]         160854         386947         36.6%         39.7%         [32.2%, 47.5%]           Heterogeneity: Tau <sup>2</sup> = 235         962590         5550375         100.0%         34.2%         [24.5%, 44.6%]           Total [95% CI]         962590         5550375         100.0%         34.2%         [24.5%, 44.6%]									
Total [95% CI]         160854         386947         36.6%         39.7% [32.2%, 47.5%]           Heterogeneity: Tau <sup>2</sup> = 235         962590         5550375         100.0%         34.2% [24.5%, 44.6%]           Total [95% CI]         962590         5550375         100.0%         34.2% [24.5%, 44.6%]           Test for subgroup interaction: p = 0.3         9         3         3         3									-
Heterogeneity: Tau <sup>2</sup> = 235 <b>Total [95% CI]</b> 962590 5550375 100.0% 34.2% [24.5%, 44.6%] Test for subgroup interaction: p = 0.3									÷
Total [95% CI]         962590         5550375         100.0%         34.2%         [24.5%, 44.6%]           Test for subgroup interaction: p = 0.3		160854	386947	36.6%	39.7% [32.2%, 47.5%]			-	
Test for subgroup interaction: p = 0.3	Heterogeneity: Tau <sup>2</sup> = 235								
Test for subgroup interaction: p = 0.3	Total (95% CI)	962590	5550375	100.0%	34 2% [24 5% 44 6%]				
			3333313	100.0 /0	J. 2 /0 [24.J /0, 44.J /0]	_	_	-	
0 0.2 0.4	reaction subgroup interaction.								
		. p = 0.3							

**Supplementary Material 12.** Subgroup analysis of chronic non-cancer pain prevalence with respect to ROB item #2. CI = confidence interval; IV = inverse variance.

Study					
or Subgroup	Events	Total	Weight	IV, Random, 95% CI	
Low ROB (Item #3)			-		
Adams 2015	102	175	2.4%	58.3% [50.6%, 65.7%]	
Barry 2003	263	1045	2.4%	25.2% [22.6%, 27.9%]	<b></b>
Burgess 2013	131778	296918	2.4%	44.4% [44.3%, 44.6%]	<b>1</b>
Cichowski 2017	94398	516950	2.4%	18.3% [18.2%, 18.4%]	•
Crosby 2006	30	114	2.4%	26.3% [18.5%, 35.4%]	- <mark></mark>
DeBeer 2017	1124	2755	2.4%	40.8% [39.0%, 42.7%]	
Dobscha 2009	86726	251691	2.4%	34.5% [34.3%, 34.6%]	
Donaldson 2018	749	1818	2.4%	41.2% [38.9%, 43.5%]	
Hall 2020	1124	2755	2.4%	40.8% [39.0%, 42.7%]	+
Hendrikx 2020	159	383	2.4%	41.5% [36.5%, 46.6%]	
Kerns 2003	332	685	2.4%	48.5% [44.7%, 52.3%]	
Lei 2019	237	367	2.4%	64.6% [59.4%, 69.5%]	
Mancuso 2020	558	996	2.4%	56.0% [52.9%, 59.1%]	
Mudumbai 2016	25870	49812	2.4%	51.9% [51.5%, 52.4%]	•
Reid 2002	297	516	2.4%	57.6% [53.2%, 61.9%]	· · · · ·
Riggs 2020	2161	5694	2.4%	38.0% [36.7%, 39.2%]	
Stroupe 2013	91	458	2.4%	19.9% [16.3%, 23.8%]	<b>.</b> .
Suri 2019	110	220	2.4%	50.0% [43.2%, 56.8%]	
Tsai 2015	34582	89142	2.4%	38.8% [38.5%, 39.1%]	
VanDenKerkhof 2015	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Vidakovic 2016	59	101	2.4%	58.4% [48.2%, 68.1%]	· · · · · · · · · · · · · · · · · · ·
Wallace 2019	340	630	2.4%	54.0% [50.0%, 57.9%]	
Ziobrowski 2017	596	3157	2.4%	18.9% [17.5%, 20.3%]	
Total [95% CI]	580627	1227001	56.1%	41.9% [35.7%, 48.3%]	
Heterogeneity: Tau <sup>2</sup> = 237	000021	122/001	00.170	41.0 % [00.7 %, 40.0 %]	-
Lieteregeneny: Fau 207					
High ROB (Item #3)					
Bishop 2020	5607	18940	2.4%	29.6% [29.0%, 30.3%]	
Copeland 2014	29080	89995	2.4%	32.3% [32.0%, 32.6%]	
Figoni 2015	85	178	2.4%	47.8% [40.2%, 55.4%]	
Gironda 2006	219	970	2.4%	22.6% [20.0%, 25.3%]	_
Goulet 2016	91	458	2.4%	19.9% [16.3%, 23.8%]	
Graham 2019	8385	280681	2.4%	3.00% [2.90%, 3.10%]	
Hadlandsmyth 2018	2943	6653	2.4%	44.2% [43.0%, 45.4%]	· · · · · · · · · · · · · · · · · · ·
Haskell 2009	3427	16611	2.4%	20.6% [20.0%, 21.3%]	_ =
Ho 2018	1293	3150	2.4%	41.0% [39.3%, 42.8%]	•
Huerta 2016	596	3157	2.4%	18.9% [17.5%, 20.3%]	•
Kalpakci 2018	6228	345204	2.4%	1.80% [1.80%, 1.80%]	•
Lagisetty 2019	398452	485513	2.4%	82.1% [82.0%, 82.2%]	
Mathew 2016	13936	618565	2.4%	2.30% [2.20%, 2.30%]	
Mudumbai 2019	5316	5514	2.4%	96.4% [95.9%, 96.9%]	• • •
Powell 2015	65	171	2.4%	38.0% [30.7%, 45.7%]	•
Rozet 2014	44	102	2.4%	43.1% [33.4%, 53.3%]	
Seal 2017	66966	116913	2.4%	57.3% [57.0%, 57.6%]	
Yoon 2015	12889	309374	2.4%	4.20% [4.10%, 4.20%]	
			43.9%		1
Total [95% CI] Heterogeneity: Tau <sup>2</sup> = 1352	381963	4323374	43.3%	24.9% [11.9%, 40.8%]	
Heterogeneity: Tau <sup>2</sup> = 1352					
Total [95% CI]	962950	5550375	100.0%	34.2% [24.5%, 44.6%]	
Test for subgroup interaction:		3330373	100.0 %	54.2 /0 [24.5 /0, 44.0 /0]	-
rescion subgroup interaction.	p = 0.05				
					0 0.2 0.4 0.6 0.8 1

**Supplementary Material 13.** Subgroup analysis of chronic non-cancer pain prevalence with respect to ROB item #3. CI = confidence interval; IV = inverse variance.

Study					
or Subgroup	Events	Total	Weight	IV, Random, 95% CI	
High ROB (Item #4)	210110	. o.ui		, / ana only 00 /0 01	
Adams 2015	102	175	2.4%	58.3% [50.6%, 65.7%]	
Bishop 2020	5607	18940	2.4%	29.6% [29.0%, 30.3%]	
Copeland 2014	29080	89995	2.4%	32.3% [32.0%, 32.6%]	
Crosby 2006	30	114	2.4%	26.3% [18.5%, 35.4%]	
Donaldson 2018	749	1818	2.4%	41.2% [38.9%, 43.5%]	
Figoni 2015	85	178	2.4%	47.8% [40.2%, 55.4%]	
Graham 2019	8385	280681	2.4%	3.00% [2.90%, 3.10%]	
Hall 2020	1124	2755	2.4%	40.8% [39.0%, 42.7%]	
Hendrikx 2020	159	383	2.4%	41.5% [36.5%, 46.6%]	
Kerns 2003	332	685	2.4%	48.5% [44.7%, 52.3%]	
Lei 2019	237	367	2.4%	64.6% [59.4%, 69.5%]	
Mancuso 2020	558	996	2.4%	56.0% [52.9%, 59.1%]	-
Mudumbai 2019	5316	5514	2.4%	96.4% [95.9%, 96.9%]	•
Riggs 2020	2161	5694	2.4%	38.0% [36.7%, 39.2%]	-
Stroupe 2013	91	458	2.4%	19.9% [16.3%, 23.8%]	-
Suri 2019	110	220	2.4%	50.0% [43.2%, 56.8%]	
VanDenKerkhof 2015	1293	3150	2.4%	41.0% [39.3%, 42.8%]	-
Ziobrowski 2017	596	3157	2.4%	18.9% [17.5%, 20.3%]	· · · · · · · · · · · · · · · · · · ·
Total [95% CI]	56015	415280	43.9%	41.5% [26.7%, 57.1%]	
Heterogeneity: Tau <sup>2</sup> = 1136					
Low ROB (Item #4)					_
Barry 2003	263	1045	2.4%	25.2% [22.6%, 27.9%]	· · · · · · · · · · · · · · · · · · ·
Burgess 2013	131778	296918	2.4%	44.4% [44.3%, 44.6%]	_ 8
Cichowski 2017	94398	516950	2.4%	18.3% [18.2%, 18.4%]	•
DeBeer 2017	1124	2755	2.4%	40.8% [39.0%, 42.7%]	
Dobscha 2009	86726	251691	2.4%	34.5% [34.3%, 34.6%]	_ •
Gironda 2006	219	970	2.4%	22.6% [20.0%, 25.3%]	_ =
Goulet 2016	91	458	2.4%	19.9% [16.3%, 23.8%]	· · · · · · · · · · · · · · · · · · ·
Hadlandsmyth 2018	2943	6653	2.4%	44.2% [43.0%, 45.4%]	
Haskell 2009	3427	16611	2.4%	20.6% [20.0%, 21.3%]	
Ho 2018	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Huerta 2016	596	3157	2.4%	18.9% [17.5%, 20.3%]	•
Kalpakci 2018	6228	345204	2.4%	1.80% [1.80%, 1.80%]	•
Lagisetty 2019	398452	485513	2.4%	82.1% [82.0%, 82.2%]	
Mathew 2016	13936	618565	2.4%	2.30% [2.20%, 2.30%]	-
Mudumbai 2016	25870	49812	2.4%	51.9% [51.5%, 52.4%]	
Powell 2015 Roid 2002	65 297	171	2.4%	38.0% [30.7%, 45.7%]	
Reid 2002	297 44	516	2.4%	57.6% [53.2%, 61.9%]	
Rozet 2014		102	2.4%	43.1% [33.4%, 53.3%]	
Seal 2017 Tsai 2015	66966 34582	116913 89142	2.4% 2.4%	57.3% [57.0%, 57.6%] 38.8% [38.5%, 39.1%]	· · · · · · · · · · · · · · · · · · ·
Vidakovic 2016	3456Z 59	101	2.4%	58.4% [48.2%, 68.1%]	
Wallace 2019	340	630	2.4%		-
	12889	309374	2.4% 2.4%	54.0% [50.0%, 57.9%]	
Yoon 2015 Total [95% CI]	906575	5135095	2.4% 56.1%	4.20% [4.10%, 4.20%] 28.8% [16.6%, 42.8%]	-
Heterogeneity: Tau <sup>2</sup> = 1286	300373	3133033	50.176	20.0 /0 [10.0 /0, 42.0 /0]	
neterogeneity. rau – 1200					
Total [95% CI]	962950	5550375	100.0%	34.2% [24.5%, 44.6%]	
Test for subgroup interaction:					
					0 0.2 0.4 0.6 0.8 1

**Supplementary Material 14.** Subgroup analysis of chronic non-cancer pain prevalence with respect to ROB item #4. CI = confidence interval; IV = inverse variance.

Study					
or Subgroup	Events	Total	Weight	IV, Random, 95% CI	
Small (n < 1000)					
Adams 2015	102	175	2.4%	58.3% [50.6%, 65.7%]	
Crosby 2006	30	114	2.4%	26.3% [18.5%, 35.4%]	
DeBeer 2017	1124	2755	2.4%	40.8% [39.0%, 42.7%]	
Figoni 2015	85	178	2.4%	47.8% [40.2%, 55.4%]	
Gironda 2006	219	970	2.4%	22.6% [20.0%, 25.3%]	
Hendrikx 2020	159	383	2.4%	41.5% [36.5%, 46.6%]	
Huerta 2016	596	3157	2.4%	18.9% [17.5%, 20.3%]	
Kerns 2003	332	685	2.4%	48.5% [44.7%, 52.3%]	
Lei 2019	237	367	2.4%	64.6% [59.4%, 69.5%]	
Mancuso 2020	558	996	2.4%	56.0% [52.9%, 59.1%]	· · · · · · · · · · · · · · · · · · ·
Powell 2015	65	171	2.4%	38.0% [30.7%, 45.7%]	
Reid 2002	297	516	2.4%	57.6% [53.2%, 61.9%]	
Rozet 2014	44	102	2.4%	43.1% [33.4%, 53.3%]	
Stroupe 2013	91	458	2.4%	19.9% [16.3%, 23.8%]	
Suri 2019	110	220	2.4%	50.0% [43.2%, 56.8%]	· · · · · · · · · · · · · · · · · · ·
Vidakovic 2016	59	101	2.4%		
Wallace 2019	340	630	2.4%	58.4% [48.2%, 68.1%] 54.0% [50.0%, 57.9%]	
		7128	41.3%		=
Total [95% CI]	2848	/120	41.3%	42.0% [30.3%, 54.0%]	
Heterogeneity: Tau <sup>2</sup> = 635					
Large (n > 1000)					
Barry 2003	263	1045	2.4%	25.2% [22.6%, 27.9%]	_
	5607	18940	2.4%	29.6% [29.0%, 30.3%]	••••••••••••••••••••••••••••••••••••••
Bishop 2020	131778	296918	2.4%		• • • • • • • • • • • • • • • • • • •
Burgess 2013	94398		2.4%	44.4% [44.3%, 44.6%]	
Cichowski 2017		516950			🛄 🚊
Copeland 2014	29080	89995	2.4%	32.3% [32.0%, 32.6%]	<b>.</b>
Dobscha 2009	86726	251691	2.4%	34.5% [34.3%, 34.6%]	<b>1</b>
Donaldson 2018	749	1818	2.4%	41.2% [38.9%, 43.5%]	
Goulet 2016	91	458	2.4%	19.9% [16.3%, 23.8%]	<b>1</b>
Graham 2019	8385	280681	2.4%	3.00% [2.90%, 3.10%]	
Hadlandsmyth 2018	2943	6653	2.4%	44.2% [43.0%, 45.4%]	E 💌
Hall 2020	1124	2755	2.4%	40.8% [39.0%, 42.7%]	+
Haskell 2009	3427	16611	2.4%	20.6% [20.0%, 21.3%]	
Ho 2018	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Kalpakci 2018	6228	345204	2.4%	1.80% [1.80%, 1.80%]	
Lagisetty 2019	398452	485513	2.4%	82.1% [82.0%, 82.2%]	
Mathew 2016	13936	618565	2.4%	2.30% [2.20%, 2.30%]	
Mudumbai 2016	25870	49812	2.4%	51.9% [51.5%, 52.4%]	-
Mudumbai 2019	5316	5514	2.4%	96.4% [95.9%, 96.9%]	
Riggs 2020	2161	5694	2.4%	38.0% [36.7%, 39.2%]	-
Seal 2017	66966	116913	2.4%	57.3% [57.0%, 57.6%]	
Tsai 2015	34582	89142	2.4%	38.8% [38.5%, 39.1%]	
VanDenKerkhof 2015	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Yoon 2015	12889	309374	2.4%	4.20% [4.10%, 4.20%]	
Ziobrowski 2017	596	3157	2.4%	18.9% [17.5%, 20.3%]	• • •
Total [95% CI]	959742	5543247	58.7%	29.0% [17.3%, 42.3%]	
Heterogeneity: Tau <sup>2</sup> = 1214					
Total [95% CI]	962950	5550375	100.0%	34.2% [24.5%, 44.6%]	
Test for subgroup interaction:	p = 0.1				
					0 02 04 06 09 4
					0 0.2 0.4 0.6 0.8 1

**Supplementary Material 15.** Subgroup analysis of small studies (n < 1000) vs large studies (n > 1000) for the outcome of chronic non-cancer pain prevalence. CI = confidence interval; IV = inverse variance.



**Supplementary Material 16.** Funnel plot of studies in the Generic CNCP prevalence subgroup. Begg's test: p = 0.008.



**Supplementary Material 17.** Funnel plot of studies in the Specific CNCP prevalence subgroup. Begg's test: p = 0.1.



**Supplementary Material 18.** Meta-regression of chronic non-cancer pain prevalence using the predictor of proportion lost to follow-up; p < 0.0001.

Model	CNCP	Prevalence	Factor(s) ‡	<i>p</i> value
No.	No. of studies†	Total sample size ( <i>N</i> )		
1	35	5,159,532	Proportion lost to follow-up	< 0.0001
2	35	5,159,532	Proportion lost to follow-up	0.05
			Prevalence measure type	< 0.0001
			ROB Item #3	0.4

Supplementary Material 19. Summative data of all meta-regression models. \*

\* ROB = Risk of bias; CNCP = Chronic non-cancer pain; No. = Number.

<sup>†</sup> Calculation of proportion lost to follow-up included military veterans that were excluded for the reason of missing data. Six studies stated that there *is* missing data that was excluded but failed to report the proportion that was missing. These six studies are excluded, and hence there are 35 studies in the meta-regression.

‡ Effect modifiers that had a statistically significant test of interaction were then placed together into a meta-regression model alongside the factor of proportion lost to follow-up.

<b>Study</b> Adams 2015	Events 102	Total 175	Weight 2.4%	IV, Random, 95% Cl 58.3% [50.6%, 65.7%]	· : _ <b>_</b> _
Barry 2003	263	1045	2.4%	25.2% [22.6%, 27.9%]	
Bishop 2020	5607	18940	2.4%	29.6% [29.0%, 30.3%]	
Burgess 2013	131778	296918	2.4%	44.4% [44.3%, 44.6%]	
Cichowski 2017	94398	516950	2.4%	18.3% [18.2%, 18.4%]	
Copeland 2014	29080	89995	2.4%	32.3% [32.0%, 32.6%]	
Crosby 2006	30	114	2.4%	26.3% [18.5%, 35.4%]	
DeBeer 2017	1124	2755	2.4%	40.8% [39.0%, 42.7%]	
Dobscha 2009	86726	251691	2.4%	34.5% [34.3%, 34.6%]	
Donaldson 2018	749	1818	2.4%	41.2% [38.9%, 43.5%]	
Figoni 2015	85	178	2.4%	47.8% [40.2%, 55.4%]	
Gironda 2006	219	970	2.4%	22.6% [20.0%, 25.3%]	
Goulet 2016	91	458	2.4%	19.9% [16.3%, 23.8%]	
Graham 2019	8385	280681	2.4%	3.00% [2.90%, 3.10%]	•
Hadlandsmyth 2018	2943	6653	2.4%	44.2% [43.0%, 45.4%]	
Hall 2020	1124	2755	2.4%	40.8% [39.0%, 42.7%]	_ =
Haskell 2009	3427	16611	2.4%	20.6% [20.0%, 21.3%]	
Hendrikx 2020	159	383	2.4%	41.5% [36.5%, 46.6%]	_ =
Ho 2018	1293	3150	2.4%	41.0% [39.3%, 42.8%]	
Huerta 2016	596	3157	2.4%	18.9% [17.5%, 20.3%]	+
Kalpakci 2016	6228	345204	2.4%	1.80% [1.80%, 1.80%]	•
Kerns 2003	332	685	2.4%	48.5% [44.7%, 52.3%]	-
Lagisetty 2019	398452	485513	2.4%	82.1% [82.0%, 82.2%]	
Lei 2019	237	367	2.4%	64.6% [59.4%, 69.5%]	
Mancuso 2020	558	996	2.4%	56.0% [52.9%, 59.1%]	
Mathew 2016	13936	618565	2.4%	2.30% [2.20%, 2.30%]	
Mudumbai 2016	25870	49812	2.4%	51.9% [51.5%, 52.4%]	-
Mudumbai 2019	5316	5514	2.4%	96.4% [95.9%, 96.9%]	
Powell 2015	65	171	2.4%	38.0% [30.7%, 45.7%]	
Reid 2002	297	516	2.4%	57.6% [53.2%, 61.9%]	-
Riggs 2020	2161	5694	2.4%	38.0% [36.7%, 39.2%]	
Rozet 2014	44	102	2.4%	43.1% [33.4%, 53.3%]	· · · · · · · · · · · · · · · · · · ·
Seal 2017	66966	116913	2.4%	57.3% [57.0%, 57.6%]	<b>—</b>
Stroupe 2013	91	458	2.4%	19.9% [16.3%, 23.8%]	
Suri 2019	110	220	2.4%	50.0% [43.2%, 56.8%]	
Tsai 2015	34582	89142	2.4%	38.8% [38.5%, 39.1%]	<b>—</b>
VanDenKerkhof 2015	1293	3150	2.4%	41.0% [39.3%, 42.8%]	— <mark>—</mark> —
Vidakovic 2016	59	101	2.4%	58.4% [48.2%, 68.1%]	
Wallace 2019	340	630	2.4%	54.0% [50.0%, 57.9%]	
Ziobrowski 2017	596	3157	2.4%	18.9% [17.5%, 20.3%]	<b>*</b>
Total [95% Cl]	962950	5550375	100%	29.8% [20.1%, 41.7%]	
Heterogeneity: Tau <sup>2</sup> = 29014					
					0 0.2 0.4 0.6 0.8 1

**Supplementary Material 20**. Sensitivity analysis of chronic non-cancer pain prevalence based on the use of a logit transformation. CI = confidence interval; IV = inverse variance.

Analysis	Subgroup	No. of studies	No. with CNCP	Total	Effect Size	Point estimate	95% CI	Heterogeneity	<i>p</i> value for test of interaction
Overall analysis	NA	41	962,590	5,550,375	Prevalence	34.2	(24.5, 44.6)	$\tau^2 = 1240$	NA
Study size	Large studies	24	959,752	5,543,247	Prevalence	29.0	(17.3, 42.3)	$\tau^2 = 1214$	0.15
Study size	Small studies	17	2,848	7,128	Prevalence	42.0	(30.3, 54.1)	$\tau^2 = 635$	
Sex difference	Male	6	124,890	662,208 males	Prevalence	26.2	(6.50, 53.1)	$\tau^2 = 1213$	0.76
Sex difference	Female	6	12,776	48,175 females	Prevalence	31.1	(13.9, 51.6)	$\tau^2 = 682$	
Pain-reporting	Patient- reported	16	97,647	287,330	Prevalence	37.8	(33.3, 42.4)	$\tau^2 = 88$	0.41
Pain-reporting	Clinician- assessed	25	864,943	5,263,045	Prevalence	31.9	(19.8, 45.4)	$\tau^2 = 1245$	
Pain threshold	High	5	8,095	12,909	Prevalence	56.1	(18.2, 90.3)	$\tau^2 = 2131$	0.24
Pain threshold	Low	36	954,495	5,537,466	Prevalence	31.3	(21.3, 42.3)	$\tau^2 = 1204$	
ROB Item 1 – Population representativeness	High	29	867,632	5,267,697	Prevalence	35.2	(23.5, 47.9)	$\tau^2 = 1246$	0.62
ROB Item 1 – Population representativeness	Low	12	94,958	282,678	Prevalence	31.8	(26.6, 37.3)	$\tau^2 = 99$	
ROB Item 2 – Outcome measure validity	Low	15	160,854	5,163,428	Prevalence	39.7	(32.2, 47.5)	$\tau^2 = 235$	0.26
ROB Item 2 – Outcome measure validity	High	26	801,736	386,947	Prevalence	31.2	(19.6, 44.1)	$\tau^2 = 1204$	
ROB Item 3 – Under-reporting risk	High	18	580,627	4,323,374	Prevalence	24.9	(11.9, 40.8)	$\tau^2 = 1352$	0.05
ROB Item 3 – Under-reporting risk	Low	23	381,963	1,227,001	Prevalence	41.9	(35.7, 48.3)	$\tau^2 = 237$	

Supplementary Material 21. Summative data of all meta-analyses.\*
MSc. Thesis – A.R. Qureshi; McMaster University – Health Research Methodology

ROB Item 4 – Incomplete data	Low	23	906,575	5,135,095	Prevalence	28.8	(16.6, 42.8)	$\tau^2 = 1283$	0.22
ROB Item 4 – Incomplete data	High	18	56,015	415,280	Prevalence	41.5	(26.7, 57.1)	$\tau^2 = 1136$	
Type of prevalence measure	Generic	31	778,907	1,641,972	Prevalence	42.8	(30.5, 55.5)	$\tau^2 = 1304$	< 0.0001
Type of prevalence measure	Specific	10	183,683	3,908,403	Prevalence	11.4	(6.42, 17.5)	$\tau^2 = 196$	
Sensitivity analysis using logit transformation	NA	41	962,950	5,550,375	Prevalence	29.8	(20.1, 41.7)	$\tau^2 = 29,014$	NA

\* The grey table rows indicate the results of the overall effect estimate; CNCP = chronic non-cancer pain; NA = not applicable; No. = number; ROB = risk of bias.

# CHAPTER 3 - Research Priorities among Canadian Military Veterans living with Chronic Pain

## **3.2. ABSTRACT**

**Background:** Chronic pain is a pervasive and debilitating condition that disproportionately affects military veterans. We recently completed a qualitative study of Canadian veterans living with chronic pain to identify their research priorities; however, the generalizability of our findings was uncertain.

**Methods:** From January to March 2021, we emailed a 45-item cross-sectional survey to a list of Canadian veterans that asked about the relative importance of 20 research priorities regarding chronic pain. We explored for statistical significance between male and female responses for any item in which the proportion of endorsement showed a  $\geq 10\%$  difference.

**Results:** 313 of 699 Canadian military veterans living with chronic pain completed  $\geq$ 50% of the survey (45% response rate). Respondents were predominantly male (77%) with a median age of 52 (interquartile range [IQR] 44-58). All 20 research priorities listed in the survey were endorsed as very important by  $\geq$ 52% of respondents, and three received endorsement by  $\geq$ 85%: (I) optimizing chronic pain management after release from the military; and (II) identifying and (III) treating mental illness among veterans living with chronic pain. Women were more likely than men to endorse research on post-surgical care for chronic pain prevention or research on holistic care for chronic pain. Men were more likely than women to endorse research on physical activity or exercise for chronic pain. Individuals with higher gross income ( $\geq$ \$80,000) were less likely to endorse research into physiotherapy for chronic pain, or chiropractic for chronic pain compared to those with lower gross income. Individuals with greater age are less likely to endorse research on medical cannabis for chronic pain.

**Conclusions:** The most salient research priorities among our respondents were optimizing chronic pain management during service and after discharge from the military, including comorbid mental illness. Differences in gender, gross income, and age are implicated in the endorsement of therapy-related priorities, which include surgery, physical activity or exercise, chiropractic, and medical cannabis. Our findings provide insight into the research priorities of Canadian military veterans living with chronic pain. These findings should be considered by granting agencies when formulating calls for proposals, and by researchers who wish to undertake research that will address the needs of military veterans living with chronic pain.

#### **3.3. INTRODUCTION**

Pain that persists for 3 months or more is defined as chronic [1]. Over 6 million Canadians suffer from chronic pain and its associated consequences, [2] including decreased quality of life and increased use of healthcare resources [3]. In 2019, chronic pain-related costs (direct and indirect) in Canada were estimated to range from \$38 to \$40 billion [5]. Chronic pain disproportionality affects veterans, and observational studies have found that 25-72% of ex-military personnel report chronic pain, [6] which is associated with disability, financial strain, and difficulties transitioning to civilian life [7].

In recognition of the need to optimize management of chronic pain among veterans, the Chronic Pain Centre of Excellence for Canadian Veterans was launched in April 2020. To ensure that research efforts by the centre are relevant to veterans, a qualitative study was completed that drew upon interviews with Canadian veterans living with chronic pain [8]. This study found that veterans supported research into prevention of chronic pain, including identification of barriers to care while in the military (e.g., stigma) and after transition to civilian life. Veterans also

identified the need to explore the effect of treatment options on more than just pain relief (e.g., function, emotional health, financial well-being), and the importance of comparative effectiveness research for available management strategies [8]. Overall, while the qualitative study did suggest several research priorities the generalizability of findings was uncertain.

We conducted a cross-sectional survey of Canadian veterans living with chronic pain to establish the generalizability of research priorities identified through this qualitative study, and to explore whether research priorities differ between male and female veterans. Understanding the research priorities of military veterans living with chronic pain will assist researchers and funders in prioritizing topics of greatest importance to veterans.

#### 3.4. METHODS

The reporting of this study is consistent with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement (**Additional file 1**) [9]. We registered our study protocol on the Open Science Framework (<u>https://osf.io/pgukx</u>).

#### 3.4.1. Study design

With the assistance of veterans, epidemiologists, and the results of a qualitative study of research priorities among veterans living with chronic pain, we developed a 45-item English and Frenchlanguage survey using LimeSurvey (LimeSurvey GmbH, Hamburg, Germany). The survey was designed to capture demographic information and the importance of 20 research topics pertaining to chronic pain. The survey framed response options with either checkboxes or a 5-point Likert scale (very important, somewhat important, unsure, somewhat unimportant, and very unimportant), as closed-ended questions result in fewer incomplete questionnaires than openended formats [10]. We also included an option for veterans to provide written comments regarding any other thoughts they may have on research priorities.

We pretested the final questionnaire with 7 Canadian veterans living with chronic pain, who commented on its clarity and comprehensiveness and on the time required to complete it (10-15 minutes). No further modifications were suggested by pretest participants. (Additional file 2). As the study was for a quality improvement initiative without an initial intent to publish, the Hamilton Integrated Research Ethics Board (HiREB) approved our survey for dissemination without ethics review [11].

#### **3.4.2.** Survey administration

From January 2021 to March 2021, we sent email invitations for our survey to 729 Canadian veterans that had signed up to support chronic pain research with the Chronic Pain Centre of Excellence for Canadian Veterans. Interested recipients were eligible to complete the survey, in either English or French, after they confirmed both their veteran status and living with chronic pain. In addition to completing the survey online, we provided the option to have a paper-based version mailed along with a return envelope with pre-paid postage, or to fax the survey (RingCentral Inc, Belmont, California, U.S.) with a toll-free return number. At 2 and 4 weeks from the start date of survey distribution, invitation emails were re-sent to all non-responders.

#### 3.4.3. Data analysis

All survey responses were entered into a de-identified Microsoft Excel database, with a unique identifier number assigned to each participant. As participants were permitted to skip questions, missing values were present and only data that was reported contributed to analyses. If

participants completed <50% of survey items, their questionnaire was removed from all analyses. Categorical variables were presented as counts and percentages. Continuous variables were presented as mean and standard deviation when normally distributed, and median and interquartile range (IQR) when not. The Shapiro-Wilk test was used to determine the normality of the distribution for continuous variables. For purposes of presentation, we collapsed responses to individual research priorities into important ("Very important" and "Somewhat important"), "Unsure", and unimportant ("Somewhat unimportant" and "Very unimportant"), as well as a separate section for "Very important" and "Important or less" (i.e., "Somewhat important", "Unsure", "Somewhat unimportant" and "Very unimportant").

To reduce the risk of spurious associations due to multiple testing, an exploratory analysis was conducted in which we identified any individual research priority that was endorsed as important or less (i.e., "Important", "Unsure", "Unimportant" or "Very Unimportant") by ≥20% of respondents, created a dichotomous variable based on this dichotomization (i.e., very important; important or less), and thereafter conducted univariable logistic regression analyses for the following predictors: age, gender, final military rank, gross income level, and years since discharge from the military. Subsequently, a multivariable logistic regression was conducted for each of these identified priorities, which was always adjusted for age and gender, and included any of the other three variables if they were statistically significant in the univariable logistic regression analysis for a given research priority. For the purposes of these analyses, gross income level was dichotomized based on the median gross income level category, in which all individuals at the median gross income level as well as below it were in one category, while all the individuals with a gross income level that is higher than the median in the other category. Final military rank was dichotomized based on commission status: commissioned members

(Officer, Chief warrant officer, and Petty officer) and non-commissioned members (Recruit, Junior non-commissioned member, and Senior non-commissioned member). A p-value of 0.05 was used as the threshold for statistical significance. All analyses were performed using SPSS Statistics 26.0 (IBM Corp., New York, NY).

## 3.4.4. Thematic analysis

A thematic analysis was conducted on the open-ended response question (Q45). Two independent reviewers evaluated the written responses to determine themes and subthemes with a coding strategy that was developed through discussion. An *a priori* decision was made that a subtheme would only be presented if it was endorsed by  $\geq 2$  survey respondents. Illustrative quotes were selected for themes and subthemes, guided by a consensus on informativeness and representativeness among the two reviewers.

#### **3.5. RESULTS**

#### 3.5.1. Characteristics of respondents

Among 729 Canadian military veterans who were invited to complete our survey, 30 were not experiencing chronic pain. Of the remaining 701, we received surveys with >50% of items completed from 313 respondents (45% response rate) (**Figure 1**). Respondents were predominantly male (77%) with a median age of 52 (IQR 46-59), and most (66%) were married. A third of all veterans were receiving disability benefits (32%) and a third were retired (34%) (**Table 1**). Most respondents identified as White or European (87%), and the most reported formal education level completed was high school (40%). Similar proportions of veterans resided in urban (33%), suburban (39%), or rural (28%) areas.

Most veterans had served in the army (67%) as an active force member (87%) and had an operational or combat-related focus in their military vocation (58%). The top three final military ranks by frequency were junior non-commissioned member (39%), senior non-commissioned member (24%), and officer (17%). Respondents served in the military for a median of 20 years (IQR 12-28) and had been out of the military for a median of 8 years (IQR 3-15). (**Table 2**). Veterans reported having lived with chronic pain for a median of 15 years (IQR 9-22), and only 6% were very satisfied with their current chronic pain care (**Table 3**).



Figure 1. Survey administration results.

Variable*	Frequency, n	n (%) or Median	or Median (IQR)		
	Overall †	Male	Female		
Age (n)	(n=312)	(n=239)	(n=70)		
Median (IQR)	52 (44-58)	53 (46-59)	51 (42-58)		
Current province or territory of residence	(n=311)	(n=239)	(n=70)		
Ontario	94 (30%)	70 (29%)	24 (34%)		
Manitoba	10 (3%)	8 (3%)	2 (3%)		
Quebec	22 (7%)	13 (6%)	8 (11%)		
Nova Scotia	48 (15%)	35 (15%)	13 (19%)		
New Brunswick	18 (6%)	14 (6%)	3 (4%)		
Newfoundland and Labrador	18 (6%)	16 (7%)	2 (3%)		
Alberta	44 (14%)	36 (15%)	8 (11%)		
British Columbia	46 (15%)	37 (16%)	9 (13%)		
Other	11 (4%)	10 (4%)	1 (2%)		
Current relationship status	(n=311)	(n=241)	(n=70)		
Single/Never Married	22 (7%)	15 (6%)	7 (10%)		
Married	207 (66%)	171 (71%)	34 (48%)		
Common law	36 (12%)	30 (13%)	6 (9%)		
Separated	18 (6%)	10 (4%)	8 (11%)		
Divorced	26 (8%)	15 (6%)	11 (16%)		
Widowed	4 (1%)	0 (0%)	4 (6%)		
Living situation with other individual(s) ‡	(n=313)	(n=241)	(n=70)		
Spouse/Partner	247 (79%)	205 (85%)	40 (57%)		
Children	110 (35%)	83 (34%)	26 (37%)		
Parent(s)	9 (3%)	6 (3%)	3 (4%)		
No one, I live alone	45 (14%)	27 (11%)	18 (26%)		
Other	12 (4%)	10 (4%)	2 (3%)		
Current region of residence	(n=312)	(n=241)	(n=69)		
Urban (in the city)	102 (33%)	77 (32%)	25 (36%)		
Suburban (mixed-use or residential area, existing either as	121 (39%)	96 (40%)	23 (33%)		
part of a city area or as a separate residential community	× ,	~ /			
within commuting distance of a city)					
Rural (in the country)	89 (28%)	68 (28%)	21 (31%)		
Current housing situation	(n=312)	(n=240)	(n=70)		
Own property	245 (78%)	189 (78%)	56 (79%)		
Rent property	62 (20%)	47 (20%)	13 (19%)		
Other	5 (2%)	4 (2%)	1 (2%)		
Current employment status	(n=312)	(n=241)	(n=69)		
Employed, full-time	68 (22%)	57 (24%)	11 (16%)		
Employed, part-time	15 (5%)	14 (6%)	1 (2%)		
Unemployed	9 (3%)	9 (4%)	1 (2%)		
Unemployed, and receiving disability benefits	99 (32%)	63 (26%)	33 (47%)		
Retired	107 (34%)	87 (36%)	20 (29%)		
Other	14 (4%)	11 (4%)	3 (4%)		
Current gross income level	(n=309)	(n=238)	(n=69)		
Below \$25,000	6 (2%)	6 (3%)	0 (0%)		
\$25,000 to \$49,000	49 (16%)	37 (15%)	12 (17%)		
\$50,000 to \$59,000	57 (18%)	42 (18%)	13 (19%)		
\$60,000 to \$79,000	79 (26%)	60 (25%)	19 (28%)		
\$80,000 to \$99,000	56 (18%)	42 (18%)	14 (20%)		

 Table 1. Demographic characteristics of survey respondents

\$100,000 to \$150,000	49 (16%)	40 (17%)	9 (13%)
More than \$150,000	13 (4%)	11 (4%)	2 (3%)
People supported by gross income (n)	(n=311)	(n=240)	(n=69)
Median (IQR)	2 (2-3)	2 (2-3)	2 (1-3)
Race/ethnicity	(n=311)	(n=239)	(n=70)
Asian – Southeast (e.g., Malaysian, Filipino, Vietnamese, Cambodian)	2 (1%)	0 (0%)	2 (3%)
Black – Caribbean Region (e.g., Barbadian, Jamaican)	3 (1%)	1 (1%)	2 (3%)
Indigenous (e.g., Inuit, First Nations, Non-Status Indian, Metis, Indigenous person from outside Canada)	11 (3%)	8 (3%)	2 (3%)
White/European (e.g., English, Italian, Portuguese,	267 (85%)	209 (88%)	57 (81%)
Russian)			
Prefer not to answer	14 (5%)	13 (5%)	1 (1%)
French Canadian	5 (2%)	3 (1%)	2 (3%)
Other	9 (3%)	5 (2%)	4 (6%)
Highest formal education level completed	(n=310)	(n=238)	(n=70)
University Degree	68 (22%)	44 (18%)	24 (34%)
College Degree	93 (30%)	72 (30%)	21 (30%)
College Diploma	7 (2%)	2 (1%)	5 (7%)
Trades	8 (3%)	8 (3%)	0 (0%)
High School	126 (40%)	106 (45%)	19 (27%)
Other	8 (3%)	6 (3%)	1 (2%)

\* "Other" for "Current province or territory of residence" includes Prince Edward Island, Saskatchewan, USA and Unspecified; "Other" for "Living situation with other individual(s)" includes Caregiver, Grandchildren, Roommate(s) and Friend(s); "Other" for Current housing situation includes Partner owns property, Family member owns property, Military housing, and RV housing; "Other" for Current employment status includes Retired and receiving disability benefits, Employed, casual and receiving disability benefits, Self-employed, unspecified-time, Self-employed, and receiving disability benefits, Retired but employed, part-time, Retired but employed, unspecified-time, Unspecified, Employed, unspecified time, and Employed, on-call; "Other" for Race/ethnicity includes Asian – East (e.g. Chinese, Japanese, Korean), Asian – South (e.g. Indian, Pakistani, Sri Lankan, Indo-Caribbean/West Indian), Asian – West (e.g., Afghani, Israeli, Saudi Arabian, Iranian, Turkish), Australasian – (e.g. Australian, New Zealander, Papuan, Melanesian), Black – Africa (e.g. Ghanaian, Kenyan, Somali), Black – North America, Hispanic, Latin American (e.g. Argentinean, Chilean, Salvadoran), Do not know, Black and Indigenous, White/European and Indian – Unspecified, and White/European and Asian – Unspecified; "Other" for Highest formal education level completed includes College Certificate, Post-Secondary Diploma, Military College Courses, Certificate – Unspecified institution, and Unspecified; IQR = interquartile range. † 1 individual reported to be "Another Gender Identity", and another individual selected "Prefer not to answer" for the question on Gender.

‡ Categories are *not* mutually exclusive.

Variable*		y, n (%) or <u>Med</u>	lian (IQR)
	Overall †	Male	Female
Country of military presence ‡	(N=313)	(n=241)	(n=70)
Canada	310 (99%)	239 (99%)	69 (99%)
United States of America	19 (6%)	19 (8%)	0 (0%)
Bosnia	8 (3%)	3 (1%)	5 (7%)
Afghanistan	11 (4%)	9 (4%)	2 (3%)
Germany	12 (4%)	10 (4%)	2 (3%)
Other	39 (12%)	33 (14%)	6 (9%)
Military branch of service ‡	(N=313)	(n=241)	(n=70)
Air Force	131 (42%)	99 (41%)	32 (46%)
Army	209 (67%)	163 (68%)	44 (63%)
Navy	83 (27%)	66 (27%)	17 (24%)
Special Forces	16 (5%)	14 (6%)	2 (2.9%)
Unspecified	5 (2%)	1 (1%)	4 (6%)
Other	4 (1%)	3 (1%)	1 (1%)
Final military rank	(N=312)	(n=240)	(n=69)
Officer	52 (17%)	37 (15%)	14 (20%)
Warrant officer	47 (15%)	42 (18%)	5 (7%)
Senior non-commissioned member	75 (24%)	65 (27%)	10 (15%)
Junior non-commissioned member	122 (39%)	87 (36%)	34 (49%)
Recruit	10 (3%)	5 (2%)	5 (7%)
Petty officer	6 (2%)	5 (2%)	1 (2%)
Military component	(N=313)	(n=241)	(n=70)
Regular (or Active Force)	272 (87%)	220 (91%)	50 (72%)
Reserve Force – Primary	31 (10%)	14 (6%)	17 (24%)
Other	10 (3%)	7 (3%)	3 (4%)
Primary focus of occupational specialty in military	(N=313)	(n=241)	(n=70)
Operational or Combat-related	180 (58%)	158 (66%)	20 (29%)
Operational support (i.e., Non-operational or non- combat related positions that assisted operational or combat-related forces to deliver their mission).	100 (32%)	67 (28%)	33 (47%)
Institutional support (i.e., Non-operational or non- combat related positions that were not involved in assisting operational or combat-related forces directly; e.g., base/wing positions, support for educational institutions)	26 (8%)	12 (5%)	14 (20%)
Other	7 (2%)	4 (1%)	3 (4%)
Years of service in military (n)	(n=313)	(n=241)	(n=70)
Median (IQR)	20 (12-28)	21 (13-30)	16 (8-24)
Years since discharge from military (n)	(n=312)	( <i>n</i> =240)	(n=70)
Median (IQR)	8 (3-15)	8 (3-15)	7 (3-17)

Table 2. Military characteristics of survey respondents.\*

\* "Other" for *Country of military presence* includes UK, Australia, Italy, Cyprus, Belgium, Haiti, Croatia, Israel, Egypt, UAE, Macedonia, Syria, Bahrain, Saudi Arabia, Nairobi, Uganda, Turkey, Kuwait, Scotland, Mexico, Democratic Republic of the Congo, Africa, Persian Gulf, Southeast Asia and Eastern Europe; "Other" for "Military branch of service" includes Logistics, Medical Services, and Marines; "Other" for "Military component" included Reserve Force – Cadet Organizations Administration and Training Service and Regular (or Active) Force and Reserves – Unspecified and Regular Force and Reserve – Primary; "Other" for "Primary focus of occupational specialty in military" included All of the above, Operational and Unspecified support, Operational support and Institutional support and Operational and Operational support; IQR = interquartile range.

† "n=313" for Overall results from 1 individual selecting "Prefer not to answer" and another selecting "Another Gender Identity" for the "Gender" question.

‡ Categories are *not* mutually exclusive.

Variables	Frequency, n	(%) or Median (	IQR)
	Overall †	Male	Female
Number of years living with chronic pain (n)	(n=311)	(n=239)	(n=70)
Median (IQR)	15 (9-22)	15 (10-22)	12 (8-21)
Chronic pain as part of claim to Veteran Affairs Canada	(N=311)	(n=239)	(n=70)
All of the time	156 (50%)	119 (50%)	35 (50%)
Most of the time	72 (23%)	53 (22%)	19 (27%)
Sometimes	39 (13%)	32 (13%)	7 (10%)
Rarely	15 (5%)	11 (4%)	4 (6%)
Never	24 (7%)	21 (9%)	3 (4%)
I have never filed a claim to Veterans Affairs Canada	6 (2%)	4 (2%)	2 (3%)
Rating of satisfaction with current chronic pain care	(N=313)	(n=241)	(n=70)
Very unsatisfied	71 (22%)	60 (25%)	10 (14%)
Somewhat unsatisfied	78 (25%)	58 (24%)	20 (29%)
Unsure	62 (20%)	45 (19%)	17 (24%)
Somewhat satisfied	84 (27%)	66 (27%)	17 (24%)
Very satisfied	18 (6%)	12 (5%)	6 (9%)

 Table 3. Chronic pain-related characteristics among respondents.\*

\* IQR = interquartile range; SD = standard deviation.

<sup>†</sup> Overall total includes one individual that stated "Another Gender Identity" for the question about sex.

## **3.5.2. Research priorities**

All 20 research priorities listed in the survey were endorsed by  $\geq$ 75% of respondents as important, and no more than 8% of veterans designated any priority as unimportant. Four research priorities received endorsement by  $\geq$ 95% of military veterans: (i) optimizing chronic pain management after release from the military (97%); (ii) establishing the effectiveness of selfcare (96%); and (iii) identifying (95%) and (iv) treating (95%) mental illness among veterans living with chronic pain.

Ten research priorities received endorsement by  $\geq$ 90% of military veterans: (i) improving chronic pain care while in the military (93%); (ii) addressing barriers to chronic pain management in the military (92%); (iii) reducing the length of time for chronic pain claims to be adjudicated by Veterans Affairs Canada (94%); (iv) improving civilian doctors' knowledge on military life and impact of military service in relation to chronic pain (94%); (v) understanding risk factors during military service that are associated with chronic pain development (93%); (vi) optimizing post-surgical care to prevent chronic pain development (91%); (vii) establishing the effectiveness of physiotherapy (93%), (viii) massage therapy (91%) or (ix) physical activity/exercise (94%) for chronic pain; and (x) exploring the contribution of administrative barriers to chronic pain development and perpetuation (93%).

Two research priorities received the endorsement of  $\geq 85\%$  of military veterans: (i) improving acute pain care while in the military to avoid development of chronic pain (88%), and (ii) exploring the impact of treatment decision aids (89%), (**Table 4**).

Table 4. Responses to	questions on the "	'Research Priorities"	section of the 45-item	survey.*
-----------------------	--------------------	-----------------------	------------------------	----------

Table 4. Responses to questions on the "Research Priorities" section of the 45-item survey.*Research Priority identified from thenFrequency stratified byFrequency									
Survey Question	n	Very Importa				n (%) ‡	<u></u>		
<u>Surrey Question</u>		Very Important	Important or less	Very Important	Somewhat Important	Unsure	Somewhat Unimportant	Very Unimportant	
Improving acute pain (<1 month in duration) care while in the military to reduce risk of developing chronic pain.	313	230 (73%)	83 (27%)	230 (73.5%)	46 (14.7%)	26 (8.3%)	7 (2.2%)	4 (1.3%)	
(Q23) Improving chronic pain (≥3 months duration) care while in the military. (Q24)	313	253 (80%)	60 (20%)	253 (80.8%)	37 (11.8%)	14 (4.5%)	6 (1.9%)	3 (1.0%)	
Addressing barriers to chronic pain management within the military (e.g., stigma, lack of knowledge, inadequate treatment options or access to care). (Q25)	312	258 (82%)	54 (28%)	258 (82.4%)	30 (9.6%)	17 (5.4%)	3 (1.0%)	4 (1.3%)	
Improving health care for chronic pain management after release from the military (e.g., improving access to a civilian family doctor). (Q26)	313	285 (91%)	28 (9%)	285 (91.1%)	17 (5.4%)	4 (1.3%)	3 (1.0%)	4 (1.3%)	
Reducing the length of time for chronic pain claims to be adjudicated by Veterans Affairs Canada. (Q27)	313	264 (84%)	49 (16%)	264 (84.3%)	31 (9.9%)	13 (4.2%)	2 (0.6%)	3 (1.0%)	
Improving civilian doctors' knowledge of military life and the impact of military service as it relates to the development of chronic pain. (Q28)	312	257 (82%)	55 (18%)	257 (82.1%)	32 (10.2%)	14 (4.5%)	6 (1.9%)	3 (1.0%)	
Understanding risk factors during military service that are associated with the development of chronic pain. (Q29)	309	245 (79%)	64 (21%)	245 (78.3%)	43 (13.7%)	11 (3.5%)	6 (1.9%)	4 (1.3%)	
Optimizing post-surgical care to prevent the development of chronic pain. (Q30)	312	221 (71%)	91 (29%)	221 (70.6%)	62 (19.8%)	20 (6.4%)	5 (1.6%)	4 (1.3%)	
Establishing the effectiveness of physiotherapy for chronic pain. (Q31)	312	221 (71%)	91 (29%)	221 (70.6%)	68 (21.7%)	11 (3.5%)	9 (2.9%)	3 (1.0%)	
Establishing the effectiveness of massage therapy for chronic pain. (Q32)	313	229 (73%)	84 (27%)	229 (73.2%)	55 (17.6%)	22 (7.0%)	5 (1.6%)	2 (0.6%)	
Establishing the effectiveness of physical activity/exercise for chronic pain. (Q33)	312	232 (74%)	80 (26%)	232 (74.1%)	61 (19.5%)	13 (4.2%)	3 (1.0%)	3 (1.0%)	
Establishing the effectiveness of holistic care (e.g., addressing all relevant factors, not just pain, such as mental health, financial health and quality of life) for chronic pain. (Q34)	313	231 (74%)	82 (26%)	231 (73.8%)	53 (16.9%)	21 (6.7%)	5 (1.6%)	3 (1.0%)	
Effectiveness of self-care (i.e., what patients can do for themselves) for chronic pain. (Q35)	312	241 (77%)	71 (23%)	241 (77.0%)	59 (18.8%)	6 (1.9%)	3 (1.0%)	3 (1.0%)	
Exploring the contribution of administrative barriers (e.g., delay in VA claim approval) to the development and perpetuation of chronic pain. (Q36)	311	242 (78%)	69 (22%)	242 (77.3%)	48 (15.3%)	12 (3.8%)	5 (1.6%)	4 (1.3%)	
Establishing the effectiveness of chiropractic care for chronic pain. (Q37)	313	172 (55%)	141 (45%)	172 (55.0%)	70 (22.4%)	49(15.7%)	9 (2.9%)	13 (4.2%)	
Establishing the effectiveness of medical cannabis for chronic pain. (Q38)	313	164 (52%)	149 (48%)	164 (52.4%)	72 (23.0%)	53 (16.9%)	14 (4.5%)	10 (3.2%)	
Reducing the use of opioids for chronic pain. (Q39)	313	214 (68%)	99 (32%)	214 (68.4%)	42 (13.4%)	33 (10.5%)	10 (3.2%)	14 (4.5%)	
Identifying mental illness among veterans living with chronic pain. (Q40)	313	270 (86%)	43 (14%)	270 (86.3%)	26 (8.3%)	14 (4.5%)	1 (0.3%)	2 (0.6%)	
Treatment of mental illness among veterans living with chronic pain. (Q41)	313	276 (88%)	37 (12%)	276 (88.2%)	23 (7.3%)	11 (4.0%)	1 (0.3%)	2 (0.6%)	
Effectiveness of providing treatment decision aids (evidence summaries conveying benefits and harms of different therapeutic options) to veterans living with chronic pain. (Q42)	312	217 (70%)	95 (30%)	217 (69.3%)	62 (19.8%)	28 (8.9%)	4 (1.3%)	1 (0.3%)	

\* Q = Question; VA = Veterans Affairs; † = "Important or less" includes "Somewhat important", "Unsure", "Somewhat unimportant" and "Very unimportant"; ‡ = "Important" includes "Very important" and "Somewhat important", while "Unimportant" includes "Somewhat unimportant" and "Very unimportant".

#### 3.5.3. Highest and lowest research priorities

There was no clear indication as to which research priority was most or least important to respondents. The leading three priorities were: (i) improving care for chronic pain after release from the military (17%); (ii) improving management of chronic pain while in the military (11%); and (iii) addressing barriers to chronic pain care in the military (9%). The three research areas of lowest priority were: (i) establishing the effectiveness of chiropractic care (13%); (ii) clarifying the role of medical cannabis for chronic pain (12%); and (iii) exploring strategies to reduce use of opioids among veterans living with chronic pain (11%) (Additional file 3).

#### 3.5.4. Uni- and Multi-variable Logistic Regressions

After adjusting for age, women are 2.1 times more likely to endorse the optimization of postsurgical care to prevent the development of chronic pain compared to men (OR = 2.16, 95% CI 1.11 to 4.20, p = 0.02). After adjusting for age and gender, individuals with a gross income level  $\geq$ \$80,000 are 55% less likely to endorse research into establishing the effectiveness of physiotherapy for chronic pain, compared to those with a gross income level  $\leq$  \$79,000 (OR = 0.45, 95% CI 0.27 to 0.75, p = 0.002). After adjusting for age, women are 52% less likely than men to endorse research into establishing the effectiveness of physical activity or exercise for chronic pain (OR = 0.48, 95% CI 0.27 to 0.85, p = 0.01). After adjusting for age, women are 2.2 times more likely to endorse research into establishing the effectiveness of holistic care for chronic pain (OR = 2.15, 95% CI 1.07 to 4.35, p = 0.03). After adjusting for age and gender, individuals with a gross income level  $\geq$ \$80,000 are 43% less likely to endorse research into establishing the effectiveness of chiropractic care for chronic pain compared to those with a gross income level  $\leq$ \$79,000 (OR = 0.57, 95% CI 0.36 to 0.91, p = 0.02). For every 10-year increase in age, odds of endorsing research exploring the effectiveness of medical cannabis for chronic pain decreases by 32%, after adjusting for gender (OR = 0.68, 95% CI 0.54 to 0.85, p = 0.001), (**Table 5**).

**Table 5.** Univariable and multi-variable regression analyses of research priorities with  $\geq 20\%$  endorsement for important or less.

Research	Variable	Reference	Univ	ariable a	nalysis	Μ	Multivariable analysis			
priority		category	OR	95%	P-value	OR	95% CI	P-value		
				CI						
Improving	Age	Every 10-	1.00	0.77 to	0.9	1.00	0.78 to	0.8		
acute pain (<1		year		1.30			1.28			
month in		increase								
duration) care	Gender	Male	1.80	0.92 to	0.08	1.83	0.94 to	0.08		
while in the military to reduce risk of developing chronic pain. (Q23)				3.49			3.56			
	Gross	≤\$79,000	1.35	0.79 to	0.3					
	income			2.30						
	level Final	Non-	0.64	0.27.	0.1					
	rank	Non- Officer	0.64	0.37 to	0.1					
(2-0)	while in	Officer		1.11						
	the									
	military									
	Years	Every 10-	0.81	0.65 to	0.06					
	since	year		1.00						
	release	increase								
	from the									
	military									
Understanding risk factors	Age	Every 10-	0.99	0.75 to	0.9	0.99	0.83 to	1.0		
during military		year increase		1.32			1.19			
service that are	Gender	Male	1.12	0.57 to	0.8	1.12	0.57 to	0.7		
associated with	Gender	Wale	1.12	2.21	0.8	1.12	2.22	0.7		
the	Gross	≤ \$79,000	0.56	0.32 to	0.05					
development of	income	,000	0.50	0.92 10	0.05					
chronic pain.	level			0.77						
(Q29)	Final	Non-	0.83	0.45 to	0.5					
	rank	Officer		1.51						
	while in									
	the									
	military									

	V	E 10	0.04	0.65	0.1			
	Years	Every 10-	0.84	0.65 to	0.1			
	since	year		1.09				
	release	increase						
	from the							
	military	F 10	1 1 1	0.06.	0.24	1 1 1	0.061	0.2
Optimizing	Age	Every 10-	1.11	0.86 to	0.34	1.11	0.86 to	0.3
post-surgical		year		1.43			1.41	
care to prevent the	~ 1	increase						
development of	Gender	Male	2.07	1.07 to	0.03	2.16	1.11 to	0.02
chronic pain.				4.01			4.20	
(Q30)	Gross	≤\$79,000	0.67	0.40 to	0.1			
(250)	income			1.11				
	level							
	Final	Non-	0.85	0.50 to	0.5			
	rank	Officer		1.44				
	while in							
	the							
	military							
	Years	Every 10-	1.00	0.78 to	0.8			
	since	year		1.28				
	release	increase						
	from the							
	military							
Establishing the	Age	Every 10-	1.00	0.77 to	0.9	0.99	0.79 to	0.9
effectiveness of		year		1.30			1.23	
physiotherapy		increase						
for chronic	Gender	Male	0.79	0.45 to	0.4	0.74	0.41 to	0.3
pain. (Q31)				1.40			1.33	
	Gross	≤\$79,000	0.46	0.28 to	0.003	0.45	0.27 to	0.002
	income			0.77			0.75	
	level							
	Final	Non-	0.87	0.51 to	0.6			
	rank	Officer		1.47				
	while in							
	the							
	military							
	Years	Every 10-	1.00	0.78 to	0.8			
	since	year		1.28				
	release	increase						
	from the							
	military							
Establishing the	Age	Every 10-	0.73	0.57 to	0.01	0.74	0.54 to	0.06
effectiveness of		year		0.93			1.00	
massage		increase						
therapy for	Gender	Male	0.97	0.53 to	0.9	0.88	0.48 to	0.7
chronic pain.				1.77			1.63	
(Q32)	Gross	≤\$79,000	0.68	0.41 to	0.1			
	income			1.14				
	level							
	Final	Non-	1.20	0.71 to	0.5			
	rank	Officer	-	2.04				
	while in							
[		1			1		ı	1

	.1		1	1	1	1		
	the							
	military Years since release from the	Every 10- year increase	0.78	0.63 to 0.97	0.03	0.94	0.72 to 1.23	0.7
	military							
Establishing the effectiveness of physical	Age	Every 10- year increase	1.11	0.88 to 1.38	0.5	1.11	0.87 to 1.40	0.6
activity/exercise for chronic	Gender	Male	0.48	0.27 to 0.85	0.01	0.48	0.27 to 0.85	0.01
pain. (Q33)	Gross income level	≤\$79,000	0.72	0.43 to 1.22	0.2			
	Final rank while in the military	Non- Officer	0.86	0.49 to 1.49	0.6			
	Years since release from the military	Every 10- year increase	0.89	0.71 to 1.11	0.3			
Establishing the effectiveness of holistic care	Age	Every 10- year increase	0.93	0.72 to 1.21	0.5	0.95	0.74 to 1.22	0.7
(e.g., addressing all relevant	Gender	Male	2.20	1.09 to 4.43	0.03	2.15	1.07 to 4.35	0.03
factors, not just pain, such as mental health, financial health	Gross income level	≤ \$79,000	0.80	0.47 to 1.34	0.4			
and quality of life) for chronic pain. (Q34)	Final rank while in the military	Non- Officer	0.94	0.55 to 1.61	0.8			
	Years since release from the military	Every 10- year increase	1.00	0.78 to 1.29	0.9			
Effectiveness of self-care (i.e., what patients	Age	Every 10- year increase	1.22	0.92 to 1.61	0.2	1.11	0.81 to 1.51	0.6
can do for themselves) for	Gender	Male	1.51	0.76 to 2.30	0.2	1.44	0.71 to 2.90	0.3
chronic pain. (Q35)	Gross income level	≤\$79,000	0.57	0.33 to 0.98	0.04	0.60	0.34 to 1.05	0.08

· · · · · · · · · · · · · · · · · · ·							Т	
	Final rank while in the military	Non- Officer	0.63	0.35 to 1.15	0.1			
	Years since release from the military	Every 10- year increase	1.48	1.07 to 2.05	0.03	1.22	0.85 to 1.74	0.2
Exploring the contribution of administrative	Age	Every 10- year increase	1.00	0.77 to 1.30	0.8	1.00	0.78 to 1.29	0.8
barriers (e.g., delay in VA	Gender	Male	1.48	0.74 to 2.95	0.3	1.51	0.76 to 3.02	0.2
claim approval) to the development and perpetuation of chronic pain. (Q36)	Gross income level	≤\$79,000	0.64	0.37 to 1.11	0.1			
	Final rank while in the military	Non- Officer	1.27	0.73 to 2.22	0.4			
	Years since release from the military	Every 10- year increase	1.11	0.84 to 1.46	0.5			
Establishing the effectiveness of chiropractic	Age	Every 10- year increase	1.00	0.82 to 1.22	0.8	0.34	0.28 to 0.42	0.9
care for chronic pain. (Q37)	Gender	Male	0.88	0.52 to 1.50	0.6	0.84	0.49 to 1.46	0.5
	Gross income level	≤ \$79,000	0.56	0.35 to 0.89	0.02	0.57	0.36 to 0.91	0.02
	Final rank while in the military	Non- Officer	0.82	0.51 to 1.33	0.4			
	Years since release from the military	Every 10- year increase	0.95	0.76 to 1.19	0.6			
Establishing the effectiveness of medical	Age	Every 10- year increase	0.68	0.54 to 0.85	0.001	0.68	0.54 to 0.85	0.001
cannabis for	Gender	Male	1.19	0.70 to 2.03	0.5	1.08	0.63 to 1.87	0.8

chronic pain.	Gross	≤\$79,000	0.95	0.60 to	0.8			
(Q38)	income level			1.51				
	Final rank while in the	Non- Officer	1.56	0.97 to 2.51	0.07			
	military Years since release from the military	Every 10- year increase	0.86	0.69 to 1.08	0.2			
Reducing the use of opioids for chronic	Age	Every 10- year increase	1.00	0.81 to 1.23	1.0	1.00	0.81 to 1.23	1.0
pain. (Q39)	Gender	Male	1.12	0.63 to 1.99	0.7	1.11	0.62 to 1.98	0.7
	Gross income level	≤\$79,000	1.02	0.62 to 1.67	0.9			
	Final rank while in the military	Non- Officer	0.94	0.57 to 1.57	0.8			
	Years since release from the military	Every 10- year increase	0.95	0.75 to 1.20	0.6			
Effectiveness of providing treatment	Age	Every 10- year increase	1.11	0.89 to 1.37	0.4	1.11	0.90 to 1.36	0.4
decision aids (evidence	Gender	Male	1.11	0.62 to 2.00	0.7	1.15	0.64 to 2.08	0.6
summaries conveying benefits and harms of	Gross income level	≤ \$79,000	0.66	0.40 to 1.08	0.1			
harms of different therapeutic options) to veterans living with chronic pain. (Q42)	Final rank while in the military	Non- Officer	1.17	0.71 to 1.95	0.5			
	Years since release from the military	Every 10- year increase	1.11	0.89 to 1.37	0.4			

\* For the purposes of analysis, this variable is dichotomized. The reference category is those with a gross income level  $\leq$  median, and the other category is those with a gross income level > median.

<sup>†</sup> For the purposes of analysis, this variable is dichotomized. The reference category is Non-Officer (includes Junior non-commissioned member, senior non-commissioned member and Recruit), and the other category is Officer (includes Officer, Warrant officer, and Petty officer).

## 3.5.5. Thematic analysis

Written comments were provided by almost half of respondents (147 of 313; 47%), which revealed 5 themes: (i) enthusiasm for studying specific therapeutic interventions (e.g., osteopathy, acupuncture, yoga, meditation), (n = 19; 6.1%); (ii) administrative barriers to care through Veterans Affairs Canada, (n = 10; 3.2%); (iii) challenges with civilian healthcare providers (n = 9; 2.9%); (iv) barriers to care after release from the military (n = 6; 1.9%); and (v) understanding the impact of chronic pain on certain subgroups (e.g., different military ranks, women, family), (n = 6; 1.9%), (Additional file 4). No subtheme was endorsed by more than 5 respondents.

## **3.6. DISCUSSION**

#### 3.6.1. Main findings

Our survey found strong support for several research themes among Canadian veterans living with chronic pain. Leading priorities included improving chronic pain management after discharge from the military, and the identification and treatment of mental illness among military veterans living with chronic pain. More women than men endorsed chronic pain prevention through the optimization of post-surgical care, as well as endorsing research into the effectiveness of holistic care for chronic pain. Conversely, more men than women endorsed investigation into the effectiveness of physical activity or exercise for chronic pain. Individuals with a gross income ≥\$80,000 were less likely to endorse physiotherapy or chiropractic for chronic pain. Age was found to significantly predict the endorsement of research into the

effectiveness of medical cannabis for chronic pain, as with every 10-year increase in age, the endorsement for this research priority decreases.

#### 3.6.2. Relation to other studies

There is a lack of information from the literature on establishing research priorities for military veterans living with chronic pain. The Canadian Pain Task Force included veterans as a population that is disproportionally impacted by pain and emphasized the need for research that considered gender and sex differences in response to treatment, risk and protective factors for the development of chronic pain, and the unique circumstances that veterans encounter in relation to development and management of chronic pain [5].

A recent Canadian study on adults living with chronic pain identified four themes of research priorities: (i) improving knowledge of chronic pain among healthcare providers and communities, as well as improving the competency of healthcare providers in treating chronic pain; (ii) the prevention of chronic pain and chronic pain-related symptoms; and research directed towards the (iii) treatment and assessment of patient-centered chronic pain care, as well as (iv) improving the access and coordination of patient-centered chronic pain care [12]. Our survey confirmed support for these research priorities and identified additional areas endorsed by veterans living with chronic pain, including the impact of co-morbid mental illness, studying barriers to pain management in the military, and optimizing engagement with civilian healthcare providers after release.

Age, gender, and gross income level were found to impact the likelihood of the endorsement of certain therapy-related research priorities. With increase in age, endorsement for research into medical cannabis became less likely. Similarly, a study found that military veterans from an older age group (45-64 years) had lower instances of 6-month cannabis use or cannabis

use disorder compared to a younger age group (18-44 years) [13]. Moreover, more women than men prioritized research towards establishing the effectiveness of holistic care for chronic pain. A study found that more female than male military veterans are seeking out services to meet their mental and psychological needs for their chronic pain-related care, such as psychotherapy and mental health assessments [14]. A need for such services may predispose women to seek out research that will substantiate the use of holistic care for chronic pain.

In the case of the other four forthcoming results from our regression analyses, there is currently not any prior literature to provide further insight into these findings. Women are more likely than men to prioritize research into optimizing post-surgical care for chronic pain. Compared to men, women report greater intensity of post-surgical pain [15] and are more likely to report acute post-procedural pain [16] and have higher incidence of severe pain episodes [17]. Moreover, women are less likely to receive adequate analgesia after surgery, which may increase their risk for under-treatment after surgery [18]. These experiences may be implicated in women expressing greater interest in optimizing post-surgical care compared to men.

Men were more likely than women to prioritize research towards establishing the effectiveness of physical activity or exercise for chronic pain. In patients with chronic pain, women score less than men on physical functioning [19]. Moreover, women with chronic pain are more likely to report pain catastrophizing and greater pain [20], as well as lower self-efficacy compared to men [21]. Altogether, these experiences may pre-dispose women to have less interest compared to men in active strategies such as physical activity or exercise to manage pain.

Individuals with a higher gross income level were less likely to endorse research towards establishing the effectiveness of physiotherapy or chiropractic for chronic pain, compared to

those with a lower gross income level. A study in one clinic found that the typical chiropractic patient was overwhelmingly unemployed (86%; N = 1803), and hence this may translate to having lower gross income [22]. Furthermore, physiotherapy and chiropractic are not covered by the Government of Canada, and largely become out-of-pocket expenses if patients do not have insurance benefits to cover such services. While the "Programs of Choice 12 – Related Health Services" from Veterans Affairs (VA) Canada provides coverage for chiropractic and physiotherapy to military veterans, a physician must prescribe such a service prior to it being approved by VA Canada [23]. Those patients that have less income and have not received physician approval to utilize physiotherapy or chiropractic may be more interested in prioritizing research that substantiates the efficacy of such services in reducing chronic pain, which may then influence payers such as government stakeholders to consider at least partially covering the expenses for these treatment options and may also influence physicians to be more inclined in prescribing such services.

#### **3.6.3. Strengths and limitations**

The strengths of our study include pre-testing our survey, providing our survey in English and French (Canada's two official languages), use of closed-ended response options, and reminders to potential participants to increase response rate. Our study also has limitations. Our sample did not include ex-members of the RCMP, which are considered by Canada to be veterans, and our results may not apply to this group. Moreover, our participants were veterans that expressed interest in research and willingness to be included in the mailing list of the Chronic Pain Centre of Excellence for Canadian Veterans which may have introduced selection bias. Further, our response rate of 45% may have also introduced selection bias. Also, we did not collect data on

mental illness or other comorbidities, nor data on types and location of chronic pain, and hence we are unable to make conclusions on how these factors may influence the endorsement of the research priorities.

## 3.6.4. Conclusion

A large majority of Canadian veterans living with chronic pain endorsed all 20 research priorities they were presented with as important, with the most enthusiasm for optimization of chronic pain care after discharge, exploring the effectiveness of self-care, and the importance of identifying and treatment co-morbid mental illness. Women were more likely to endorse research into post-surgical care or holistic care for chronic pain, while men were more likely to endorse research into physical activity or exercise for chronic pain. Endorsement for research into medical cannabis for chronic pain decreased with increase in age. Military veterans with a gross income level of ≥\$80,000 were less likely to endorse research into physiotherapy or chiropractic care for chronic pain. Our findings provide insight into the research priorities of Canadian military veterans living with chronic pain. These results should be considered by granting agencies when formulating calls for proposals, and by researchers who wish to undertake research that will address the needs of Canadian military veterans living with chronic pain.

## **3.7. ETHICS DECLARATION**

HiREB waived the ethics review of this study as this survey was for a quality improvement initiative with no initial intent to publish.

## **3.8. REFERENCES**

[1] Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015 Jun;156(6):1003.

https://dx.doi.org/10.1097%2Fj.pain.000000000000160.

[2] Hadjistavropoulos HD, Schneider LH, Hadjistavropoulos T, Titov N, Dear BF. Effectiveness, acceptability and feasibility of an Internet-delivered cognitive behavioral pain management

program in a routine online therapy clinic in Canada. Can J Pain. 2018 Jan 1;2(1):62-73.

https://doi.org/10.1080/24740527.2018.1442675.

[3] Otis JD, Keane TM, Kerns RD. An examination of the relationship between chronic pain and post-traumatic stress disorder. J Rehabil Res Dev. 2003 Sep 1;40(5):397–406.

https://doi.org/10.1682/jrrd.2003.09.0397.

[4] Busse J, Guyatt G, Carrasco A, Akl E, Agoritsas T. The 2017 Canadian guideline for opioids for chronic non-cancer pain. 2017. [cited 2021 May 13]. Available from:

https://www.josephparkandassociates.com/wp-content/uploads/2018/03/Canadian-Opioid-

Guidelines-for-opioids-for-chronic-non-cancer-pain-2017.pdf.

[5] Canadian Pain Task Force. Canada Pain Task Force Report. 2021. [cited 2021 Jun 2].

Available from: <u>https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-</u>engagement/external-advisory-bodies/canadian-pain-task-force/report-2021.html.

[6] Vun E, Turner S, Sareen J, Mota N, Afifi TO, El-Gabalawy R. Prevalence of comorbid chronic pain and mental health conditions in Canadian Armed Forces active personnel: analysis of a cross-sectional survey. CMAJ Open. 2018 Oct;6(4):E528.

https://dx.doi.org/10.9778%2Fcmajo.20180093.

[7] VanDenKerkhof EG, VanTil L, Thompson JM, Sweet J, Hopman WM, Carley ME, et al.

Pain in Canadian veterans: analysis of data from the survey on transition to civilian life. Pain Res

Manag. 2015 Jan 20;20(2):89–95. https://dx.doi.org/10.1155%2F2015%2F763768.

[8] Kithulegoda N, Strachan PH, Zacharias R, Buckley N, Busse JW. Exploring Canadian Veterans' priorities regarding chronic pain research: A qualitative study. J Mil Veteran Fam Health. 2021 Aug;e20210045. <u>https://doi.org/10.3138/jmvfh-2021-0045</u>

[9] Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007 Oct 16;147(8):573–7.

https://doi.org/10.7326/0003-4819-147-8-200710160-00010.

 [10] Griffith LE, Cook DJ, Guyatt GH, Charles CA. Comparison of open and closed questionnaire formats in obtaining demographic information from Canadian general internists. J Clin Epidemiol. 1999;52:997–1005. https://doi.org/10.1016/S0895-4356(99)00106-7.

[11] Health Research Authority / INVOLVE. Public involvement in research and research ethics committee review. 2016. [cited 2021 Jun 4]. Available from:

https://www.invo.org.uk/wp-content/uploads/2016/05/HRA-INVOLVE-updated-statement-2016.pdf.

[12] Poulin P, Shergill Y, Romanow H, Busse JW, Chambers CT, Cooper L, et al. Researching what matters to improve chronic pain care in Canada: a priority-setting partnership process to support patient-oriented research. Can J Pain. 2018 Jan 1;2(1):191–204.

https://doi.org/10.1080/24740527.2018.1433959.

[13] Hill ML, Loflin M, Nichter B, Norman SB, Pietrzak RH. Prevalence of cannabis use, disorder, and medical card possession in US military veterans: Results from the 2019–2020

National Health and Resilience in Veterans Study. Addict Behav. 2021 Sep 1;120:106963. https://doi.org/10.1016/j.addbeh.2021.106963.

[14] Oliva EM, Midboe AM, Lewis ET, Henderson PT, Dalton AL, Im JJ, et al. Sex differences in chronic pain management practices for patients receiving opioids from the Veterans Health Administration. Pain Med. 2015 Jan 1;16(1):112–8. <u>https://doi.org/10.1111/pme.12501</u>.

[15] Morin C, Lund JP, Villarroel T, Clokie CM, Feine JS. Differences between the sexes in post-surgical pain. Pain. 2000 Mar 1;85(1-2):79–85. <u>https://doi.org/10.1016/S0304-3959(99)00248-1</u>.

[16] Mattila K, Toivonen J, Janhunen L, Rosenberg PH, Hynynen M. Postdischarge symptoms after ambulatory surgery: first-week incidence, intensity, and risk factors. Anesth Analg. 2005
 Dec 1;101(6):1643–50. <u>https://doi-org/10.1213/01.ane.0000184189.79572.28</u>.

[17] Tighe PJ, Riley III JL, Fillingim RB. Sex differences in the incidence of severe pain eventsfollowing surgery: a review of 333,000 pain scores. Pain Med. 2014 Aug 1;15(8):1390–404.

https://doi-org/10.1111/pme.12498.

[18] Calderone KL. The influence of gender on the frequency of pain and sedative medication administered to postoperative patients. Sex Roles. 1990 Dec;23(11):713–25.

https://doi.org/10.1007/BF00289259.

[19] Rovner GS, Sunnerhagen KS, Björkdahl A, et al. Chronic pain and sex-differences; women accept and move, while men feel blue. PloS one. 2017 Apr 25;12(4):e0175737. <u>https://doi-org/10.1371/journal.pone.0175737</u>.

[20] Keogh E, McCracken LM, Eccleston C. Do men and women differ in their response to interdisciplinary chronic pain management? Pain. 2005 Mar 1;114(1-2):37–46. <u>https://doi-org/10.1016/j.pain.2004.12.009</u>.

[21] Stubbs D, Krebs E, Bair M, Damush T, Wu J, Sutherland J, et al. Sex differences in pain and pain-related disability among primary care patients with chronic musculoskeletal pain. Pain Med. 2010 Feb 1;11(2):232–9. <u>https://doi-org/10.1111/j.1526-4637.2009.00760.x</u>.

[22] Passmore SR, Toth A, Kanovsky J, Olin G. Initial integration of chiropractic services into a provincially funded inner city community health centre: a program description. The Journal of the Canadian Chiropractic Association. 2015 Dec;59(4):363. Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711334/.

[23] Veterans Affairs Canada. Treatment Benefits - Programs of Choice (POC) [Internet].

Canada: Government of Canada; n.d. [updated 2019; cited 2021 Aug 28]. Available from:

https://www.veterans.gc.ca/eng/health-support/physical-health-and-wellness/medical-

costs/coverage-services-prescriptions-devices/programs-of-choice.

# **3.9. SUPPLEMENTARY MATERIAL**

Item	Item No.	Recommendation	Page in the Manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what	2
		was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2,3
Objectives	3	Specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	2,3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2,3
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	2,3
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4,5
Data	8	For each variable of interest, give sources of data and details of methods of assessment	4,5
sources/measurement		(measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	4
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 1

Additional file 1. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Checklist.

		(b) Give reasons for non-participation at each stage	5,6; Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Tables 1,2
		(b) Indicate number of participants with missing data for each variable of interest	Tables 1,2,3,4, Additional files 2,3
Outcome data	15	Report numbers of outcome events or summary measures	6,7,8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A
		(b) Report category boundaries when continuous variables were categorized	4,5
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10, 11
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

Additional file 2. English and French versions of the survey.

Research Priorities of Veterans living with Chronic Pain

Dear\_\_\_\_\_,

I am the Director of Research for the Chronic Pain Centre of Excellence for Canadian Veterans, and our group is conducting a study on research priorities of military veterans living with chronic pain.

The results of this study will help researchers identify the areas that future research should focus on, so that it aligns with the priorities of military veterans living with chronic pain.

Following this cover page is a 45-question survey which should take between 15 to 20 minutes to complete. These questions are based on a series of interviews that explored research priorities for military veterans living with chronic pain. Prior to the actual survey, there are two questions to assess your eligibility for completion of the survey.

If you feel there are important research topics that are not highlighted in this survey, we would request that you indicate these topics in a written response to the last question.

If you have any questions or concerns at any point regarding the survey, please feel free to contact me through email (<u>bussejw@mcmaster.ca</u>).

Thank you very much for your time and assistance.

Sincerely,

Jason Busse Associate Professor, Dept. of Anaesthesia McMaster University

# **Screening Questions**

We would like to first ask you two questions to determine your eligibility for completing the survey.

I. Are you a military veteran?

- $\Box$  Yes
- 🗆 No

II. Do you live with chronic pain?

Chronic pain is defined as pain that has persisted for 3 months or more.

 $\Box$  Yes  $\Box$  No

## **Demographic Questions**

1. What is your gender?  $\Box$  Female

□ Male

 $\Box$  Another Gender Identity

 $\Box$  Prefer not to answer

2. What is your age? \_\_\_\_\_

3. In which country/countries have you served in the military (check all that apply)? □ Canada

 $\Box$  United States of America

□ United Kingdom

🗆 Australia

□ Other: \_\_\_\_\_

- 4. What branch(s) of the military did you serve in (check all that apply)?
- $\Box$  Air Force

5. What was your final rank in the military?

□ Officer

□ Warrant officer

 $\Box$  Junior non-commissioned member

 $\Box$  Senior non-commissioned member

□ Recruit

□ Other:
litary were you a part of?
□ Regular (or Active) Force
Reserve Force – Primary
Reserve Force – Supplementary
□ Reserve Force – Cadet Organizations Administration and
Charge Reserve – Rangers
□ Other:
t describes the primary focus of your occupational specialty in the Non-operational or non-combat related positions that assisted forces to deliver their mission). Non-operational or non-combat related positions that were not nal or combat-related forces directly; e.g., base/wing positions, tions) Other:

	<ul> <li>with (check all that apply)?</li> <li>Spouse/Partner</li> <li>Children</li> <li>Caregiver</li> <li>Grandchildren</li> <li>Parent(s)</li> <li>Roommate(s)</li> <li>Friend(s)</li> <li>No one, I live alone</li> </ul>
12. What best describes your of	<ul> <li>current region of residence?</li> <li>□ Urban (in the city)</li> <li>□ Rural (in the country)</li> <li>□ Suburban (mixed-use or residential area, existing either as part</li> </ul>
of a city area or as a separate residential comr Other:	nunity within commuting distance of a city)
<ul><li>13. What best describes your o</li><li>□ Own property</li></ul>	current housing situation?
14. What best describes your o	current employment status? Employed, full-time Employed, part-time Unemployed
□ Unemployed, and receivin □ Retired □ Other:	1 /
<ul> <li>15. What best describes your on □ Below \$25,000</li> <li>□ \$25,000 to \$49,000</li> </ul>	<ul> <li>□ \$50,000 to \$59,000</li> <li>□ \$60,000 to \$79,000</li> <li>□ \$80,000 to \$79,000</li> <li>□ \$80,000 to \$99,000</li> <li>□ \$100,000 to \$150,000</li> <li>□ More than \$150,000</li> </ul>

16. How many people does your current gross income support (including yourself)?
- 17. Which of the following best describes your race or ethnicity?:
- □ Asian East (e.g. Chinese, Japanese, Korean)
- 🗆 Asian South (e.g. Indian, Pakistani, Sri Lankan, Indo-Caribbean/West Indian)
- Asian Southeast (e.g. Malaysian, Filipino, Vietnamese, Cambodian)
- 🗆 Asian West (e.g. Afghanistani, Israeli, Saudi Arabian, Iranian, Turkish)
- □ Australasian (e.g. Australia, New Zealand, New Guinea, Melanesia)
- 🗆 Black Africa (e.g. Ghanaian, Kenyan, Somali)
- $\Box$  Black North America

Black – Caribbean Region (e.g. Barbadian, Jamaican)

□ Hispanic

□ Indigenous (e.g. Inuit, First Nations, Non-Status Indian, Metis, Indigenous person from outside Canada)

□ Latin American (e.g. Argentinean, Chilean, Salvadoran)

- □ White/European (e.g. English, Italian, Portugeuse, Russian)
- $\Box$  Prefer not to answer
- $\Box$  Do not know
- □ Other: \_\_\_\_\_

18. What is your highest formal education level?

### □ Elementary School

□ High School

University Degree

 $\Box$  College Degree

□ Other: \_\_\_\_\_

19. What best describes your current relationship status?

 $\Box$  Single/Never Married

- □ Married
- $\Box$  Common law
- $\Box$  Separated
- $\Box$  Widowed

20. How many years have you lived with chronic pain?

21. How often do you include chronic pain as a part of a claim that you submit to Veterans Affairs Canada?

- $\Box$  All of the time
- $\Box$  Most of the time
- $\Box$  Sometimes
- $\Box$  Rarely

□ Never

 $\Box$  I have never filed a claim to Veterans Affairs Canada

22. How would you rate your satisfaction with your current chronic pain care?

 $\Box$  Very satisfied  $\Box$  Somewhat satisfied  $\Box$  Unsure  $\Box$  Somewhat unsatisfied  $\Box$  Very unsatisfied

### **Research Priorities Survey**

The following questions seek to understand your priorities for chronic pain research. There are no right or wrong answers. Please answer based on your own experiences and opinions.

23. How important is research into improving <u>acute</u> pain (<1 month in duration) care while in the military to reduce the risk of developing chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

24. How important is research into improving <u>chronic</u> pain ( $\geq$ 3 months duration) care while in the military?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

25. How important is research into addressing barriers to <u>chronic</u> pain management within the military (e.g., stigma, lack of knowledge, inadequate treatment options or access to care)?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

26. How important is research into improving health care for chronic pain management <u>after</u> release from the military (e.g., improving access to a civilian family doctor)?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

27. How important is research into reducing the length of time for chronic pain claims to be adjudicated by Veterans Affairs Canada?

□ Very important	$\Box$ Somewhat important	□ Unsure	□ Somewhat unimportant	□ Very
unimportant				

28. How important is research into improving civilian doctors' knowledge of military life and the impact of military service as relates to the development of chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

29. How important is research into understanding risk factors during military service that are associated with the development of chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

30. How important is research into optimizing post-surgical care to prevent the development of chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

31. How important is research into establishing the effectiveness of physiotherapy for chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

32. How important is research into establishing the effectiveness of massage therapy for chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

33. How important is research into establishing the effectiveness of physical activity/exercise for chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

34. How important is research into establishing the effectiveness of holistic care (e.g., addressing all relevant factors, not just pain, such as mental health, financial health and quality of life) for chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

35. How important is research into establishing the effectiveness of self-care (i.e., what patients can do for themselves) for chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

36. How important is research into exploring the contribution of <u>administrative barriers</u> (e.g., delay in VA claim approval) to the development and perpetuation of chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

37. How important is research into establishing the effectiveness of chiropractic care for chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

38. How important is research into establishing the effectiveness of medical cannabis for chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

39. How important is research into reducing the use of opioids for chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

40. How important is research into identifying mental illness among veterans living with chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

41. How important is research into treatment of mental illness among veterans living with chronic pain?

 $\Box$  Very important  $\Box$  Somewhat important  $\Box$  Unsure  $\Box$  Somewhat unimportant  $\Box$  Very unimportant

42. How important is research into the effectiveness of providing treatment decision aids (evidence summaries conveying benefits and harms of different therapeutic options) to veterans living with chronic pain?

□ Very important	$\Box$ Somewhat important	□ Unsure	□ Somewhat unimportant	□ Very
unimportant				

43. From the research priorities listed, which one would be your overall top priority?

44. From the research priorities listed, which one would be your overall lowest choice priority?

45. Is there a research priority not mentioned that you think should be included? Please explain.

End of Survey

Thank you for your time! If you have any further questions please contact Jason Busse at: <u>bussejw@mcmaster.ca</u> Priorités de Recherche pour des Vétérans Souffrant de Douleur Chronique

Cher/ Chère \_\_\_\_\_,

Je suis le directeur de la recherche au Centre d'excellence sur la douleur chronique pour les vétérans canadiens/ canadienne, et notre groupe mène une étude sur les priorités de recherche des vétérans souffrant de douleur chronique.

Les résultats de cette étude aideront les chercheurs à identifier les domaines sur lesquels la recherche future devrait se concentrer, afin qu'elle corresponde aux priorités des vétérans.

À la suite de cette page de couverture se trouve un sondage de 42 questions qui devrait prendre environ [xx] minutes. Ces questions sont basées sur une série d'entrevues qui ont exploré les priorités de recherche pour les anciens combattants souffrant de douleur chronique. Avant le sondage, nous vous demandons de répondre à deux questions pour évaluer votre admissibilité à répondre au sondage.

Si vous pensez qu'il y a des sujets de recherche importants qui ne sont pas mis en évidence dans cette enquête, nous vous demandons de les indiquer dans une réponse écrite à la dernière question.

Si vous avez des questions à tout moment concernant le sondage, n'hésitez pas à me contacter par courriel (bussejw@mcmaster.ca).

Merci beaucoup pour votre coopération.

Cordialement,

Jason Busse Professeur Agrégé, Département d'Anesthésie Université de McMaster

### **Questions de Sélection**

Nous voulons vous poser deux questions pour déterminer votre éligibilité pour répondre au sondage.

I. Êtes-vous un vétéran militaire?

Oui Non

II. Vivez-vous avec une douleur chronique?

La douleur chronique est définie comme une douleur qui persiste pendant une période d'au moins 3 mois.

Oui Non

# **Questions Démographiques**

1. Quel est votre genre?:       Femme         Homme       Une autre identité de genre         Préfère ne pas répondre					
2. Quel âge avez-vous?					
3. Quel est votre pays de naissance?: Canada					
Les Etats Unis					
Autre:					
<ul> <li>4. Quel était votre rôle dans la militaire?</li> <li>Soldat(e)</li> <li>Officier de Police</li> <li>Technicien(ne)</li> <li>Commis Militaire</li> <li>Autre:</li></ul>					
5.Combien d'années avez-vous servi dans la militaire?:					
6. Depuis combien d'années vous êtes démobilisé de la militaire?					
7. Quelle est votre province ou territoire de résidence? Ontario					
Manitoba					

Québec

	Nouvelle-Écosse Nouveau-Brunswick Île-du-Prince-Édouard Terre-Neuve-et-Labrador Saskatchewan Alberta Colombie-Britannique Yukon Territoires du nord-ouest
	Nunavut Autre:
<ul> <li>8. Avec qui vivez-vous maintenant?</li> <li>(cochez toutes qui applique)</li> </ul>	Épouse/ Époux ou Partenaire Enfants Soignant(e) Petits Enfants Parent(es) Camarade(s) de Chambre Ami(s) Seule
9. lequel des énoncés suivants d	écrit le mieux votre région de résidence? Urbain (en ville)
	Rural (dans le pays) Banlieue (zone à usage mixte ou résidentielle, existant dans le
cadre	
distincte à une d'une ville) Autre:	d'une zone urbaine ou en tant que communauté résidentielle - distance proche
10. Ce qui décrit le mieux votre Propre propriété	situation actuelle en matière de logement? Propriété louer Autre:
11. Lequel des énoncés suivants	décrit le mieux votre situation professionnelle? Employé à temps complet Employé, à temps partiel

Sans emploi Sans emploi, et recevoir des bénéficiaires de prestations d'invalidité Retraité(e) Autre: \_\_\_\_\_

12. Lequel des énoncés suivants décrit le mieux votre niveau de revenu brut actuel? Moins de 25 000 \$

25 000 \$ à 49 000 \$

50 000 \$ à 59 000 \$ 60 000 \$ à 79,000 \$ 80 000 \$ à 99 000 \$ 100 000 \$ à 150 000 \$ Plus de 150 000 \$

13. Combien de personnes votre revenu actuel soutient-il (y compris vous-même)?

14. Lequel des énoncés suivants décrit le mieux votre race ou votre appartenance ethnique?:

Asie - Est (par exemple chinois, japonais, coréen) Asie - Sud (par exemple, indienne, pakistanaise, sri-lankaise, indo-caribéenne / antillaise) Asie - Sud-est (par exemple malais, philippin, vietnamien, cambodgien) Asie - Ouest (par exemple, Afghanistani, israélien, saoudien, iranien, turc) Australasie - (par exemple, Australie, Nouvelle-Zélande, Nouvelle-Guinée, Mélanésie) Noir - Afrique (par exemple, ghanéen, kenyan, somalien) Noir – Amérique du Nord Noir - Région des Caraïbes (par exemple, Barbadienne, Jamaïcaine) Hispanique Autochtones (p. Ex., Inuits, Premières nations, Indiens non inscrits, Métis, Autochtones personne de l'extérieur du Canada) Amérique latine (par exemple argentin, chilien, salvadorien) Européen (par exemple anglais, italien, portugais, russe) Préfère ne pas répondre Ne sait pas Autre:

15. Quel est votre niveau d'éducation formelle le plus élevé??

École primaire

Ecole Secondaire

Diplôme universitaire Diplôme de collège Autre:

16. Lequel des énoncés suivants décrit le mieux l'état de votre relation?

Marié Loi commune Séparé(e) Divorcé(e) Veuf/ veuve

17.Combien d'années avez-vous vécu avec une douleur chronique?

18. Avez-vous déjà présenté une demande de règlement pour douleur chronique à Anciens Combattants Canada?

Non, je n'ai jamais déposé de réclamation

Oui, j'ai déposé une réclamation

19. Comment évalueriez-vous votre satisfaction à l'égard de vos soins actuels contre la douleur chronique?

Très satisfait Plutôt satisfait Incertain(e) Plutôt insatisfait Très insatisfait

## Sondage sur les Priorités de Recherche

Les questions suivantes visent à comprendre vos priorités de recherche concernant les anciens combattants et la douleur chronique. Il n'y a pas de bonnes ou de mauvaises réponses. Veuillez répondre en fonction de vos propres expériences et opinions.

20. Quelle est l'importance de la recherche sur l'amélioration des soins de la douleur **aiguë** (d'une durée 1 > mois) dans l'armée afin d'éviter le développement de la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

21. Quelle est l'importance de la recherche pour améliorer les soins de la douleur **chronique** (d'une durée  $\geq$  3 mois) pendant que vous êtes dans l'armée?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

22. Quelle est l'importance de la recherche pour éliminer les obstacles à la gestion de la douleur **chronique** au sein de l'armée (p. Ex., Stigmatisation)?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

23. Quelle est l'importance de la recherche sur l'amélioration des soins de santé pour la gestion de la douleur chronique <u>après</u> la libération de l'armée (p. Ex., L'amélioration de l'accès à un médecin de famille civil)?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

24. Dans quelle mesure la recherche est-elle importante pour réduire la durée pendant laquelle les demandes de remboursement de la douleur chronique doivent être traitées par Anciens Combattants Canada?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

25. Quelle est l'importance de la recherche pour améliorer les connaissances des médecins civils sur la vie militaire et l'impact du service militaire sur le développement de la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

26. Quelle est l'importance de la recherche sur la compréhension des facteurs de risque pendant le service militaire qui sont associés au développement de la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

27. Quelle est l'importance de la recherche sur l'optimisation des soins post-chirurgicaux pour prévenir le développement de la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

28. Quelle est l'importance de la recherche pour établir l'efficacité de la physiothérapie contre la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

29. Quelle est l'importance de la recherche pour établir l'efficacité de la massothérapie contre la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

30. Quelle est l'importance de la recherche pour établir l'efficacité de l'activité physique / de l'exercice contre la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

31.Dans quelle mesure la recherche est-elle importante pour établir l'efficacité des soins holistiques (p.ex., traiter tous les facteurs pertinents, et pas seulement la douleur, comme la santé mentale, la santé financière et la qualité de vie) pour la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

32. Quelle est l'importance de la recherche pour établir l'efficacité des autosoins (ce que les patients peuvent faire pour eux-mêmes) pour la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

33.Dans quelle mesure la recherche est-elle importante pour explorer la contribution des <u>barrières administratives</u> (par exemple: retard dans l'approbation des demandes d'AV) au développement et à la perpétuation de la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

34. Quelle est l'importance de la recherche pour établir l'efficacité des soins chiropratiques pour la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

35. Quelle est l'importance de la recherche pour établir l'efficacité du cannabis médical contre la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

36. Quelle est l'importance de la recherche pour réduire l'utilisation d'opioïdes pour la douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

37. Quelle est l'importance de la recherche sur l'identification de la maladie mentale chez les anciens combattants souffrant de douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

38. Quelle est l'importance de la recherche sur le traitement de la maladie mentale chez les anciens combattants souffrant de douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

39. Quelle est l'importance de la recherche sur l'effet de la preuve des avantages et des inconvénients des options de traitement disponibles pour les anciens combattants souffrant de douleur chronique?

Très important Assez important Incertain(e) Sans importance vraiment sans importance

40. Parmi les priorités de recherche répertoriées, laquelle serait votre priorité absolue?

41. Parmi les priorités de recherche répertoriées, <u>laquelle</u> serait votre **priorité de choix la plus basse**?

42. Y a-t-il une priorité de recherche non mentionnée qui, selon vous, devrait être incluse? S'il vous plaît, expliquez.

## Fin du Sondage

Merci pour votre temps! Si vous avez d'autres questions, veuillez contacter Jason Busse à: <u>bussejw@mcmaster.ca</u>

Research Priority identified from the Survey Question	<b>Overall Top</b>	<b>Overall Lowest</b>	
	<b>Priority</b>	<b>Priority</b>	
	(n=308)	(n=306)	
Improving acute pain (<1 month in duration) care while in the military to reduce risk of	21 (7%)	28 (9%)	
developing chronic pain. (Q23)			
Improving chronic pain ( $\geq$ 3 months duration) care while in the military. (Q24)	33 (11%)	9 (3%)	
Addressing barriers to chronic pain management within the military (e.g., stigma, lack of	29 (9%)	9 (3%)	
knowledge, inadequate treatment options or access to care). (Q25)			
Improving health care for chronic pain management after release from the military (e.g.,	52 (17%)	4 (1%)	
improving access to a civilian family doctor). (Q26)			
Reducing the length of time for chronic pain claims to be adjudicated by Veterans Affairs	26 (8%)	6 (2%)	
Canada. (Q27)			
Improving civilian doctors' knowledge of military life and the impact of military service as it	28 (9%)	19 (6%)	
relates to the development of chronic pain. (Q28)			
Understanding risk factors during military service that are associated with the development of	7 (2%)	11 (4%)	
chronic pain. (Q29)			
Optimizing post-surgical care to prevent the development of chronic pain (Q30)	2 (1%)	20 (7%)	
Establishing the effectiveness of physiotherapy for chronic pain. (Q31)	0 (0%)	4 (1%)	
Establishing the effectiveness of massage therapy for chronic pain. (Q32)	6 (2%)	9 (3%)	
Establishing the effectiveness of physical activity/exercise for chronic pain. (Q33)	3 (1%)	6 (2%)	
Establishing the effectiveness of holistic care (e.g., addressing all relevant factors, not just pain,	20 (6%)	15 (5%)	
such as mental health, financial health and quality of life) for chronic pain. (Q34)			
Effectiveness of self-care (i.e., what patients can do for themselves) for chronic pain. (Q35)	10 (3%)	5 (2%)	
Exploring the contribution of administrative barriers (e.g., delay in VA claim approval) to the	9 (3%)	20 (7%)	
development and perpetuation of chronic pain. (Q36)			
Establishing the effectiveness of chiropractic care for chronic pain. (Q37)	0 (0%)	39 (13%)	
Establishing the effectiveness of medical cannabis for chronic pain. (Q38)	9 (3%)	36 (12%)	
Reducing the use of opioids for chronic pain. (Q39)	9 (3%)	34 (11%)	
Identifying mental illness among veterans living with chronic pain. (Q40)	18 (6%)	7 (2%)	
Freatment of mental illness among veterans living with chronic pain. (Q41)	18 (6%)	3 (1%)	
Effectiveness of providing treatment decision aids (evidence summaries conveying benefits	8 (3%)	22 (7%)	
and harms of different therapeutic options) to veterans living with chronic pain. (Q42)	× /		

Additional file 3. Responses to the question on the overall top priority and overall lowest priority item from the 45-item survey.

Theme	Subtheme	Endorsements	Research Priority	Exemplary Quotation
Therapeutic	Osteopathy	4 ( <b>2 M, 2 F</b> )	Establishing the effectiveness of	"I discovered osteopathy and it was this treatment above all others,
interventions			osteopathy for the treatment of	massage therapy, physiotherapy, and acupuncture that made a
			chronic pain.	dramatic difference with helping me to manage my pain and to move
				forward in my recovery. Please include this as a form of treatment. It
				is well known in Germany and France and yet, here in Canada this
	Acupuncture	5 (3 M, 2 F)	Establishing the effectiveness of	modality is not very well known." "Acupuncture are all important to study. The first two are most
	Acupuncture	J (J WI, 2 F)	acupuncture for the treatment of	important to me"
			chronic pain	important to me
	Occupational	2 (1 M, 1 F)	Establishing the effectiveness of	"Occupational therapy, specifically treatment utilizing the dolphin
	therapy		occupational therapy for the	pen. I have experienced great success from this form of therapy."
			treatment of chronic pain	
	Surgery	2 (2 M, 0 F)	Increasing the accessibility and/or	"How about surgical options, if I lived in Europe I could have my
			availability of surgery for chronic	back repaired and live a long pain free life, not here though."
	37			
	Yoga	2 (2 M, 0 F)	Establishing the effectiveness of different forms of yoga (power	"Research the effects of Yogawhile dealing with chronic pain."
			yoga, somatic yoga) for the	
			treatment of chronic pain	
	Meditation	2 (2 M, 0 F)	Establishing the effectiveness of	"Research the effects ofmeditation while dealing with chronic
			meditation for the treatment of	pain."
			chronic pain	
	Group-based	2 ( <b>0 M, 2 F</b> )	Establishing the effectiveness of	"The effect of a group approach to dealing with and living with
	approach to		group-based support for chronic	chronic pain (how socialization is key in the development of both
	chronic pain		pain management	mental and physical health)."
Administrative	management Barriers arising	3 (1 M, 2 F)	Reducing VA-related barriers to	"Providing solutions for people like myself who have been suffering
Issues	from VA when	J (I IVI, 2 F)	delivery of chronic pain care	for decades and have had to fight VAC every step of the way."
involving VA	accessing			for accures and have nut to fight the every step of the way.
	adequate			
	chronic pain-			
	related care			

Additional file 4. Findings from a thematic analysis based on open-ended responses to a question on the 45-item survey (Question #45), (*N* = 147).\*

	Receptiveness of VA to cover a broader range of pain treatment options	4 (2 M, 2 F)	Increasing the types of chronic pain treatments covered by VA	"I found in the military my options were physio, or more physio. If I wanted to see a chiropractor, I had to pay for that on my own. We could be told it was under our scope of care, but we were not allowed to engage that option."
	Continuation of medical care after release	3 (2 M, 1 F)	Establishing effective transfer of veterans' medical records from VA to health professionals	"Research into continued medical support after release. I have been out for over a year and still can't find a medical doctor to fill out my increasing paperwork. Causes me more anxiety and undue stress!"
Competency Issues of Civilian Healthcare Staff	Enhancing civilian doctor knowledge of and training with dealing with VA	2 (1 M, 1 F)	Education/training for civilian doctors on interacting with VA for information relevant to veterans' care	<i>"When you go to your family doctor</i> <i>they have no idea in how to deal with the veterans affairs and</i> <i>because of this I get very poor service from them and it isn't there</i> <i>fault. There should be more help and training for them</i> "
	Improving opioid prescription habits of doctors to military veterans with chronic pain	2 (2 M, 1 F)	Education/training for civilian doctors on healthy opioid prescription for military veterans with chronic pain	"The over prescription of various drugs to reduce chronic pain ie antidepressants etc"
	Identifying civilian doctors that are adequately trained in treating and caring for military veterans	2 (2 M, 0 F)	Providing support for veterans lacking civilian doctors trained to treat/care for military veterans	"All the doctors I have met, look at me with disbelief and all they suggest to shut me up, is take Tylenol. Is it because family doctors should be trained to recognize my needs?"
	Need for follow-up	3 (3 M, 0 F)	Establishing routine follow-ups on health conditions of veterans	<i>"How about instituting a program were a person actually reaches out to the veteran as part as a follow up to the care given to them."</i>
	medical	<u> </u>	and medical report update	The doctors are so busy that don't have enough time to contact"

	appointments for veterans			
Barriers to the accessibility of quality care	Need for military veteran- oriented pain management clinic	2 (2 M, 0 F)	Increasing the accessibility and/or availability of a pain management clinic dedicated to treating military veterans	"I am a firm believer in the fact the Ontario should have a Veterans Hospital, and doctors and nurses."
	Remote, rural or northern areas or isolated areas that lack vicinities for chronic pain management.	2 (2 M, 0 F)	Increasing the accessibility of chronic pain-related care in remote, rural, northern or isolated areas.	"Research into regional barriers affecting acute pain management, chronic pain management and mental health management. ie. Remote or far northern postings, even provincial differences in receiving treatment and effective management"
	COVID-19 related inaccessibility to chronic pain- related care	2 (2 M, 0 F)	Assessing the effect of COVID- 19 restrictions on accessibility to chronic pain treatment	"Due to COVID-19 the VA Qualified doctors who can assess my condition and are familiar with the military are inaccessible as they are closed to us"
Impact of chronic pain on subgroups	Military rank- based differences in the type(s) of chronic pain	2 (2 M, 0 F)	Assessing the variety of chronic pain manifestations in relation to military ranks	"I would like to see research into the types of chronic pain (ie. back, knees, disease causing chronic pain, etc) and its relation to the types of trades within the military. Meaning, is an Infantry Soldier in the Army more likely to develop chronic pain in his back than say an Airforce Pilot?"
	Focus on chronic pain experience of women	2 (0 M, 2 F)	Examining the factors that contribute to chronic pain experience of women veterans	"Chronic pain and gender related issues: biological, physiological, experiential and environmental military life and its effects on women). Too often research is done on men and extrapolated to women and it denies women their own experiences, health and well- being and opportunities for improvement."
	Effects of chronic pain on the family	2 (2 M, 0 F)	Determining the impact of chronic pain on veterans' family members	"Effects on family members that have to take care/live with us."

\* VA = Veterans Affairs; COVID-19 = coronavirus disease of 201

## **CHAPTER 4 – Thesis Conclusion**

#### **4.1 THESIS CONCLUSION**

This dissertation underscored two aspects with regards to chronic pain in military veterans. Specifically, low certainty evidence suggests that the overall prevalence of CNCP among military veterans is 43%; however, there is still considerable unexplained variability between studies, and hence this pooled estimate may change with additional research. Future research would benefit from improved participant retention, systematic assessment of chronic pain among all participants, and employing a standardized definition of CNCPb. Second, from among 20 research priorities that were investigated, the majority of military veterans living with chronic pain endorsed the importance of all priorities; however, postdischarge chronic pain management and identifying and treating co-morbid mental health issues were almost universally endorsed. Several therapy-related research priorities had predictors that impacted their likelihood. As age increased, individuals were less likely to endorse research into medical cannabis for chronic pain. Women were more likely to endorse research into the optimization of post-surgical care or holistic care for treating chronic pain, while men were more likely to endorse research into physical activity or exercise for chronic pain. Individuals with higher income were less likely to endorse research into chiropractic or physiotherapy for chronic pain. These findings will help guide research funders and investigators to optimize alignment between empirical studies and the needs of veterans living with chronic pain.